---
document_datetime: 2023-09-21 19:25:38
document_pages: 106
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-3985-ii-0019-epar-assessment-report-variation_en.pdf
document_name: opdivo-h-c-3985-ii-0019-epar-assessment-report-variation_en.pdf
version: success
processing_time: 289.0926156
conversion_datetime: 2025-12-21 18:36:01.730451
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

21 April 2017 EMA/CHMP/392346/2017 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## OPDIVO

International non-proprietary name: nivolumab

Procedure No. EMEA/H/C/003985/II/0019

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 5                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................5                                                 |
| 2. Scientific discussion................................................................................                   | 6                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................6 |
| 2.2. Non-clinical aspects..............................................................................................7   |                                                                                                           |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................7               |                                                                                                           |
| 2.2.2. Discussion on non-clinical aspects                                                                                  | .......................................................................7                                  |
| 2.2.3. Conclusion on the non-clinical aspects                                                                              | .................................................................7                                        |
| 2.3. Clinical aspects                                                                                                      | ....................................................................................................8     |
| 2.3.1. Introduction......................................................................................................8 |                                                                                                           |
| 2.3.2. Pharmacokinetics                                                                                                    | ..............................................................................................8           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 12                                                                                                        |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 14                                                                                                        |
| 2.3.5. Conclusions on clinical pharmacology.................................................................               | 15                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 15     |
| 2.4.1. Dose response study........................................................................................         | 15                                                                                                        |
| 2.4.2. Main studies                                                                                                        | ................................................................................................... 15    |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 57                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy                                                                                | .................................................................... 61                                   |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 62   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 94                                                                                                        |
| 2.5.2. Conclusions on clinical safety                                                                                      | ............................................................................ 96                           |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 96  |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 97                |
| 2.7. Update of the Product information......................................................................               | 100                                                                                                       |
| 2.7.1. User consultation                                                                                                   | .......................................................................................... 100            |
| 3. Benefit-Risk Balance...........................................................................                         | 100                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................         | 100                                                                                                       |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 100                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 101                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 101                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 101                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 101                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 102                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 102                                                               |
| 3.6. Effects Table....................................................................................................     | 103                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 104                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 104                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 105                            |
| 3.7.3. Additional considerations on the benefit-risk balance                                                               | ......................................... 105                                                             |
| 4. Recommendations                                                                                                         | ...........................................................................................105            |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-drug antibody

ADR

adverse drug reaction

AE

adverse event

ALT

alanine aminotransferase

AST

aspartate aminotransferase

BIRC

blinded independent review committee

BMS

Bristol-Myers Squibb Company

BOR

best overall response

BSC

best supportive care

cHL

classical Hodgkin lymphoma

CI

confidence interval

CR

complete response

CSR

clinical study report

DBL

database lock

DC

discontinuation

DOR

duration of response

E-R

exposure-response

ECL

electrochemiluminescence

ECOG

Eastern Cooperative Oncology Group

EMA

European Medicines Agency

EORTC

European Organisation for Research and Treatment of Cancer

ESMO

European Society for Medical Oncology

EU

European Union

FDA

Food and Drug Administration

GC

Gastric carcinoma

GHS

Global Health Status

GI

gastrointestinal

HRQoL

health-related quality of life

IC

immune cell(s)

IHC

immunohistochemistry

IMAE

immune-mediated adverse event

IMM

immune modulating medication

IND

investigational new drug

IV

intravenous(ly)

K-M

Kaplan-Meier

LDH

lactate dehydrogenase

Max

maximum

MedDRA

Medical Dictionary for Regulatory Activities

Min

minimum

NA

not applicable, not available

NCCN

National Comprehensive Cancer Network

NR

not reached

NSCLC

non-small cell lung cancer

NSQ

non-squamous

OESI

other event(s) of special interest

ORR

objective response rate

OS

overall survival

PD

progressive disease

PD-1

programmed death receptor 1

PD-L1

programmed death ligand 1

PFS

progression-free survival

PI

prescribing information

PK

pharmacokinetic(s)

PPK

population pharmacokinetics

PR

partial response

PT

preferred term

<div style=\"page-break-after: always\"></div>

| Q2W     | every 2 weeks                                |
|---------|----------------------------------------------|
| QLQ-C30 | Quality of Life Questionnaire - 30-item core |
| QoL     | quality of life                              |
| RCC     | renal cell carcinoma                         |
| RECIST  | Response Evaluation Criteria in Solid Tumors |
| SAE     | serious adverse event                        |
| SAP     | statistical analysis plan                    |
| SCCHN   | squamous cell carcinoma of the head and neck |
| SCE     | Summary of Clinical Efficacy                 |
| SCLC    | small cell lung cancer                       |
| SCS     | Summary of Clinical Safety                   |
| SD      | stable disease; standard deviation           |
| SmPC    | Summary of Product Characteristics           |
| SOC     | system organ class                           |
| SQ      | squamous                                     |
| TTR     | time to response                             |
| UC      | urothelial carcinoma                         |
| US      | United States                                |
| VAS     | visual analog scale                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 25 August 2016 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy for Opdivo.

As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add the proposed indication, add a warning about the patient populations excluded from the clinical trial, and update the safety information. The Package Leaflet is updated in accordance.

Moreover, the updated RMP version 7.0 has been submitted.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/1/2011 on the granting of a class waiver.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Aranzazu Sancho-Lopez

Co-Rapporteur:   Paula Boudewina van Hennik

| Timetable                                      | Actual dates      |
|------------------------------------------------|-------------------|
| Submission date                                | 25 August 2016    |
| Start of procedure:                            | 17 September 2016 |
| CHMP Co-Rapporteur Assessment Report           | 16 November 2016  |
| CHMP Rapporteur Assessment Report              | 21 November 2016  |
| PRAC Rapporteur Assessment Report              | 18 November 2016  |
| PRAC Outcome                                   | 1 December 2016   |
| CHMP members comments                          | N/A               |
| Request for supplementary information (RSI)    | 15 December 2016  |
| CHMP Rapporteur Assessment Report on Responses | 03 March 2017     |
| CHMP members comments                          | 13 March 2017     |

<div style=\"page-break-after: always\"></div>

| Updated CHMP Rapporteur Assessment Report        | 16 March 2017   |
|--------------------------------------------------|-----------------|
| 2 nd Request for supplementary information (RSI) | 23 March 2017   |
| Submission of MAH's responses                    | 28 March 2017   |
| Restart of the procedure                         | 30 March 2017   |
| CHMP Rapporteur Assessment Report                | 7 April 2017    |
| CHMP members comments                            | 10 April 2017   |
| Opinion                                          | 21 April 2017   |

## 2. Scientific discussion

## 2.1. Introduction

Nivolumab (Opdivo) is a programmed death receptor 1 (PD-1) blocking antibody that is currently approved in the EU in indications for melanoma (as monotherapy and in combination with ipilimumab), lung cancer, classical Hodgkin's lymphoma and renal cell carcinoma. The CHMP recently gave a positive opinion on an extension of indication to include treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy for Opdivo as monotherapy. The approved dose and schedule of nivolumab monotherapy for the approved indications is 3 mg/kg administered as an IV infusion over 60 minutes Q2W.

## Problem statement

Bladder cancer is the ninth most common cancer in the world, with approximately 430,000 new cases (330,380 in men and 99,413 in women) diagnosed in 2012. It is three times more prevalent in men than in women, resulting in 123,051 deaths in men and 42,033 deaths in women in 2012. In the EU, bladder cancer is the fifth most common cause of cancer, with approximately 124,188 new cases and 40,635 resulting deaths reported in 2012 1 .

Urothelial carcinoma (UC), also known as transitional cell carcinoma, is the most common type of bladder cancer, accounting for 90% of cases. Among patients diagnosed with UC, the majority have non-muscle invasive (approximately half) or localised muscle-invasive disease (approximately 1 in 3) at the time of diagnosis, with the remaining patients having metastatic disease. Approximately 50% of patients presenting with muscle-invasive urothelial cancer eventually develop metastatic recurrence after therapy for clinically localised disease. The most important risk factor identified in bladder cancer is smoking, with the presence of visceral or liver metastases, ECOG performance scores greater than 0, and baseline hemoglobin lower than 10 g/dL predicting worse clinical outcomes for patients with advanced or metastatic disease after platinum failure.

For patients with advanced and metastatic UC, standard first-line treatment involves platinum-based combination chemotherapy 2 . Despite responses in 40 - 60% of patients with advanced UC receiving firstline cisplatin-based chemotherapy, disease progression occurs in nearly all patients at a median of about 8 months 3 . In addition, 50% of patients are cisplatin-ineligible due to poor performance status, impaired

1  GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012

2 J. Bellmunt et al., Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 25 3 Von der Maase H et al. 2005. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Onc. 2005. 23:4602-08.

<div style=\"page-break-after: always\"></div>

renal function, or comorbidity 4 . These patients receive carboplatin regimens such as gemcitabine+carboplatin, which offer a response rate of 41% and a median PFS of 5.8 months 5 .

Adverse prognostic factors for survival for patients with advanced and metastatic disease failing platinumbased chemotherapy have been defined (PS &gt;0, haemoglobin level &lt;10 g/dl, and the presence of liver metastasis) 6 . In patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, there is no global standard of care. ESMO guidelines 2 recommend second-line treatment with single-agent vinflunine, taxanes, or enrollment in clinical trials. Standard regimens described in the NCCN Guidelines 7  are taxanes (i.e., paclitaxel or docetaxel), gemcitabine, pemetrexed, and atezolizumab which are only approved in the US.

The MAH applied for the following indication: Opdivo is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.

The recommended indication is: Opdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy (see SmPC section 5.1).

The recommended dose of Opdivo in the above indication is 3 mg/kg nivolumab administered intravenously over 60 minutes every 2 weeks which is consistent with existing approved dose and schedule of nivolumab monotherapy in adults (see SmPC section 5.2). Treatment with Opdivo should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Nivolumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), nivolumab is exempt from ERA studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion on non-clinical aspects

The applicant did not submit studies for the ERA. According to the guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), an ERA justifying the lack of ERA studies is acceptable.

## 2.2.3. Conclusion on the non-clinical aspects

The lack of non-clinical studies is acceptable given that no changes to the SmPC section 5.3 have been proposed. Nivolumab is not expected to pose a significant risk to the environment.

4 Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432-8.

5 13 De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial

assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol.2012;30:191-9.

6 Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850-1855. 7 NCCN Clinical Practices guidelines in Oncology: Bladder Cancer, Version 2.2017

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## Table 1

- Tabular overview of clinical studies

<!-- image -->

| Study Type       | Study Identifier/Report Location (Study Status)                              | Study Objective                                                                                                                                                                                                                                                               | Study Design                                                                                 | Treatment Cohorts        | No.of Treated Subjects (No. of Nivolumab- treated subjects)   | Study Population                                                                                                                                                       |
|------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy, Safety | CA209275/ Module 5.3.5.2 (clinical study report available)                   | To estimate ORR basedonBIRC assessments (using RECIST 1.1) of nivolumab monotherapyin subjects with tumor expressing PD-L1 andoveralltreated subjects with metastatic or surgically unresectable UC who have progressed or recurred following treatment with a platinum agent | Phase 2 single arm trial of nivolumab monotherapy                                            | Nivolumab 3 mg/kg IV Q2W | 270 (270)                                                     | Adult (≥18 years) subjects withmetastatic orsurgically unresectable UC with disease progression or recurrence on or after at least one platinum- based chemotherapy    |
| Efficacy, Safety | CA209032 (UC mono cohort) / Module 5.3.5.2 (clinical study report available) | To evaluate the ORR of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors                                                                                                                                       | A Phase 1/2, open-label Study of nivolumab monotherapy or nivolumab combined with ipilimumab | Nivolumab 3 mg/kg IV Q2W | 78 (78)                                                       | Adult (≥ 18 years) subjects with metastatic or surgically unresectable UC with disease progression or recurrence on or after at least one platinum- based chemotherapy |

## 2.3.2. Pharmacokinetics

The clinical pharmacology data in this application support the proposed use of nivolumab as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following a platinum-containing chemotherapy regimen or within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy regimen.

The recommended dose and schedule is 3 mg/kg every 2 weeks (Q2W), which is the same as that approved for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).

The PK of nivolumab in subjects with solid tumours and cHL have been previously characterised by PPK analysis. Nivolumab PK in these analyses was described by a stationary model, in which nivolumab CL was constant with respect to time. However, in a subsequent exploratory analysis following guidance from the US FDA, it was found that nivolumab CL tended to decrease with time. A PPK model with timevarying CL was thus used to characterise the nivolumab serum concentration-time profile in subjects with

<div style=\"page-break-after: always\"></div>

multiple solid tumours and cHL, including subjects with UC (subjects from a Phase ½ study, Study CA209032 and a Phase 2 single arm trial with nivolumab 3 mg/kg, Study CA209275, were included).

An assessment of the effect of the following covariates on nivolumab PK was also performed: body weight (BW), age, sex, race, hepatic function status, eGFR, baseline performance status (PS) and tumour type.

## Pharmacokinetics in UC - Population Pharmacokinetic Analysis

The PPK analysis was performed using data from 3458 subjects with solid tumours or cHL. The analysis population consisted of all subjects enrolled in studies who received nivolumab monotherapy, and for whom nivolumab concentration values were available.

These studies were selected to enable a robust characterisation of nivolumab PK in the following tumour types: NSCLC, melanoma, RCC, SCCHN, UC, gastric carcinoma (GC), and cHL, as well as Phase 1 studies in which there was intense PK sampling.

The PPK model development consisted of: 1) Base Model to re-assess the structural model, in particular time-varying CL, and 2) Full Model to assess the effect of covariates on nivolumab PK, which included an assessment of tumour type (including UC vs NSCLC 2L+) effect on nivolumab CL, and 3) Final model to attain the parsimonious model including significant covariates on nivolumab PK, which was further utilised for model applications.

The Final Model was a two-compartment, zero-order IV infusion with time-varying CL (sigmoidal-Emax function) with a proportional residual error model, random effect on CL, VC, VP and Emax, and correlation of random effects between CL and VC. The final PPK model, contained baseline BWT (BBWT), eGFR, PS, sex, race and tumour type on CL and BBWT and sex on VC and the parameter estimates are described in the table below.

<div style=\"page-break-after: always\"></div>

Table 2 Parameter estimates of the final PPK Model

| Name\",b [Units]   | Symbol   | Estimatec      | Standard Error (RSE%)d   | 95% Confidence Intervaler   |
|-------------------|----------|----------------|--------------------------|-----------------------------|
| Fixcd Effects     |          |                |                          |                             |
| CLREF [L/h]       | 0        | 0.0108         | 3.11E-04 (2.88)          | 0.01, 0.011                 |
| VCREF [L]         | 02       | 4.26           | 0.0397 (0.932)           | 4.187,4.339                 |
| QREF [L/h]        | 03       | 0.0334         | 0.00190 (5.69)           | 0.03, 0.039                 |
| VPREF [L]         | 04       | 2.64           | 0.0899 (3.41)            | 2.472,2.796                 |
| CLBBWT            | 0        | 0.584          | 0.0326 (5.58)            | 0.517,0.645                 |
| CLGFR             | θ        | 0.137          | 0.0228 (16.6)            | 0.09,0.185                  |
| CLsEX             | 012      | -0.161         | 0.0165 (10.2)            | -0.197, -0.13               |
| CLps              | 013      | 0.172          | 0.0138 (8.02)            | 0.144, 0.198                |
| CLoTH             | 015      | 0.0214         | 0.0166 (77.6)            | -0.017,0.055                |
| VCBBWT            | 017      | 0.619          | 0.0359 (5.80)            | 0.556, 0.699                |
| VCsEx             | 018      | -0.142         | 0.0181 (12.7)            | -0.173, -0.103              |
| CLGC              | 021      | 0.186          | 0.0486 (26.1)            | 0.084,0.275                 |
| CLEMAX            | 024      | 115'0-         | 0.0336 (10.8)            | -0.384,-0.251               |
| CLT50             | 025      | 1.40E+03       | 76.1 (5.44)              | 1246,1566                   |
| HILL              | 026      | 2.77           | 0.530 (19.1)             | 1.983, 4.274                |
| CLRAAA            | 027      | 0.0576         | 0.0406 (70.5)            | -0.027,0.138                |
| CLRAAS            | 028      | -0.0769        | 0.0264 (34.3)            | -0.129,-0.025               |
| CLCHL             | 030      | -0.320         | 0.0270 (8.44)            | -0.376, -0.268              |
| Random Effects    |          |                |                          |                             |
|                   | 01,1     | 0.111 (0.333)  | 0.00575 (5.18)           | 0.099, 0.122                |
| @²-vC [-]         |          | 0.127 (0.356)  | 0.0139 (10.9)            | 0.1,0.158                   |
| ²-VPI-1           | 03.3     | 0.231 (0.481)  | 0.0243 (10.5)            | 0.187,0.288                 |
| ?^-EMAX [-] 2     | 04,4     | 0.0509 (0.226) | 0.00914 (18.0)           | 0.034, 0.071                |
| 2 -CL: ∞'vC       | 01,2     | 0.0361 (0.304) | 0.00351 (9.72)           | 0.029,0.045                 |
| Residual Error    |          |                |                          |                             |
| PERR [-]          | 06       | 0.206          | 0.00518 (2.51)           | 0.197, 0.216                |

a Parameters with fixed values (not estimated) are denoted with a superscript'f' after the names, with the fixed value givenintheEstimatecolumn

bRandomEffects and Residual Errorparameter names containing a colon()denote correlated parameters

c Random Effects and Residual Error parameter estimates are shown as Variance (Standard Deviation) for diagonal elements (oi,i or oi,i) and Covariance (Correlation) for off-diagonal elements (oi.j or ci,j)

d RSE% is the relative standard error (Standard Error as a percentage of Estimate)

e Confidenceintervals ofRandomEffects and ResidualErrorparameters areforVariance or Covariance

f-ConfidenceInterval values are takenfrombootstrap calculations(433successful out ofa totalof 500).

g-CL and VC are typical value of CL and VC at the reference values. Covariate effect was estimated relative to reference subject who is a male, weighing 80kg, eGFR of 80 [mL/min/1.73 m2], age of 65 years, NSCLC2L+ tumor type and performance status of O. The reference value for hepatic impairment is normal, and race is Caucasian or other. The reference values for continuous valued covariates were selected to be approximately the median of the covariate values in the analysis data set. RAAA indicates race (african american) and RAAS indicates(RaceAsian)

h-Eta shrinkage:ETA\\_CL:14.2,ETA\\_VC:21.6,ETA\\_VP:45.8,ETA\\_EMAX:54.0

Source: /global/pkms/data/CA/209/C16/prd/ppk/final/nm/e-final3-2-line-adj/e-final3-2.-line-adj.rtf

<div style=\"page-break-after: always\"></div>

The model estimated Emax (CLEMAX, -0.311, Table 2), indicates that nivolumab CL decreases with time, and that the maximal decrease is approximately 26% [calculated as: 1 -exp(Emax)]. The change in CL is estimated to occur soon after initiation of treatment, with the half-maximal change estimated to occur at approximately 2 months (T50 = 1400 h). The geometric mean CL of 10.8 mL/h after the first dose reaches a steady-state value of 7.91 mL/h.

The results of the PPK analysis indicated that the PK of nivolumab was linear in the dose range of 0.1 to 20 mg/kg.

A summary of the individual PK parameter estimates obtained from the final PPK model is provided in Table 3.

Table 3 Summary Statistics of individual PK parameter Values (N=3458)

| PKParameter             | Mean         | Geometric Mean   | Median (min, max)                             | SD           | CV%     |
|-------------------------|--------------|------------------|-----------------------------------------------|--------------|---------|
| Baseline CL (BCL) [L/h] | 0.0115       | 0.0108           | 0.0107 (0.00155,0.0425)                       | 0.00455      | 39.5    |
| CLSS [L/h] VC [L]       | 0.00858 4.08 | 0.00791 3.88     | 0.00783 (0.000597, 0.0884) 3.95 (0.133, 11.9) | 0.00394 1.23 | 46 30.1 |
| VP [L]                  | 2.73         | 2.63             | 2.63 (0.351, 21.6)                            | 0.911        | 33.4    |
| VSS [L]                 | 6.81         | 6.62             | 6.61 (0.748, 25.3)                            | 1.66         | 24.4    |
| T-HALFα [h]             | 31.5         | 30.6             | 31 (2.23, 95.2)                               | 6.97         | 22.1    |
| T-HALFβ [d]             | 27           | 25.2             | 25.4 (3, 525)                                 | 14.9         | 55.4    |
| EMAXP                   | 26           | NA               | 26.7 (-125, 64.4)                             | 8.49         | 32.6    |

NA: Not applicable

?T1/2β and T1/2a were calculated using formula as below:

KE =CL/VC;K12=Q/VC;K21 =Q/VP;AA=KE +K12+k21

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

VSS was calculated using formula: VSS=VC+VP.

EMAXP was a percentage of maximal CL change from baseline and was calculated as (1-exp(EMAX))*100. Individual estimates of Q,T50 and HILL are 0.0336L/h,58.3 and 2.76,respectively,as there are no random or covariate effect parameters associated with these parameters in the final PPK model.

Analysis -Directory: /global/pkms/data/CA/209/C16/prd/ppk/final

R-ProgramSource:Analysis-Directory/R/scripts/exposure-summary.r

Source: Analysis-Directory/R/export/stats-para.csv

The geometric mean Cavgss in all subjects administered 3 mg/kg Q2W was 86.6 μg/mL.

## Analysis of Covariate Effects

Inferences regarding the effect of covariates were based upon the full model parameter estimates, which incorporated all pre-specified covariate parameter relationships of interest into the model.

The effects of categorical (tumour type, race, performance status, hepatic function and sex) and continuous covariates (eGFR, age and body weight) on PK parameters (CL and VC) in the full covariate model are summarized in Figure 1. The assessment for the effect of solid tumors on CL was done by including a separate parameter for each solid tumor type, except for cHL.

The effect of the following covariates were found to be statistically significant on nivolumab CL: baseline body weight (BBWT), performance status (PS), sex, race (Asian), tumor type (GC), eGFR; and the effect of BBWT and sex were found to be significant on nivolumab VC. The magnitude of the effect of covariates on CL, accounting for uncertainty, was within the ± 20% boundaries for all covariates, except baseline body weight. Sex appears to have some level of effect on CL and VC; it was close the ± 20% boundary for CL and VC, where female subjects had lower CL and VC than males.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Estimate (95% Cl): Continuous (P05)

Estimate(Continuous Values&gt;Reference)

Note 1: Categorical covariate effects (95% CI) are represented by open symbols (horizontal lines).

Note 2: Continuous covariate effects (95% Cl) at the 5th/95th percentiles of the covariate are represented by the end of horizontal boxes

(horizontal lines). Open/shaded area of boxes represents the range of covariate effectsfrom the median to the 5th/95th percentile of the covariate.

Note 3:Reference subject is white/others male age=65yr,PS=0,eGFR=90 ml/min/1.73m^2 and body weight=80kg,subject with normal hepatic and 120% of this value.

functionwithNSCLC2L+.Parameter estimate in reference subjectis considered as 100%(verticalsolid line)and dashedverticallines are at S0%

CIvaluesweretakenfrombootstrapcalculations(289successfuloutof atotalof500)

Figure 1 Covariate effects on PK Model Parameters (Full PPK Model excluding cHL patients)

## 2.3.3. Pharmacodynamics

E-R analyses for safety and efficacy in subjects with UC from study CA209275 and CA209032 (UC arm) were not conducted, as data were available from only one dose level.

The rate of AE-DC/D in studies CA209032 (UC cohort) and CA209275 was similar to that seen in previous studies (see clinical safety).

## Immunogenicity

The immunogenicity of nivolumab at 3 mg/kg Q2W monotherapy has been well characterised in the nivolumab development program across multiple tumour types. An updated immunogenicity analysis integrated with data from studies CA209032 and CA209275 was presented.

## Study CA209032:

Nine subjects (13.0%) were ADA positive following administration of nivolumab. No subject was considered persistent positive and one subject was neutralising ADA positive. The titer values observed in ADA positive subjects ranged from 1 to 8.

<div style=\"page-break-after: always\"></div>

Only 1 ADA positive subject (not neutralising ADA positive) had Grade 1 hypersensitivity/infusion reaction on Day 1 after the first dose of nivolumab. Given that this subject was ADA positive on Days 1 (baseline), 15, 29, and 99 and continued to receive nivolumab treatment for 6 months with no other occurrences of hypersensitivity/infusion reaction, it is unlikely that the Day 1 occurrence was ADA related. Thus, there were no apparent effects of nivolumab immunogenicity on safety in nivolumab monotherapy treated UC subjects in this study.

Among 9 ADA positive subjects, 1 had CR, 1 had PR, 4 had a SD, and 3 (including the neutralising ADA positive subject) had a PD.

## Study CA209275:

Fifty-two subjects (23.7%) were ADA positive following administration of nivolumab. No subject was considered persistent positive and four subjects were neutralising ADA positive. In all ADA positive subjects the ADA titres were low, ranging from 1 to 32.

Hypersensitivity/infusion related reactions were not observed in any ADA positive subjects. Thus, the presence of ADA was not associated with the occurrence of hypersensitivity and/or infusion-related reactions in Study CA209275. Of the 52 subjects that were ADA positive, 1 subject had a BOR of CR, 6 subjects had a BOR of PR, and 9 subjects had a BOR of SD. Thus, approximately 30% of the ADA positive subjects had a response of CR, PR, or had SD. This response was consistent to the overall response observed in CA209275, which included the ADA negative subjects.

Table 4 Summary of nivolumab antibody assessments using method ICDIM 140 following nivolumab 3 mg/kg every 2 weeks

| Number of Subjects (%)        | Number of Subjects (%)               | Number of Subjects (%)        | Number of Subjects (%)   | Number of Subjects (%)   |
|-------------------------------|--------------------------------------|-------------------------------|--------------------------|--------------------------|
| Study Number                  | Summary of Previous Studies (N=1734) | CA209032 (UC Subjects) (N=69) | CA209275 (N=219)         | Pooled Summary (N=2022)  |
| BaselineADAPositive           | 92 (5.3)                             | 4 (5.8)                       | 11 (5.0)                 | 107 (5.3)                |
| ADA Positive                  | 170 (9.8)                            | 9 (13.0)                      | 52 (23.7)                | 231 (11.4)               |
| Persistent b Positive         | 2 (0.1)                              | 0                             | 0                        | 2 (0.1)                  |
| Not PP - Last Sample Positive | 63 (3.6)                             | 1 (1.4)                       | 24 (11)                  | 88 (4.4)                 |
| Other Positive                | 105 (6.1)                            | 8 (11.6)                      | 28 (12.8)                | 141 (7.0)                |
| Neutralizing ADA Positive     | 10 (0.6)                             | 1 (1.4)                       | 4 (1.8)                  | 15 (0.7)                 |
| ADA Negative                  | 1564 (90.2)                          | 60 (87.0)                     | 167 (76.3)               | 1791 (88.6)              |

11 12 Source: See note a and Table 8.13.1-1 of the CA209032 UC CSR and 8.14.1-1 of the CA209275 CSR

Previous studies includes studies CA209-063, -037, -066, -017, -057, -067, -025, -039, -205, -141 summarized in 20 Module 2.7.2 Summary of Clinical Pharmacology for Squamous Cell Carcinoma of the Head and Neck

Persistent positive subject defined as a subject with ADA-positive samples at 2 or more consecutive time points, where the first and last ADA positive samples were at least 16 weeks apart.

To further explore the relationship between immunogenicity and safety, an integrated assessment of the potential impact of nivolumab ADA on immunogenicity-related effects was performed by summarising the

<div style=\"page-break-after: always\"></div>

select adverse events in the hypersensitivity/infusion reaction category by ADA Status (positive or negative) for those subjects who were treated with nivolumab monotherapy.

Data was available from studies CA209063, CA209037, CA209066, CA209017, CA209057, CA209067, CA209025, CA209039 (cHL all), CA209205 (cohorts A+B+C), CA209141, CA209032 (UC subjects), and CA209275. Of the 2071 subjects evaluable for the presence of ADA and hypersensitivity/infusion reactions, a total of 116 experienced hypersensitivity/infusion reactions. Of the 116 subjects who experienced hypersensitivity/infusion reactions, 5 were positive for nivolumab ADA and 111 were negative for nivolumab ADA. A total of 5/241 (2.07%) ADA positive subjects experienced adverse events in the hypersensitivity/infusion reaction category.

- One subject that was ADA positive (in Study CA209037) had an ADA positive status only for the last sample and experienced a Grade 1 hypersensitivity reaction after the first nivolumab dose when the ADA status was negative.
- One subject from Study CA209067 (monotherapy arm) had one ADA positive sample after one dose of nivolumab. This subject then continued nivolumab treatment, but ADA samples that were collected after 4 and 7 weeks of treatment were negative. This subject experienced bronchospasm prior to the last ADA sample at 7 weeks after initiation of treatment. Thus, the bronchospasm was not associated with the positive ADA status.
- Two subjects from Study CA209057 were ADA positive and had Grade 1-2 infusion related reactions on the same day. These subjects went on to receive additional nivolumab doses and mADA were not detectable in subsequent assessments.
- One subject from Study CA209032 had Grade 1 hypersensitivity/infusion reaction on Day 1 after the first dose of nivolumab. Given that this subject was ADA positive on Days 1 (baseline), 15, 29, and 99 and continued to receive nivolumab treatment for 6 months with no other occurrences of hypersensitivity/infusion reaction, it is unlikely that the Day 1 occurrence was ADA related.

## 2.3.4. Discussion on clinical pharmacology

A new PPK model has been developed for the evaluation of the PK of subjects that received nivolumab for the treatment of solid tumours (including the new urothelial cancer (UC) indication) as well as patients with cHL. Following FDA guidance, the applicant has now characterised nivolumab CL as time-dependent, rather than constant as considered in the previously developed PPK models.

Nivolumab PK was described by a linear 2-compartiment model with time decreasing CL (~26%). The estimated parameters were similar to the estimated parameters from the previous final models and remain in line with what could be expected for an IgG monoclonal antibody (CL=0.0108 L/h; VC=4.26 L; VP=2.64 L). The effect of baseline body weight (BBWT) was found to be statistically significant and clinically relevant on both nivolumab CL and VC in line with previous PPK models. The effect of sex, race (Asian), PS, and eGFR are unlikely to be clinically relevant. Sex appears to have some level of effect on CL and VC; it was close the ± 20% boundary for CL and VC, where female subjects had lower CL and VC than males. These results are in alignment with the previous reported analyses, and the magnitude of the effect of PS, body weight and eGFR on CL, and the effect of sex and body weight on VC are comparable to what was previously reported in other solid tumour populations including RCC, NSCLC and melanoma.

Overall, no relevant changes are observed in the estimated PK parameters of the effect of covariables on nivolumab PK compared to previous models. The SmPC has been changed according to the new estimated parameters (see SmPC section 5.2).

<div style=\"page-break-after: always\"></div>

Nivolumab has low immunogenic potential. The pooled analysis of all tumour types showed that approximately 11% of subjects who were treated with nivolumab 3 mg/kg every 2 weeks (Q2W) monotherapy tested positive for treatment-emergent anti-nivolumab antibody. There is no apparent effect of ADA on efficacy of nivolumab.

The impact of immunogenicity on nivolumab clearance has been assessed as part of the PPK analyses as a time-varying covariate, and was associated with a 14% increase in nivolumab CL, which was not considered clinically relevant.

Overall immunogenicity results are in line with previous information (see also clinical safety).

The applicant did not conduct E-R analysis in subjects with UC from study CA209275 and CA209032 (UC arm) as data were available from only one dose level which would limit the interpretability of the data. This is considered acceptable.

## 2.3.5. Conclusions on clinical pharmacology

A new PPK model including time-dependent CL, has been developed for the evaluation of the PK of subjects that received nivolumab for the treatment of solid tumours (including the new urothelial cancer (UC) indication) as well as patients with cHL. No relevant changes are observed in the estimated PK parameters or the effect of covariables on nivolumab PK compared to previous models. The SmPC has been changed according to the new estimated parameters.

The updated immunogenicity data is in line with previous analysis showing that nivolumab has low immunogenic potential.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No dose response study was submitted. The dose and schedule of nivolumab, 3 mg/kg IV infusion over 60 minutes Q2W was selected for CA209275 and CA209032 based upon the collective experience of nivolumab monotherapy across multiple tumour types i.e. for melanoma, NSCLC, RCC, and classical Hodgkin lymphoma.

## 2.4.2. Main studies

## Study CA209275

This was a Phase 2 Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment with a Platinum Agent.

<div style=\"page-break-after: always\"></div>

## Methods

Figure 2 study design scheme (Study CA209275)

<!-- image -->

## Study participants

## Main inclusion criteria

- Subjects ≥18 years and older.
- Histological or cytological evidence of metastatic or surgically unresectable UC (bladder, urethra, ureter, or renal pelvis). Minor histologic variants (&lt; 50% overall) were acceptable.
- Metastatic or surgically unresectable (cT4b, or any N+ [N1-3] or any M-1) disease.
- Measurable disease by CT or MRI per RECIST 1.1 criteria.
- Subjects must have progression or recurrence after treatment

- with at least 1 platinum-containing chemotherapy regimen for metastatic or surgically unresectable locally advanced urothelial cancer, or

- within 12 months of peri-operative (neo-adjuvant or adjuvant) treatment with platinum agent in the setting of cystectomy for localised muscle-invasive urothelial cancer.

- Subjects that have received more than 2 prior lines of chemotherapy must not have liver metastases.
- Evaluable tumour tissue (fresh or archival) for biomarker analysis.
- ECOG PS 0 or 1.
- Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl) ≥ 30 mL/min (using the Cockcroft-Gault formula).

## Main exclusion criteria

- Active brain metastases or leptomeningeal metastases.
- Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger were permitted to enrol.

<div style=\"page-break-after: always\"></div>

- Systemic treatment with either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, anti-CD137, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
- Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 28 days of first administration of study treatment.

## Treatments

Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W. Subjects received treatment with nivolumab on Day 1 of a treatment cycle every 2 weeks (14 days). No pre-medications were recommended on the first cycle.

Dose reductions or escalations were not permitted for nivolumab.

Dose delays were permitted.

Prior palliative radiotherapy must have been completed at least 2 weeks prior to study drug administration.

Treatment beyond initial investigator-assessed RECIST, version 1.1-defined progression was permitted if the patient experienced a clinical benefit, did not have rapid disease progression, and was tolerating study drug as determined by the investigator.

## Objectives

The primary objective of the CA209275 study was to estimate ORR based on (BIRC) assessments of nivolumab monotherapy in subjects with tumour expressing PD-L1 (membranous staining in ≥ 5% and ≥ 1% tumor cells) and overall treated subjects with metastatic or surgically unresectable UC who have progressed or recurred following treatment with a platinum agent.

The secondary objectives were the following:

- To evaluate progression free survival (PFS) based on BIRC assessments in subjects with tumor expressing PD-L1 (membranous staining in 5% and 1% tumour cells) and overall subjects treated with nivolumab monotherapy.
- To evaluate overall survival (OS) in subjects with tumour expressing PD-L1 (membranous staining in 5% and 1% tumor cells) and overall subjects treated with nivolumab monotherapy.
- To estimate investigator assessed ORR in subjects with tumour expressing PD-L1 (membranous staining in 5% and 1% tumor cells) and overall subjects treated with nivolumab monotherapy

The first tumour assessments were conducted 8 weeks after the start of treatment and continued every 8 weeks thereafter up to 48 weeks, then every 12 weeks until disease progression or treatment discontinuation, whichever occurred later. Tumour assessments were continued after treatment discontinuation in patients who discontinued treatment for reasons other than progression.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

## Primary and secondary endpoints for Study CA209275

## Table 5 Summary of Primary and Secondary Objectives (Study CA209275)

| Objective                                                                                                                                                                                                  | Endpoint               | Endpoint Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PRIMARY                                                                                                                                                                                                    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| To estimateORRbased onBIRC assessments (using RECIST 1.1) of nivolumab monotherapy in subjects with tumor expressing PD-L1 (membranous staining in ≥ 5% and ≥ 1% tumor cells) and overall treated subjects | ORR (per BIRC)         | The primary objectivewill be measured by the primary endpoint of ORR(based on BIRC assessments) among all treated subjects, PD-L1 ≥ 1% subjects and PD-L1 ≥ 5% subjects.It is defined as the number of subjects with a best overall response of confirmed CR or PR divided by the number of all treated subjects,PD-L1 ≥ 1% subjects or PD-L1 ≥ 5% subjects respectively. Best overallresponse is defined as thebest response designation, as determined by BIRC,recorded between the dateof first dose and the date of objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For subjects without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination.                                                                                                                                                          |
| SECONDARY                                                                                                                                                                                                  |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| To evaluatePFSbased on BIRC assessments (using RECIST 1.1) in subjects with tumor expressing PD-L1 (membranous staining in ≥ 5% and ≥ 1% tumor cells) and overall treated subjects                         | PFS (per BIRC)         | PrimaryPFSdefinition will bebased onBIRC assessments.It is defined as the time from first dosing date to the date of the first documented tumor progression, based on BIRC assessments (per RECIST 1.1), or death due to any cause. Clinical deterioration in the absence of unequivocal evidence of progression (per RECIST 1.1) is not considered progression for purposes of determining PFS. Subjects who die without a reportedpriorprogression willbe considered tohaveprogressed onthedate of their death. Subjects who did not progress or die will be censored on the date of their last tumor assessment. Subjects who did not have any on study tumor assessments and did notdiewill becensoredonthefirstdosingdate.Subjectswhostarted anysubsequent anti-cancer therapy without a priorreportedprogression willbe censored at the last tumor assessment prior to or on the date of initiation of the subsequent anti-cancer therapy |
| To evaluate overall survival (OS) in subjects with tumor expressing PD-L1 (membranous staining in ≥ 5% and ≥ 1%tumor cells)and overall subjects treated                                                    | OS                     | OSis defined as the time fromfirst dosingdate to the dateof death.A subject whohas not died will be censored at last known date alive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Objective                                                                                                                                                                                                  | Endpoint               | Endpoint Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| To estimateinvestigator assessed ORR (using RECIST 1.1) in subjects with tumor expressing PD-L1 (membranous staining in ≥ 5% and ≥ 1% tumor cells) and overall subjects treated                            | ORR (per investigator) | ORR as assessed by investigators is defined similarly as for the primary endpoint ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Objective                                                                                                                                                             | Endpoint                                                                                | Endpoint Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EXPLORATORY                                                                                                                                                           |                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| To evaluate the safety of nivolumabmonotherapy in subjects with metastatic or surgically unresectable urothelial carcinoma                                            | Deaths, AEs, SAEs, AEs leading to DC & dose delay, and specific laboratory abnomalities | Safetywas analyzed through theincidence ofdeaths,adverse events,serious adverse events, adverse events leading to discontinuation, adverse events leadingto dose delay, select adverse events, immune-mediated adverse events (IMAEs) and specific laboratory abnormalities(worstgrade).SelectAEanalysesincludedincidence,time-to- onset, and time-to-resolution.AEs andlaboratory abnormalities were graded using the National CancerInstitute (NCl) CommonTerminology CriteriaforAdverseEvents (CTCAE)version 4.0.AEs were codedusing the MedDRAVersion19.0.                                                                                                                                                                                                                                                                                                            |
| To evaluate investigator assessed PFS (using RECIST 1.1)s.                                                                                                            | PFS (per investigator)                                                                  | PFSbased oninvestigator assessments isdefined as the timefromfirstdosingdateto thedateof the first documented tumorprogression,as determined byinvestigators (per RECIST 1.1), or death due to any cause.Clinical deterioration in the absence of radiographic evidence is not considered progression for the purpose of determining PFS per investigator. Subjects who die without a reported prior progression will be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on the date of their last tumor assessment.Subjects who did not have any onstudy tumorassessments anddidnotdiewillbe censored onthefirst dosing date.Subjects who started subsequent therapy without a priorreported progressionwill becensored atthelasttumor assessmentspriortoinitiationof the subsequent anticancer therapy. |
| TocharacterizethePKof nivolumab monotherapy and to explore exposure- response relationships                                                                           | Nivolumab concentrations                                                                | PK was determinedfrom serum nivolumab concentrations.Samples were collected to characterizepharmacokinetics of nivolumabandto explore exposure-safety and exposure-efficacyrelationships                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| To characterize the immunogenicity of nivolumab monotherapy                                                                                                           | Serum ADA and neutralizing ADA response to nivolumab                                    | Human serum samples from nivolumab-treated subjects were evaluated for the presence of ADA at PPD Inc. (Richmond, VA) using a validated immunoassay method (Method ICDIM 140) andneutralizing activity at BMS (Princeton NI) using a validated functional cell-based assay (Method 15400). See Appendix 8.2 and 8.3 for immunogenicity bioanalytical studyreports.BaselineADA Positive: anADA-positive sample at baseline. ADA Positive: at least one ADA-positive sample relative tobaseline at any time after initiation of treatment.Persistent Positive: ADA-positive sample at 2 of more consecutive time points, where the first andlast ADA-positive samples are at least 16 weeks apart. Other Positive: not persistent positive with ADA-negative sample                                                                                                         |
|                                                                                                                                                                       | Endpoint                                                                                | Endpoint Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Objective                                                                                                                                                             |                                                                                         | ADA-positive sample in the last sampling time point. Neutralizing Positive: At least 1 ADA positive sample with neutralizing antibodies detected. ADA Negative: no ADA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| To investigate the associationbetween biomarkers in the tumor tissue, such as PD-L1 expression, with safety andefficacyforsubjects treated with nivolumab monotherapy | PD-L1                                                                                   | PD-L1 expression is defined as the percent of tumor cells membranestainingin a minimumof100evaluabletumorcellsperthevalidatedDakoPD-L1PharmDxIHCkit assay.This is referred to as quantifiable PD-L1 expression.If the PD-L1 staining could notbequantified,itisfurtherclassifiedas: Indeterminate:Tumor cell membranestaininghamperedforreasons attributedtothe handling. Not evaluable: Tumor tissue sample was not optimally collected or prepared and PD-L1 expressionis neither quantifiable nor indeterminate.Not evaluable can be determined from H&Eprocess before the tumorbiopsy specimen is sent for PD-L1 evaluation or                                                                                                                                                                                                                                        |
| To evaluate Health Related Quality of Life (HRQoL) as assessed by the European OrganisationforResearch andTreatmentofCare (EORTC) QLQ-C30                             | QLQ-C30 responses                                                                       | The QLQ-C30 has 30items divided among5 functional scales (physical, role, emotional, social, andcognitive),3symptom scales(fatigue,nausea and vomiting,and pain), a global health status/quality of life scale, and 6 single-item scales (dyspnea, insomnia, appetite loss,constipation, diarrhea, and financial difficulties).Two items measuringoverall health status andquality of life aregraded on a 7-point Likertscale while all remaining items are graded on a 4-point scale: 1 (not at all) to 4 (very much).                                                                                                                                                                                                                                                                                                                                                   |
| To assess changes in reported global health outcomes based on the EQ-5D index score                                                                                   | EQ-5D responses                                                                         | TheEQ-5Dis astandardizedinstrument used tomeasureself-reports ofgeneralhealth status.EQ-5Dessentially has 2 components: the EQ-5D descriptive system and the EQ following 5 dimensions:mobility, self-care, usual activities,pain/discomfort, and anxiety/depression.Each dimensionhas 3levels: no, moderate problems, and extreme health problems.The EQ-5DVAS recorded the subject's self-rated health state on a 100-point vertical VAS (0=worst imaginable health state; 100=best imaginable health state).                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

DOR and TTR were estimated in subjects with confirmed PR + CR. TTR is defined as the time from first dosing date to the date of the first confirmed response (CR or PR), as assessed by the BIRC. DOR is defined as the time from first confirmed response (CR or PR) to the date of the first documented tumour progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first.

## Sample size

Assuming ORR is 30%, 70 treated subjects with PD-L1 expression 5% would provide 99.1% power at 5% type 1 error to reject the null hypothesis of a two-sided test that the true ORR was 10% (single agent chemotherapy historical control) a threshold below which was considered not clinical meaningful in this population, and 90% power at 5% type I error to reject the null hypothesis of a two-sided test that the true ORR was 14.7%. Under the assumption of 32% prevalence rate of PD-L1 5% among all PD-L1 evaluable subjects, approximately up to 220 PD-L1 evaluable subjects would be treated. Assuming an additional 10% of treated subjects with PD-L1 indeterminate status, the total sample size was expected to be approximately 242.

Under the assumption of 50% prevalence rate of PD-L1 1% among all PD-L1 evaluable subjects, approximately up to 110 subjects with PD-L1 expression 1% would be treated. This would provide 90% power to reject the null hypothesis of ORR = 10% at a two-sided 5% type 1 error if the true ORR in this population was 20.6%.

For all treated subjects, a sample size of 242 would provide 90% power to reject the null hypothesis of ORR = 10% at a two-sided 5% type I error if the true ORR in this population was 16.9%.

The final analysis of the primary endpoint ORR (based on BIRC assessments) was to be performed six months after approximately 70 subjects with PD-L1 expression of 5% had been treated (i.e., six months after last patient first treatment).

## Randomisation

This was a single arm trial.

## Blinding (masking)

This was an open-label study. PD-L1 results were blinded to the investigator, subject and BMS study team.

## Statistical methods

Unless otherwise noted, discrete variables were tabulated by the frequency and proportion of subjects falling into each category, grouped by cohort (with total). Continuous variables were summarised by cohort (with total) using the mean, standard deviation, median, minimum and maximum values. ORR (both BIRC assessment and investigator-assessed) was summarised by a binomial response rate and its corresponding two-sided 95% exact CIs using the Clopper-Pearson method.  BOR was also summarised by response category.

Time to event distributions were estimated using Kaplan Meier techniques. This was done for endpoints progression free survival, overall survival, and duration of response (note that time to response was analysed using summary statistics such as mean, SD, median, min, max). Median survival time along with 95% CI were constructed based on a log-log transformed CI for the survivor function S(t). Rates at fixed time points were derived from the Kaplan Meier estimate and corresponding confidence interval were derived based on Greenwood formula for variance derivation and on log-log transformation applied on the survivor function S(t).

<div style=\"page-break-after: always\"></div>

## Table 6 Censoring Scheme for Primary Definition of PFS (Study CA209275)

<!-- image -->

| Situation                                                                                                  | DateofProgression orCensoring                                                                    | Outcome    |
|------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------|
| Nobaseline tumorassessments and no death                                                                   | First dosing date                                                                                | Censored   |
| Noonstudytumorassessmentsandno death                                                                       | First dosing date                                                                                | Censored   |
| Newanticancer treatment started withoutapriorreportedprogressionper RECIST1.1ordeath                       | Date oflast tumorassessment prior to oronthe dateofinitiationofthesubsequent anti-cancer therapy | Censored   |
| ProgressionperRECIST 1.1 documentedatscheduledorunscheduled visitandnonewanticancertreatment startedbefore | Dateofthefirstdocumentedtumorprogression                                                         | Progressed |
| Subjectprogressionfree(per RECIST1.1)and no new anticancer treatmentstarted                                | Dateoflasttumorassessment                                                                        | Censored   |
| Deathwithoutpriorprogressionper RECIST1.1andnonew anticancer treatmentstarted                              | Date of death                                                                                    | Progressed |

## Results

## Participant flow

Figure 3 Participant flow (updated efficacy data, Database lock (DBL) 2 Sept 2016)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 7 Subject Status Summary - All Enrolled and All Treated Subjects (Study CA209275) (updated efficacy data, DBL 2 Sept 2016)

| SUBJECTS FNROLIED                      | 386                              |
|----------------------------------------|----------------------------------|
| SUBJECTS TREATED (%)                   | 270 ( 69.9)                      |
| SUBJECTS NOT TREATED (%)               | 116 ( 30.1)                      |
| REASON FOR NOT BEING TREATED (6)       | REASON FOR NOT BEING TREATED (6) |
| ADVERSEEVENT                           | 6 1.6)                           |
| SUBJECT WITHDREWOONSENT                | 14 3.6)                          |
| DEATH                                  | 7 1.8)                           |
| FOOR/NON-OOMPLIANCE                    | 2 0.5)                           |
| SUBJECT NO IONGER MEETS STUDY CRITERIA | 80 20.7)                         |
| OTHER                                  | 7 1.8)                           |

End of Treatment Period Subject Status Sumary

All Treated Subjects

PD-L1 &lt;58

N = 187

SUBJECTS OONTINUING IN THE TRFATMENT FERIOD (8)

SUBJECTS NOT CONTINUING IN THE TRFATMENT FERIOD (3)

RFASON FOR NOT CONTINUING IN THE TREATMENT PERIOD (8)

DISEASE PROGRESSION

STUDY DRUG TOXICTTY

ADVERSEEVENTUNREIATEDTOSTUDYDRUG

SUBJECTREOUEST TODISOONTINUESTUDY TREAIMENT

SUBJECT WITHDREW CONSENT

ROOR/NONOOMPLIANCE

## Recruitment

The enrolment period lasted approximately 8 months (March 2015 to October 2015). The last patient last visit date (clinical cut-off) for this analysis was 15-Apr-2016, in order to provide pre-specified minimum follow-up of 6 months from the global enrolment last patient first treatment date of 15-Oct-2015. The clinical database lock for this analysis occurred on 30-May-2016. 386 subjects were enrolled at 63 sites in 11 countries. Of the 386 enrolled subjects, 270 (69.9%) were treated with nivolumab; 106 (39.3%) were in the US, 23 (8.5%) were in Japan, 135 (50.0%) in Europe, and 6 (2.2%) in Australia.

## Conduct of the study

The original CA209275 protocol was dated 30-Oct-2014. Four global amendments and 4 country-specific amendments were issued for this study. The history of Protocol Amendments is shown in Error! Reference source not found. .

29 ( 15.5)

158 ( 84.5)

108

57.81

28

11

5.9)

8

4.3)

15.01

0.51

0.5)

0.51

D-L1 &gt;=58

N = 83

26 ( 31.3)

57 ( 68.7)

42

50.6)

9.6)

7.21

1.2)

681000

All Treated Subjects

N = 270

55 ( 20.4)

215 ( 79.6)

150

(55.6)

36

17

6.31

9

3.3)

13.3)

0.4)

0.4)

0.4)

<div style=\"page-break-after: always\"></div>

## Table 8 Summary of Protocol Amendments (Study CA209275)

| Document (Sites)      | Date        | Summaryof Change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 01(DE)      | 26-Nov-2014 | In response to the German Health Authority request, HIV testing was added as a safety assessment at screening and a positive test for HIV was added as an exclusion criterion (3b).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Amendment 02 (A1)     | 17-Dec-2014 | Table 5.1-1ScreeningProcedural Outline,Table 5.1-2 On treatment PeriodProceduralOutline,andTable5.1-3Follow-upPeriod Procedural Outline; Laboratory tests: Added amylase and lipase. Section 5.3, Safety Assessments: Added amylase and lipase. Table 5.1- 2 OntreatmentPeriodProceduralOutline;Changedthetimingof EORTCQLQ-C30&EQ-5Dto:Assessedfollowingenrollmentbut prior to dosing on Day 1 and then at every 4th cycle up to 48 weeks, thenevery6thcycle until diseaseprogression or treatment is discontinued (whichever occurs later). Synopsis, Secondary Objectives; third bullet: changed to ≥ 1%.                                                                                                                                                                                                                                                                                                        |
| Amendment 03 (Sweden) | 26-Feb-2015 | In response to the Swedish Medical Products Agency which did not accept the contraception methods listed in Section 3.3.1.3 of the protocol, the following sections were updated: Inclusion Criteria, Age and Reproductive Status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Amendment 04 (All)    | 19-Mar-2015 | Changed thedefinitionofPD-L1positivityfrom≥1%to≥5% membranous staining in tumorcells andincreased the minimum of PD- L1positivesubjectsfrom58to70.Reduced theCreatinineClearance (CrC1)thresholdintheinclusioncriteriafrom≥40mL/min to≥30 mL/min. Other updates were made: the medical monitor, SAE reporting timeframesandcollectiontimeframes,statisticalconsiderations regarding sample size, and general protocol clarifications.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Amendment 05 (JP)     | 29-Apr-2015 | Local regulatoryrequirementsforJapanesesites were added.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Amendment 06 (All)    | 26-Aug-2015 | Included an analysis of Objective Response Rate, (ORR), in subjects with tumors expressing PD-L1 at ≥ 1% into the co-primary objective whichcurrentlyestimatesORRinall treatedandsubjectswithtumors expressing PD-L1 at ≥ 5%. ExtendedsubjectenrollmentinJapaniftheglobalenrollmentinthe  e   o rd ps s s  treatedsubjects(~10%oftheglobalnumberoftreatedsubjects),or untilNovember2015,whicheveroccurredsooner.Enrollmentintothe expression of (≥ 5% membranous staining) are treated. Subjects enrolledfromJapaninthemainstudywillbepartofthemainanalysis. Additional analyses will be also conducted on all enrolled Japanese subjects (including Japanese subjects enrolled after the global enrollment) and reported separately. Otherupdatesweremade:themedicalmonitor,statistical considerations regarding the PD-L1 tumor expression and extended enrollment in Japan, and general protocol clarifications. |

| Document (Sites)   | Date        | Summary of Change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 07 (JP)  | 03-Feb-2016 | Added changes to safety reporting requirements for serious adverse events(SAEs)inJapan, alongwith otherminor changes.These changes in the protocol were incorporated into the Amendment 05 prepared for the local regulatory requirements for Japanese sites and apply to all subjects enrolled in Japan.                                                                                                                                                                                          |
| Amendment 08 (All) | 22-Feb-2016 | Thepurpose of this amendment was toclarify themilestone timing and population for the primary analysis. In this amendment, it was clarified thatsubjectsinJapan,whostartedtreatment afterlastpatientfirst treatmentdateofsubjectswhowereenrolledbeforeclosureofglobal enrollment, were not be included in the efficacy analysis. Additionally, other items were updated, change to the study's Medical Monitor, new fax number for the Study Director, correction to a footnote in table5.6.2.6-1. |

<div style=\"page-break-after: always\"></div>

## Relevant Protocol Deviations

Relevant protocol deviations (significant protocol deviations that were programmable and could potentially affect the interpretability of study results) were reported in 3.3% of subjects. The most common relevant protocol deviation at study entry (eligibility deviation) was subjects failing to progress or recur after prior platinum treatment (1.1%). The most common relevant protocol deviation during the treatment period was receipt of concurrent anti-cancer therapy (other than palliative limited field radiation therapy or palliative surgical resection), affecting 1.9% of subjects.

## Table 9 Relevant Protocol Deviations - All Treated Subjects (Study CA209275)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Nrber of Subjects()       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | All Treated subjects OLZN |
| SUBJSCTS HITH ATLEAST CNE DEVIATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 9(3.3)                    |
| AT DRAE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                           |
| SUBJDCTSWITHBASELDE EODGFERGURMANLE STAGUS>I(A)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1(0.4)                    |
| SUBUDCTSWITHOUTMEASURAELE DISEASEAT BASSLINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0                         |
| SUBJECTS MHD DID NDT ROCEIVE PRIOR TREAIMENTHITHAT LEAST ONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0                         |
| SUBJECTS NHD DID NDT PROGRESS CR DID NOT FOCLR AFTERPRICR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3(1.1)                    |
| CIHTREAIMENT DEVTATIONS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                           |
| SUBJSLTS ROCEIVDG ATI-CACER THERAPY KHTLE CN STUOY THERAPY (D)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 5(1.9)                    |
| (Asbjec hda PSof3atDay 1 (first dy ofdosing）.PSatscreening s 1. the subject opivrd onily1 dose ofnivolurabbefone disoontinuing doe toanunrelatedewntof respiratory tailure. (B)Includes1sbject withoutrecurrenoe afoerpriorplatinum therapyand2subjects ho sburnesueanpe/oeuutaustneanhutetsopdtejesquowztueqetoupetmoar (C)ono subject didnothve a progmession date peporoed that as associated with aprior platinn regumn, but did progress after a prior regimen within the protoool definedwindow frn last dose ofplatinim,and is therefore nota deviation. (D)Subject nsideneda dwiation sinoo Fluorouracil was addnistered as a topical cream.Subject nolonger considered a dewiation because antinecplasticagent was started after last dooe of nivolumab,but deviation algorithm is bised cn imvestigator-reported date of decisicn to disoontinue nivolumab treataent. |                           |

## Baseline data

Demographic and baseline disease characteristics are shown in Table 10 and Table 11, respectively.

<div style=\"page-break-after: always\"></div>

## Table 10 Baseline Demographic Characteristics - All Treated Subjects (Study CA209275)

|                                      | All Treated Subjects N = 270   |
|--------------------------------------|--------------------------------|
| ACE (YEARS)                          |                                |
| N                                    | 270                            |
| MEAN                                 | 65.0                           |
| MEDIAN                               | 66.0                           |
| MINMOX                               | 38，90                          |
| STANDARDDEVIATION                    | 9.38                           |
| AGECATDGORIZATION(%)                 |                                |
| <65                                  | 122 (45.2)                     |
| >=65AND< 75                          | 110 40.7)                      |
| >= 75 AND < 85                       | 35 13.0)                       |
| Y85                                  | 3 1.1)                         |
| >= 75                                | 38 14.1)                       |
| >= 65                                | 148 (54.8)                     |
| GENDER (%)                           |                                |
| MALE                                 | 211 (78.1)                     |
| FEMATE                               | 59 (21.9)                      |
| RACE (%)                             |                                |
| WHITE                                | 231 1( 85.6)                   |
| BLACKORADRICANAMERICAN               | 2 0.7)                         |
| ASIAN                                | 30 11.1)                       |
| AMERICAN INDIAN OR AIASKANATIVE      | 0:0                            |
| NATIVEHAWAIIANCROIHDRPACIFICISLANDER |                                |
| OIHER                                |                                |
| NOT REPORTED                         |                                |
| EIHNICITY (%)                        |                                |
| HISPANIC ORLATINO                    | 2 0.7)                         |
| NOTHISPANICORLATINO                  | 156 57.8)                      |
| NOTREPORTED                          | 112 (41.5)                     |
| RDGION                               |                                |
| Sn                                   | 106 ( 39.3)                    |
| JAPAN                                | 23 8.5)                        |
| ROW                                  | 141 52.2)                      |

<div style=\"page-break-after: always\"></div>

Table 11 Baseline Disease Characteristics and Tumour Assessments- All Treated Subjects (Study CA209275)

|                                                                                                                     | All Treated Subjects N =270                    |
|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| CURRENT(SIUDY ENIRY)DIAGNOSIS TUMOR TYPE(%) URINARY BLADDER RENAL PELVIS URETER URETHRA                             | 197 ( 73.0) 46 (17.0) 19 7.0) 8(3.0)           |
| CURRENT (SIUDYENIRY)DISEASE SETTING() METASTATIC LOCALLY UNRESECTABLE/NON-METASTATIC                                | 261 (96.7) 9(3.3)                              |
| PERFORMANCE STATUS(ECOG)[%] 0 1 3                                                                                   | 145 ( 53.7) 124 (45.9) 1 (0.4)                 |
| BASELINE LIVER METASTASIS (A) YES NO                                                                                | 75 (27.8) 195 ( 72.2)                          |
| BASELINE VISCERAL METASTASIS (A)(B) YES NO                                                                          | 227 (84.1) 43 ( 15.9)                          |
| BASELINE LYMPH NODE ONLY (A) YES NO                                                                                 | 43 (15.9) 227 (84.1)                           |
| BASELINE CNS METASTASIS (A) (C) YES NO                                                                              | 269 ( 99.6) 1 (.0.4)                           |
| BASELINEHEMOGLOBIN <10G/DL >10 G/DL                                                                                 | 48 (17.8) 222 (82.2)                           |
| BASELINECREATININECIEARANCE <30ML/MN 30-<60ML/MIN >=60 ML/MIN NOT REPORTED                                          | 5 (1.9) 102 (37.8) 162 60.0) 1 0.4)            |
| SMOKING STATUS CURRENT/EORMER NEVER SMOKED UNKNOWN                                                                  | 194 71.9) 67 24.8) 6 3.3)                      |
| 0 12                                                                                                                | 111 41.1) 46 15                                |
|                                                                                                                     | All Treated Subjects                           |
| SUBJECIS WITH AT LEAST ONE IESION (E)(%) SITE OF LESION (D) (E) (%) ABDOMINAL WAIL ADRENAL GLAND BLADDER BONE BRAIN | N =270 270 (100.0)                             |
| DIAPHRAGM KIDNEY                                                                                                    | 28 29 50 2                                     |
| LIVER                                                                                                               |                                                |
|                                                                                                                     | 3                                              |
| LUNG                                                                                                                |                                                |
| OIHER                                                                                                               |                                                |
| PANCREAS                                                                                                            |                                                |
| PERITONEUM PLEURA PUBIC BONE                                                                                        | 15 5.6) 11 6                                   |
| SKIN                                                                                                                |                                                |
| SOFT TISSUE                                                                                                         | 1 7 2                                          |
| SPLEEN URETER                                                                                                       |                                                |
| 1                                                                                                                   |                                                |
| NUMBER OF SITES WITH AT IEAST ONE IESION (E)(%)                                                                     |                                                |
| 23                                                                                                                  |                                                |
| 4                                                                                                                   | 29 11                                          |
| NUMBEROFBELIMUNT RISKFACTORS                                                                                        | 86 36.3)                                       |
| 3                                                                                                                   | 17.0) 5.6)                                     |
|                                                                                                                     | 0.4) 85 ( 31.5) 94                             |
|                                                                                                                     | 10                                             |
|                                                                                                                     | 51                                             |
|                                                                                                                     | 34.8)                                          |
|                                                                                                                     | (18.9)                                         |
| SUM OFREFERENCEDIAMETERS OFTARGETIESIONS                                                                            |                                                |
|                                                                                                                     | (10.7) 4.1)                                    |
|                                                                                                                     | 247 ( 91.5)                                    |
| MEDIAN (MIN - MAX)                                                                                                  |                                                |
|                                                                                                                     | 61.0 (12 - 252)                                |
| (MM)                                                                                                                |                                                |
| SUBJECISWITHATIEASTONETARGETIESION（)                                                                                | 4.1) 2.2) 1 0.4) 3.7) 0.4) 2.6) 0.7)           |
|                                                                                                                     | 12 4.4) 75 27.8) 1.1) 130 48.1) 171 63.3) 0.7) |
|                                                                                                                     | REIROPERITONEUM                                |
|                                                                                                                     | 0.4) 0.7) 1 0.4)                               |
|                                                                                                                     | 25： 1.9) 0.4) 2 0.7) 30 11.1)                  |
| MUSCIE PELVIS                                                                                                       |                                                |
| MESENTERY                                                                                                           |                                                |
| LUMBAR VERTEBRA LYMPH NODE                                                                                          | CHEST WALL                                     |
|                                                                                                                     | 10.7) 18.5)                                    |
|                                                                                                                     | 10.4)                                          |
|                                                                                                                     | 3 1.1)                                         |

(A) perBIRCassessment B No if subject has lymph node only lesions and/or lesions only located in bladder, ureter, urethra and renal pelvis

(D)Subjects may have lesions at more than one site

(C) per protocol, MRI brain prior to first dose was required for subjects with history of brain metastasis

(E)Includes both target and non-target lesions

Prior cancer therapies of all treated subjects are included in Table 12

<div style=\"page-break-after: always\"></div>

## Table 12 Prior Cancer Therapy Summary - All Treated Subjects (Study CA209275)

|                                                                                          | All Treated Subjects N = 270   |
|------------------------------------------------------------------------------------------|--------------------------------|
| SUBJECTS WITH PRIOR REGIMEN IN METASTATIC DISEASE SETTING (%)                            | 193 ( 71.5)                    |
| NUMBER OF PRIOR SYSTEMIC REGIMEN IN METASTATIC SETTING                                   |                                |
| 0                                                                                        | 77 （ 28.5)                     |
| 1                                                                                        | 114 42.2)                      |
| 2                                                                                        | 57 21.1)                       |
| >3                                                                                       | 22 8.1)                        |
| SUBJECTS WITHPRIORREGIMEN INADJUVANT THERAPY SETTING(%)                                  | 83 ( 30.7)                     |
| SUBJECTS WITH PRIOR REGIMEN IN NEO-ADJUVANT THERAPY SETTING (%)                          | 60 ( 22.2)                     |
| PRIOR PLATINUM CONTAINING REGIMEN IN ANY SEITING                                         | 270 (100.0)                    |
| PRIOR PLATINUM DRUGSIN METASTATIC SETTING                                                | 179 66.3)                      |
| CISPLATIN ONLY                                                                           | 98 36.3)                       |
| CARBOPLATIN ONLY                                                                         | 61 22.6)                       |
| BOIH CISPLATIN AND CARBOPLATIN                                                           | 20 7.4)                        |
| OIHER                                                                                    | 0                              |
| SUBJECTS WITH PRIOR PLATINUM CONTAINING REGIMEN ASSOCIATED WITH RECURRENCE/PROGRESSION   | 269 ( 99.6)                    |
| MOST RECENT PRIOR PLATINUM CONTAININGREGIMEN ASSOCIATEDWITH                              |                                |
| RECURRENCE/PROGRESSION                                                                   |                                |
| RECEIVED IN NEO-ADJUVANT OR ADJUVANT SETTING (A)                                         | 92 ( 34.2)                     |
| TIMINGOFRECURRENCE/PROGRESSION: INDETERMINATE                                            | 1 0.4) 2 0.7)                  |
| RECURRENCE/PROGRESSIONMORETHAN 12MOOFLASTDOSE RECURRENCE/PROGRESSIONWITHIN12MOOFIASTDOSE | 89 (33.1)                      |
| PLATINUM DRUGS: BOIH CISPLATIN AND CARBOPLATIN                                           | 0 18 6.7)                      |
| CARBOPLATINONLY CISPLATINONLY OTHER                                                      | 74 (27.5) 0                    |
| RECEIVED IN METASTATIC SETTING (A)                                                       | 177 ( 65.8)                    |
| PLATINUM DRUGS: BOIHCISPLATIN ANDCARBOPLATIN                                             | 0.4)                           |
| CARBOPLATINONLY CISPLATIN ONLY                                                           | 71 26.4)                       |
| OTHER                                                                                    | 105 (39.0) 0                   |
| TO RECURRENCE/PROGRESSION (MONIHS）(A)                                                    |                                |
| <3MONIHS                                                                                 | 158 (58.7)                     |
| SHINON9>-                                                                                |                                |
|                                                                                          | (14.5)                         |
| NO                                                                                       | B6 器                           |
|                                                                                          | 57 (21.2)                      |
| 6-<12MONTHS                                                                              | 39                             |
| >=12MONTHS                                                                               | 15 5.6)                        |
| PRIOR SURGERY RELATEDTOCANCER                                                            |                                |
| YES                                                                                      |                                |
| PRIOR RADIOTHERAPY                                                                       | 85 (31.5)                      |
| YES NO                                                                                   | 185 ( 68.5)                    |

recurrence/progression

Table 13 Baseline poor prognostic factors per PD-L1 expression cohort (Study CA209275) (updated efficacy data, DBL 2 Sept 2016)

| Baseline poor prognostic factors    | PD-L1 < 1% n=146    | PD-L1 ≥ 1% n=124    | PD-L1 < 5% n=187    | PD-L1 ≥ 5% n=81   |
|-------------------------------------|---------------------|---------------------|---------------------|-------------------|
| ECOG PS≥1                           | 74 (50.7)           | 51 (41.1)           | 91(48.6)            | 34 (41.0)         |
| Liver metastasis                    | 44 (30.1)           | 31 (25.0)           | 52 (27.8)           | 23 (27.7)         |
| Hb <10 G/DL                         | 30 (20.5)           | 18 (14.5)           | 35 (18.7)           | 13 (15.7)         |
| Number of Bellmunt risk factors 0 1 | 49 (33.6) 56 (38.4) | 49 (39.5) 55 (44.5) | 66 (35.3) 75 (40.1) | 32 (38.6)         |
|                                     |                     |                     |                     | 36 (43.4)         |
| 2                                   | 31 (21.2)           | 15 (12.1)           | 35 (18.7)           | 11 (13.3)         |
| 3                                   | 10 (6.8)            | 5 (4.0)             | 11 (5.9)            | 4 (4.8)           |

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The number of subjects included in the population analysis is summarised in Table 10

Table 14 Analysis Populations (Study CA209275)

| Population                                                                                                                                                                                     |   Number of Subjects |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Enrolled Subjects:All subjectswho signed an informed consent form and were registered into the IVRS. This is the population for pre-treatment disposition.                                     |                  386 |
| TreatedSubjects:All subjectswhoreceived at least one dose of nivolumab. This is the population for baseline demographics and disease characteristics, efficacy, safety, and dosing evaluation. |                  270 |
| PD-L1 < 1% Subjects : All treated subjects with baseline PD-L1 expression less than 1%                                                                                                         |                  146 |
| PD-Ll ≥ 1% Subjects : All treated subjects with baseline PD-L1 expression greater than or equal to 1%                                                                                          |                  124 |
| PD-L1 < 5% Subjects: All treated subjects with baseline PD-L1 expression less than 5%                                                                                                          |                  187 |
| PD-L1 ≥ 5% Subjects: All treated subjects with baseline PD-L1 expression greater than or equal to 5%                                                                                           |                   83 |

## Outcomes and estimation

The efficacy data were provided initially with a minimum follow up of 6 months (Data cutoff 15-Apr-2016; DBL 30-May-2016) and were updated during the procedure with an additional 3 months of follow-up (minimum follow-up of 8.3 months) (Data cutoff 21 July 2016; DBL 2-Sept-2016).

## · Primary endpoint (ORR per BIRC) (DBL 30-May-2016)

Treatment with nivolumab led to an ORR of 19.6% (95% CI: 15.0, 24.9) in all treated subjects, 23.8% (95% CI: 16.5, 32.3) in PD-L1 ≥ 1% cohort, and 28.4% (95% CI: 18.9, 39.5) in PDL1 ≥ 5% cohort (Table 15). Six subjects achieved a CR. The ORR was 16.1% (95% CI: 10.5, 23.1) in PD-L1 &lt;1% cohort and 15.8% (95% CI: 10.8, 21.8) in PD-L1 &lt;5% cohort.

13 additional subjects had unconfirmed responses (1 CR and 12 PRs) per BIRC. Another 3 subjects with confirmed responses of PR had unconfirmed responses of CR.

<div style=\"page-break-after: always\"></div>

Table 15 Summary of Efficacy Results All Treated Subjects (study CA209275)

|                                                         | PD-L1<1% N=143                                          | PD-L1≥1% N=122                                          | PD-L1<5% N =184                                         | PD-L1≥5% N=81                                           | AllTreated Subjects N=265                               |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint             | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint             | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint             | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint             | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint             | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint             |
| N Responders (%)                                        | 23 (16.1)                                               | 29 (23.8)                                               | 29 (15.8)                                               | 23 (28.4)                                               | 52 (19.6)                                               |
| 95% CIa                                                 | (10.5, 23.1)                                            | (16.5, 32.3)                                            | (10.8, 21.8)                                            | (18.9, 39.5)                                            | (15.0,24.9)                                             |
| Confirmed ORR(CR+PR)per Investigator -SecondaryEndpoint | Confirmed ORR(CR+PR)per Investigator -SecondaryEndpoint | Confirmed ORR(CR+PR)per Investigator -SecondaryEndpoint | Confirmed ORR(CR+PR)per Investigator -SecondaryEndpoint | Confirmed ORR(CR+PR)per Investigator -SecondaryEndpoint | Confirmed ORR(CR+PR)per Investigator -SecondaryEndpoint |
| N Responders (%)                                        | 29 (20.3)                                               | 32 (26.2)                                               | 35 (19.0)                                               | 26 (32.1)                                               | 61 (23.0)                                               |
| 95% CIa                                                 | (14.0, 27.8)                                            | (18.7,35.0)                                             | (13.6, 25.4)                                            | (22.2,43.4)                                             | (18.1,28.6)                                             |
| DORperBIRC                                              | DORperBIRC                                              | DORperBIRC                                              | DORperBIRC                                              | DORperBIRC                                              | DORperBIRC                                              |
| Events/Responders                                       | 4/23 (17.4)                                             | 6/29 (20.7)                                             | 7/29 (24.1)                                             | 3/23 (13.0)                                             | 10/52 (19.2)                                            |
| Median (95% CI) Months                                  | N.A. (7.43, N.A.)                                       | N.A. (7.52, N.A.)                                       | 7.52 (7.43, N.A.)                                       | N.A.                                                    | N.A. (7.43, N.A.)                                       |
| Min, Max (Months)c                                      | 1.9+, 9.4+                                              | 1.9+,9.6+                                               | 1.9+, 9.4+                                              | 1.9+,9.6+                                               | 1.9+,9.6+                                               |
| Subjects with Ongoing Response per BIRC,N (%)           | 19 (82.6)                                               | 21 (72.4)                                               | 22 (75.9)                                               | 18 (78.3)                                               | 40 (76.9)                                               |
| PFSperBIRC-Secondary Endpoint                           | PFSperBIRC-Secondary Endpoint                           | PFSperBIRC-Secondary Endpoint                           | PFSperBIRC-Secondary Endpoint                           | PFSperBIRC-Secondary Endpoint                           | PFSperBIRC-Secondary Endpoint                           |
| N Events (%)                                            | 113 (79.0)                                              | 88 (72.1)                                               | 149 (81.0)                                              | 52 (64.2)                                               | 201 (75.8)                                              |
| Median (95% CI) Months                                  | 1.87 (1.77, 2.04)                                       | 3.55 (1.94, 3.71)                                       | 1.87 (1.81, 2.10)                                       | 3.71 (1.91, 5.55)                                       | 2.00 (1.87, 2.63)                                       |
| PFSperInvestigator-ExploratoryEndpoint                  | PFSperInvestigator-ExploratoryEndpoint                  | PFSperInvestigator-ExploratoryEndpoint                  | PFSperInvestigator-ExploratoryEndpoint                  | PFSperInvestigator-ExploratoryEndpoint                  | PFSperInvestigator-ExploratoryEndpoint                  |
| N Events (%)                                            | 112 (78.3)                                              | 88 (72.1)                                               | 146 (79.3)                                              | 54 (66.7)                                               | 200 (75.5)                                              |
| Median(95% CI) Months                                   | 1.94 (1.81, 2.33)                                       | 3.65 (1.94, 5.32)                                       | 2.00 (1.87,2.37)                                        | 3.71 (1.87, 5.72)                                       | 2.10 (1.87,2.83)                                        |

|                           | PD-L1< 1% N=143   | PD-L1≥1% N=122     | PD-L1<5% N =184   | PD-L1≥5% N=81      | AllTreatedSubjects N =265   |
|---------------------------|-------------------|--------------------|-------------------|--------------------|-----------------------------|
| OS-Secondary Endpoint     |                   |                    |                   |                    |                             |
| NEvents (%)               | 83 (58.0)         | 52 (42.6)          | 102 (55.4)        | 33 (40.7)          | 135 (50.9)                  |
| Median (95% CI) Months    | 5.95 (4.30, 8.08) | 11.30 (8.74, N.A.) | 6.24 (5.03, 9.49) | 11.30 (9.63, N.A.) | 8.74 (6.05, N.A.)           |
| Rate at 6 Months (95% CI) | 49.7 (41.2,57.6)  | 65.4(56.2,73.1)    | 51.5(44.0,58.5)   | 69.1 (57.8, 78.0)  | 57.0 (50.7, 62.7)           |

a CR+PR, confidence interval based on the Clopper and Pearson method. RECIST 1.1, confirmation of response required

Kaplan-Meier estimate

Symbol + indicates censored value.

Treated subjects from Japan enrolled after the main enrollment period are excluded.

ORR: objective response rate; CR: complete response; PR: partial response; DOR: duration of response; PFS: progression-fee survival; OS: overall survival.

## Table 16 Best Overall Response and Objective Response Rate per BIRC Assessment (study CA209275)

|                             | Number or Subjects (%)   | Number or Subjects (%)   | Number or Subjects (%)   | Number or Subjects (%)   | Number or Subjects (%)     |
|-----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------|
|                             | PD-L1<1% N = 143         | PD-L1 >=1 N = 122        | PD-L1<5% N = 184         | PD-L1 >=5 N = 81         | All Treated Subjects N=265 |
| BESTOVERAILRESPONSE         |                          |                          |                          |                          |                            |
| COMPLETERESPONSE(CR)        | (0.7)                    | 5 4.1)                   | 2(.1.1)                  | 4 (4.9)                  | 6 (2.3)                    |
| PARTIALRESPONSE(PR)         | 22 15.4)                 | 24 19.7)                 | 27 (14.7)                | 19 (23.5)                | 46 (17.4)                  |
| STABLE DISEASE (SD)         | 25 17.5)                 | 35 28.7)                 | 37 (20.1)                | 23 ( 28.4)               | 60 22.6)                   |
| PROGRESSIVE DISEASE (PD)    | 67 46.9)                 | 37 30.3)                 | 83 (45.1)                | 21 ( 25.9)               | 104 (39.2)                 |
| UNABIE TO DETERMINE (UTD)   | 28 (19.6)                | 21 (17.2)                | 35 (19.0)                | 14 ( 17.3)               | 49 (18.5)                  |
| OBJECTIVE RESPONSE RATE (1) | 23/143 (16.1%)           | 29/122 (23.8%)           | 29/184 (15.8%)           | 23/81 (28.4%)            | 52/265 (19.6%)             |
| (95%CI)                     | (10.5, 23.1)             | (16.5, 32.3)             | (10.8, 21.8)             | (18.9, 39.5)             | (15.0, 24.9)               |

REcIsT 1.1,confirmation of response reqquired (1）CR+PR,confidence intervalbasedontheClopperandPearson method Treatedsubjects\\_frcmJapanenrolledaftermainenrollmentperiodareexcluded

<div style=\"page-break-after: always\"></div>

Figure 4 Waterfall Plot of Best Reduction from Baseline in Sum of Diameters of Target Lesions per BIRC Response Evaluable Subjects (study CA209275)

<!-- image -->

## · Secondary endpoints (DBL 30-May-2016)

## ORR by investigator

Investigator-assessed ORR results are shown in Table 17.

Table 17 Best Overall Response and Objective Response Rate per Investigator - All Treated Subjects (study CA209275)

|                                                                                                                                                                                                                             | Number or Subjects (%)                                     | Number or Subjects (%)                                                 | Number or Subjects (%)                                                | Number or Subjects (%)                                             | Number or Subjects (%)                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------|
|                                                                                                                                                                                                                             | PD-L1 <18 N = 143                                          | PD-L1 >=1& N = 122                                                     | PD-L1 <5 N = 184                                                      | PD-L1 >=5% N = 81                                                  | All Treated Subjects N = 265                                                |
| BESTOVERALLRESFONSE                                                                                                                                                                                                         | BESTOVERALLRESFONSE                                        | BESTOVERALLRESFONSE                                                    | BESTOVERALLRESFONSE                                                   | BESTOVERALLRESFONSE                                                | BESTOVERALLRESFONSE                                                         |
| COMPLETERESFONSE(OR) PARTIAL RESPONSE (PR) STABLE DISEASE (SD) PROGRESSIVEDISEASE (PD) UNABLETODEIERMINE(UTD) NEVER TREATED WRONG CANCER DIAGNOSIS DEATHPRIOR TODISEASEASSESSMENT FARIYDISCONTINUATION DUETO TOXICITY OTHER | 2 1.4) 248200g 18.9) 16.8) 47.6) (15.4) 21 (14.7) 1 0.7) 0 | 5 4.1) 27 22.1) 33 27.0) 40 32.8) 17 13.9) 0 0 15 (12.3) 1 0.8) 1 0.8) | 2 1.1) 33 17.9) 37 20.1) 83 45.1) 29 15.8) 0 0 26 14.1) 2 1.1) 1 0.5) | 5 6.2) 21 (25.9) 20 (2 24.7) 25 (30.9) 10 (12.3) 0 0 10 (12.3) 0 0 | 7 (2.6) 54 ( 20.4) 57 21.5) 108 40.8) 39 (14.7) 0 0 36 (13.6) 2 0.8) 1 0.4) |
| OBJECTIVE RESPONSE RATE(1) (95%CI)                                                                                                                                                                                          | 29/143 (20.3%)                                             | 32/122 (26.2%)                                                         | 35/184 (19.0%)                                                        | 26/81 (32.1%)                                                      |                                                                             |
|                                                                                                                                                                                                                             | (14.0, 27.8)                                               | (18.7, 35.0)                                                           | (13.6, 25.4)                                                          | (22.2,43.4)                                                        | 61/265 ( 23.0%) (18.1, 28.6)                                                |

RECIsT 1.1,oonfirmation of response required

(1) CR+PR, confidenoe interval based on the Clopper and Pearson method

Source:Table7.2.2-1oftheCA209275CSR

## Progression-free Survival (PFS) per BIRC

The median PFS was 2.00 months in All Treated subjects, 3.55 months in PD-L1 ≥ 1% cohort, and 3.71 months in PD-L1 ≥ 5% cohort. The median PFS was 1.87 months in both PD-L1 &lt; 1% andPD-L1 &lt; 5% cohorts. 64 (24.2%) subjects were censored. 59 (22.3%) subjects had their PFS time censored on the date of last on-study tumour assessment. The most common reason for censoring among these subjects was 'still on treatment'.

<div style=\"page-break-after: always\"></div>

Figure 5 Kaplan-Meier Plot of Progression-free Survival per BIRC - All Treated Subjects (study CA209275)

<!-- image -->

## Overall Survival (OS)

The median OS was 8.74 months (95% CI: 6.05, N.A.) in all treated subjects, 11.30 months (95% CI: 8.74, N.A.) in PD-L1 ≥ 1% cohort, and 11.30 months (95% CI: 9.63, N.A.) inPD-L1 ≥ 5% cohort. The median OS was 5.95 months (95% CI: 4.30, 8.08) in PD L1 &lt; 1% cohort and 6.24 months (95% CI: 5.03, 9.49) in PD L1 &lt; 5% cohort.

Figure 6 Kaplan-Meier Plot of Overall Survival - All Treated Subjects (study CA209275)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Median follow-up for OS (time between first dose and last known date alive or death) was 7.00 months (range: 0.1 - 13.4 months) among all treated subjects.

## Updated data (DBL 2 Sept 2016)

In this updated analysis, all 270 treated subjects were analysed for efficacy, including 5 Japanese subjects excluded from the primary efficacy analysis due to insufficient follow-up. This update of efficacy provides an additional 3 months of follow-up (minimum follow-up of 8.3 months) since the time of the primary analysis for study CA209275.

In the updated analysis, treatment with nivolumab led to an ORR of 20.0% (95% CI: 15.4, 25.3) in all treated subjects, 25.0% (95% CI: 17.7, 33.6) in the PD-L1 ≥1 % cohort, and 30.1% (95% CI: 20.5, 41.2) in the PD-L1 ≥ 5% cohort.

There were 16 additional deaths at the time of this data cut-off. Among all treated subjects, the updated median OS of 8.57 months (95% CI: 6.05, 11.27) was similar to the median OS in the primary analysis (8.74 months [95% CI: 6.05, N.A.]).

More than half (34/54, 63.0%) of the responders had ongoing response at the time of the clinical cut-off for this analysis.

The median DOR was 7.59 months in subjects with PD-L1 expression &lt; 5%, but was not reached in the PD-L1 ≥ 1% or PD-L1 ≥ 5% cohorts.

Table 18 Summary of efficacy results (study CA20275)-updated analysis (DBL 2 Sept 2016)

<!-- image -->

|                                                       | PD-L1 <1% N=146                                       | PD-L1≥1% N=124                                        | PD-L1 <5% N=187                                       | PD-L1≥5% N=83                                         | All Treated Subjects N=270                            |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint           | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint           | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint           | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint           | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint           | Confirmed ORR(CR+PR)perBIRC-PrimaryEndpoint           |
| N Responders (%)                                      | 23 (15.8)                                             | 31 (25.0)                                             | 29 (15.5)                                             | 25 (30.1)                                             | 54 (20.0)                                             |
| 95% CIa                                               | (10.3, 22.7)                                          | (17.7, 33.6)                                          | (10.6, 21.5)                                          | (20.5, 41.2)                                          | (15.4, 25.3)                                          |
| Confirmed ORR(CR+PR)perInvestigator-SecondaryEndpoint | Confirmed ORR(CR+PR)perInvestigator-SecondaryEndpoint | Confirmed ORR(CR+PR)perInvestigator-SecondaryEndpoint | Confirmed ORR(CR+PR)perInvestigator-SecondaryEndpoint | Confirmed ORR(CR+PR)perInvestigator-SecondaryEndpoint | Confirmed ORR(CR+PR)perInvestigator-SecondaryEndpoint |
| N Responders (%)                                      | 28 (19.2)                                             | 34 (27.4)                                             | 35 (18.7)                                             | 27 (32.5)                                             | 62 (23.0)                                             |
| 95% CIa                                               | (13.1, 26.5)                                          | (19.8, 36.2)                                          | (13.4, 25.1)                                          | (22.6, 43.7)                                          | (18.1, 28.4)                                          |
| DOR per BIRC                                          | DOR per BIRC                                          | DOR per BIRC                                          | DOR per BIRC                                          | DOR per BIRC                                          | DOR per BIRC                                          |
| Events/Responders (%)                                 | 10/23 (43.5)                                          | 8/31 (25.8)                                           | 13/29 (44.8)                                          | 5/25 (20.0)                                           | 18/54 (33.3)                                          |
| Median (95% CI Monthsb                                | 10.35 (7.43, N.A.)                                    | N.A. (7.52, N.A.)                                     | 7.59 (7.43, N.A.)                                     | N.A.                                                  | 10.35 (7.52, N.A.)                                    |
| Min, Max (Months)c                                    | 3.7, 12.0+                                            | 1.9+, 12.0+                                           | 3.7, 12.0+                                            | 1.9+, 12.0+                                           | 1.9+, 12.0+                                           |
| Subjects with Ongoing Response per BIRC N(%)          | 13 (56.5)                                             | 21 (67.7)                                             | 16 (55.2)                                             | 18 (72.0)                                             | 34 (63.0)                                             |
| PFS per BIRC - Secondary Endpoint                     | PFS per BIRC - Secondary Endpoint                     | PFS per BIRC - Secondary Endpoint                     | PFS per BIRC - Secondary Endpoint                     | PFS per BIRC - Secondary Endpoint                     | PFS per BIRC - Secondary Endpoint                     |
| N Events (%)                                          | 124 (84.9%)                                           | 92 (74.2)                                             | 160 (85.6)                                            | 56 (67.5)                                             | 216 (80.0)                                            |
| Median (95% CI) Monthsb                               | 1.87 (1.77, 2.04)                                     | 3.55 (1.94, 3.71)                                     | 1.91 (1.84, 2.10)                                     | 3.71 (1.91, 5.55)                                     | 2.00 (1.87, 2.63)                                     |

<div style=\"page-break-after: always\"></div>

|                            | PD-L1<1% N=146       | PD-L1≥ 1% N=124      | PD-L1<5% N=187       | PD-L1≥ 5% N=83       | AllTreated Subjects N=270   |
|----------------------------|----------------------|----------------------|----------------------|----------------------|-----------------------------|
| OS-SecondaryEndpoint       | OS-SecondaryEndpoint | OS-SecondaryEndpoint | OS-SecondaryEndpoint | OS-SecondaryEndpoint | OS-SecondaryEndpoint        |
| N Events (%)               | 93 (63.7)            | 61 (49.2)            | 114 (61.0)           | 40 (48.2)            | 154 (57.0)                  |
| Median (95% CI Monthsb     | 5.95 (4.37, 8.08)    | 11.63 (9.10, N.A)    | 6.24 (4.96, 8.74)    | 12.94 (9.63, N.A.)   | 8.57 (6.05, 11.27)          |
| Rate at 6 months (95% CI)b | 49.3 (40.9, 57.2)    | 65.2 (56.1, 72.8)    | 51.2 (43.7, 58.1)    | 68.7 (57.5, 77.5)    | 56.6 (50.5, 62.3)           |
| Rate at 9 months (95% CIb  | 40.1 (32.1, 48.0)    | 59.5 (50.3, 67.5)    | 42.9 (35.6, 49.9)    | 62.7 (51.3, 72.1)    | 49.1 (42.9, 54.9)           |
| Rate at 12 months (95% CIb | 34.0 (26.1,42.1)     | 49.2 (39.6, 58.1)    | 36.9 (29.7, 44.1)    | 50.3 (38.3,61.1)     | 41.0 (34.8,47.1)            |

(a) CR+PR, confidence interval based on the Clopper and Pearson method RECIST 1.1, confimmation of response required

(b)Kaplan-Meierestimate

(c)Symbol+indicatescensoredvalue.

ORR: objective response rate;CR: complete response; PR: partialresponse;DOR: duration ofresponse; PFS: progression fee suuvival; OS: overall suvival.

## Ancillary analyses

## ORR - Sensitivity analysis

In one sensitivity analysis, all time point responses contributed to the BOR, regardless of start of subsequent therapy (palliative/curative radiotherapy, surgery or systemic therapy). In this analysis, the ORR was 20.0% (95% CI: 15.4, 25.3) in all treated subjects, 24.6% (95% CI: 17.2, 33.2) in PD-L1 ≥ 1% cohort, and 29.6% (95% CI: 20.0, 40.8) in PD-L1 ≥ 5% cohort. In the other sensitivity analysis, subjects who progressed within 1 month of start of treatment due to new brain lesion without evidence of baseline brain lesion (most subjects did not get baseline brain MRI as it was only required if there was a history of brain metastases), were excluded. In this analysis, the ORR was 19.9% (95% CI: 15.3, 25.3) in all treated subjects, 23.8% (95% CI: 16.5, 32.3) in PD-L1 ≥ 1% cohort and 28.4% (95% CI: 18.9, 39.5) in PD-L1 ≥ 5% cohort.

## PFS - Sensitivity analysis

In one sensitivity analysis, tumour assessments, progression or death that occurred after anti-cancer therapy (palliative/curative radiotherapy, surgery or systemic therapy) were taken into account. In this analysis, the median PFS was 2.00 months in all treated subjects, 3.52 months in PD-L1 ≥ 1% cohort, and 3.71 months in PD-L1 ≥ 5% cohort.

In the other sensitivity analysis, subjects who progressed within 1 month of start of treatment due to new brain lesion, without evidence of baseline brain lesion (most subjects did not get baseline brain MRI as it was only required if there was a history of brain metastases), were excluded. In this analysis, the median PFS was 2.04 months in all treated subjects, 3.55 months in PD-L1 ≥ 1% cohort, and 3.71 months in PDL1 ≥ 5% cohort

The median PFS per investigator was 2.10 months (95% CI: 1.87, 2.83) in all treated subjects, 3.65 months (95% CI: 1.94, 5.32) in PD-L1 ≥ 1% cohort, and 3.71 months (95% CI: 1.87, 5.72)in PD-L1 ≥ 5% cohort. The median PFS per investigator was 1.94 months (95% CI: 1.81, 2.33) in PD-L1 &lt; 1% cohort, and 2.00 months (95% CI: 1.87, 2.37) in PD-L1 &lt; 5% cohort.

## Subjects treated beyond investigator-assessed progression

A total of 26.4% (70/265) of treated subjects received at least one dose after initial RECIST v1.1-defined progression. Treatment beyond progression was defined as a last dosing date after a RECIST v1.1-defined progression date. Of the 70 subjects treated beyond progression, 24 were considered non-conventional benefiters, defined as subjects who had not experienced a BOR of PR/CR prior to initial RECIST v1.1defined progression.

<div style=\"page-break-after: always\"></div>

## Time to and Duration of Response (TTR and DOR) per BIRC

TTR and DOR were estimated in subjects with confirmed PR + CR and shown in Table 19.

The median DOR per BIRC was not reached in all treated subjects; the median DOR was 7.52 months in subjects with PD-L1 expression &lt; 5% but was not reached in the remaining 3 PD-L1 cohorts. Most (40/52, 76.9%) of the responders were still continuing in response at the time of database lock, with nearly all (96.2%) having a DOR of at least 3 months. Ongoing response includes responders who had neither progressed nor initiated subsequent therapy at the time of analysis, and excluded responders censored prior to 12 weeks of the clinical data cutoff date.

Table 19 Time to Objective Response and Duration of Response per BIRC - All Treated Subjects (study CA209275) (DBL 30-May-2016)

<!-- image -->

|                                                                                                          | PD-L1<1% N = 23                                  | FD-I1 >=1% N = 29                                | PD-L1<5% N = 29                                  | PD-L1 >=5 N=23                         | All Treated Subjects N=52                        |
|----------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------|--------------------------------------------------|
| TIMETORESPONSE(MONTHS)                                                                                   | TIMETORESPONSE(MONTHS)                           | TIMETORESPONSE(MONTHS)                           | TIMETORESPONSE(MONTHS)                           | TIMETORESPONSE(MONTHS)                 | TIMETORESPONSE(MONTHS)                           |
| NUMEER OFRESPONDERS MEAN MEDIAN MIN, MAX Q1,Q3 STANDARDDEVIATION DURATION OFRESPONSE(MONTHS) MIN,MAX (A) | 23 2.32 1.94 1.6, 5.9 1.81, 2.10 1.133 1.9+，9.4+ | 29 2.15 1.87 1.6, 5.6 1.81, 1.97 0.840 1.9+,9.6+ | 29 2.28 1.91 1.6, 5.9 1.81, 2.10 1.055 1.9+,9.4+ | 23 2.16 1.87 1.6, 5.6 1.81, 1.97 0.881 | 52 2.23 1.87 1.6, 5.9 1.81,1.97 0.974            |
| RESPONSE OF AT LFAST(%) 3MONTHS                                                                          | 22 (95.7)                                        | 28 (96.6) 7 (24.1)                               | 28 (96.6) 10 ( 34.5)                             | 22 (95.7) (17.4)                       | 50 (96.2) 14 (26.9)                              |
| 6MONTHS                                                                                                  | 7(30.4)                                          |                                                  |                                                  | 4                                      |                                                  |
| NEVENT/NRESP(%) SUBJECTS WITH ONGOING RESPONSE (C）19（82.6)                                               |                                                  |                                                  |                                                  |                                        |                                                  |
| MEDIAN(95%CI）(B) NUMBEROFSUBJECISWITHDURATIONOF                                                          | N.A.(7.43,N.A.) 4/23 (17.4) 0                    | N.A.(7.52,N.A.) 6/29 (20.7) 21 (72.4) 0          | 7.52 (7.43, N.A.) 7/29 (24.1) 22 ( 75.9)         | 1.9+, 9.6+ N.A. 3/23 (13.0) 18 (78.3)  | 1.9+,9.6+ N.A.(7.43,N.A.) 10/52 (19.2) 40 (76.9) |
|                                                                                                          |                                                  |                                                  | 0                                                | 0                                      |                                                  |
| 12 MONTIS                                                                                                |                                                  |                                                  |                                                  |                                        |                                                  |
|                                                                                                          |                                                  |                                                  |                                                  |                                        | 0                                                |

(A)Symbol +indicates\\_a censored value

(B) Median camputed using Kaplan-Meier method.

excludesresponders censoredprior to12weeksof the clinicaldatacutoff date

<!-- image -->

Bar indicates progresson free survival.

Response and progression as asscssed perBIRC.

RECIST 1.1Response Criteriawhere confirmation ofresponseisrequired.Horizontal axis origin corresponds tofirst dose date.

Treated subjectsfromJapanenrolled aftermain enrollment period areexcluded.

Figure 7 Event Chart for Tumour Response per BIRC - Responders among all treated subjects (study CA209275)

<div style=\"page-break-after: always\"></div>

## Concordance between BIRC and investigator assessments

The concordance rate of responders between IRRC and investigator assessments was 92.8%. Concordance rates were similar observed for all 4 PD-L1 cohorts (88.9% - 95.8%), as shown in Table 20 Table 20 Concordance rate of responders between IRRC and investigator assessments (study CA209275)

## Cohort:AllTreatedSubjects

|                                 | Number of Subjects (%) BIRCASSESSMDNT   | Number of Subjects (%) BIRCASSESSMDNT   | Number of Subjects (%) BIRCASSESSMDNT   |
|---------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                 | RESPONDER                               | NON-RESPONDER                           | UTD                                     |
| INVESTIGATORASSESSMENT          |                                         |                                         |                                         |
| RESPONDERS                      | 47 ( 17.7)                              | 14 (5.3)                                | 0                                       |
| NON-RESPONDERS                  | 5 (1.9)                                 | 146 ( 55.1)                             | 14 (5.3)                                |
| UTD                             | 0                                       | 4(1.5)                                  | 35 ( 13.2)                              |
| CONCORDANOERATEOFRESFONDERS(1): |                                         | 92.8                                    |                                         |

Responders:SubjectswithoonfirmedFR/CR.UTD:UnabletoDetermine

(1)QuantifiesthefrequencywithwhichINVandIRCagreedonclassificationofasubjectas respomder vs. non-responder/uiD as a proportion of the total number of subjects assessed by boththeinvestigatoramdBiRC

TreatedsubjectsframJapanenrolledaftermainenrollmentperiodareexcluded

## Overall Survival and subsequent cancer therapy

Subsequent cancer therapy was received by 19.6% of all treated subjects. Subsequent systemic therapy was received by 9.8% of subjects; the most common was gemcitabine (3.8%), followed by carboplatin, cisplatin, and paclitaxel (1.9% each).

<div style=\"page-break-after: always\"></div>

Table 21 Subsequent Cancer Therapy Summary - All Treated Efficacy Subjects (study CA209275) (DBL 30-May-2016)

|                                                                                                                                       | Number of Subjects (l) All Trmatod Subjocts (Effichcy) N = 265   |
|---------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| SUBJECTS WITH ANY SUBSEOUENT THERAPY (O)(1)                                                                                           | 52 ( 19.6)                                                       |
| CURATIVE PALLLATIVE OIHER.                                                                                                            | 25 C 9.4) 0.8) C 8.7) 0                                          |
| SUBJELTS WHO RELEIVED SUBSEOUENT SURGPRY () TUMDR RESECTION,CURATTVE TUMDR RESECTION,PALLTATIVE FINENDDDIEASPIRATION INCISIONALBIOPSY | 02000000 3.0) 0.8) 2.3)                                          |
| SUBJDCTS MHO RECEIVED SUBSEOUENT SYSIEMIC THERAPY ()                                                                                  |                                                                  |
| OIHER SYSIEMIC CANCPRTHERAPY=EXPERIMENTALLRUGS INMESTIGATIONALANTINEOPLASTIC                                                          | 26 (9.8)                                                         |
| IMMUNOTHERAPY (2)                                                                                                                     |                                                                  |
| PEMETRPXPD                                                                                                                            |                                                                  |
| EXCISIONALBIOPSY FLUID ASPIRATION OIHER                                                                                               |                                                                  |
|                                                                                                                                       | 0                                                                |
|                                                                                                                                       | MM                                                               |
| OIHERSYSIEMIC CANCERTHERAPY-CHEMDIHERAPY                                                                                              |                                                                  |
| CARBOPLATIN                                                                                                                           | 25 9.4) 5                                                        |
| CISPLATIN CYCLOPHOSPHAMIDE                                                                                                            | 1.9) 5 1.9) 1 0.4)                                               |
| DOLEIAXEL DOXORUBICIN                                                                                                                 | 4 1.5) 1 0.4)                                                    |
| EVEROLIMUS                                                                                                                            | 1                                                                |
|                                                                                                                                       | 10                                                               |
|                                                                                                                                       | 0.4) 3.8)                                                        |
| GSMCITABINE MEIHOTREKAIE                                                                                                              | 2 0.8)                                                           |
|                                                                                                                                       | 2 0.8) 5 1.9)                                                    |
| NIVOLUMAB (3)                                                                                                                         |                                                                  |
| PACLITAXEL                                                                                                                            |                                                                  |
|                                                                                                                                       | 2 0.8)                                                           |
| TRAMETINTB                                                                                                                            | 1 0.4)                                                           |
|                                                                                                                                       | 1 0.4)                                                           |
| VINBLASTINE VINCRISTINE                                                                                                               | 1 0.4)                                                           |
| VINFTUNINE                                                                                                                            | 4 1.5)                                                           |

wm Aderoq auonbosqps *Aderoup auonboss go'edka ouo urq oaow pospooor owry Ami qoofans (t)

(2)Two subjects dslined as therapy started on or after firat dhsing date.

Listing wnder chemotherapy category:

and received immunotherapy, see Nivolumab

(3) Niiolimsb treatment should Be listed wnder inmunotherapy. These subjects remains at 25.

Aderounounp burapeoon saooCons Jo xocpnu op os Adhrounowsup piwgooor ostu

Treated subjects\\_frcm Japan enrolled after main enrollment period are excluded

<div style=\"page-break-after: always\"></div>

## Updated analysis (DBL 02-Sep-2016)

As of database lock on 02-Sep-2016, 54 (20%) subjects received subsequent therapy with 28 (10.4%) receiving systemic anticancer therapy, most of which was chemotherapy, and 25 (9.3%) receiving radiation therapy, most of which was palliative. The median time for starting subsequent therapy was 3.98 months (range 0.5, 11.1).

Median overall survival (mOS) in subjects not receiving subsequent therapy (N=216) was 6.47 (95% CI: 4.76, 9.99) months, lower than in the all treated population (mOS 8.57 [95% CI: 6.05, 11.27]). Despite the lower mOS in patients not receiving subsequent therapy in CA209275, the 1-year OS rate of 41% (95% CI: 34.3, 47.6) was similar to the 1-year OS rate in the all treated population of 41% (95% CI: 34.8, 47.1).

## Subgroup analysis

## · ORR per BIRC in key subpopulations

## Table 22 Objective Response Rate per BIRC in Key Subpopulations (study CA209275) (DBL 30May-2016)

|                                    | Qbjective Response Rate (%)(95% CI) (a)   | Qbjective Response Rate (%)(95% CI) (a)   |
|------------------------------------|-------------------------------------------|-------------------------------------------|
|                                    | All Treated Subjects N = 265              | All Treated Subjects N = 265              |
| All Treated Subjects               | 52/265 (19.6%)                            | (15.0, 24.9)                              |
| AGECATEGORIZATION1 <65             | 16/119 (13.4%)                            | (7.9, 20.9)                               |
| 65 AND< 75                         | 24/109 9 (22.0%)                          | (14.6, 31.0)                              |
| > 75                               | 12/37 (32.4%)                             | (18.0, 49.8)                              |
| REGION                             |                                           |                                           |
| US                                 | 24/106 (22.6%)                            | (15.1, 31.8)                              |
| JAPAN                              | 3/18 (16.7%)                              | (3.6, 41.4)                               |
| ROW                                | 25/141 (17.7%)                            | (11.8, 25.1)                              |
| GENDER                             |                                           |                                           |
| MALE                               | 41/207 (19.8%)                            | (14.6, 25.9)                              |
| FEMAIE                             | 11/58 (19.0%)                             | (9.9, 31.4)                               |
| BASELINEECOGPERFORMANCESTATUS      |                                           |                                           |
| 0                                  | 32/141 (22.7%)                            | (16.1, 30.5)                              |
| 1                                  | 20/123 (16.3%)                            | (10.2, 24.0)                              |
| BASELINE LIVER METASTASES (IRC)    |                                           |                                           |
| YES                                | 8/74 (10.8%)                              | (4.8, 20.2)                               |
| NO                                 | 44/191 (23.0%)                            | (17.3, 29.7)                              |
| BASELINE VISCERAL METASTASES (IRC) |                                           |                                           |
| YES                                | 35/223 (15.7%)                            | (11.2, 21.1)                              |
| NO                                 | 17/42 (40.5%)                             | (25.6, 56.7)                              |
| BASELINE LYMPH NODE ONLY (IRC)     |                                           |                                           |
| YES                                | 17/42 (40.5%)                             | (25.6, 56.7)                              |
| NO                                 | 35/223 (15.7%)                            | (11.2, 21.1)                              |
| BASELINEHEMOGIOBIN                 |                                           |                                           |
| <10 G/DL                           | 8/46 (17.4%)                              | (7.8, 31.4)                               |
| 10 G/DL                            | 44/219 (20.1%)                            | (15.0, 26.0)                              |

<div style=\"page-break-after: always\"></div>

|                                                            | Qbjective Response Rate (%）(95% CI）(a)   |                              |
|------------------------------------------------------------|------------------------------------------|------------------------------|
|                                                            | All Treated Subjects N = 265             | All Treated Subjects N = 265 |
| NUMBER OFPRIOR REGIMENIN METASTATIC SETTING                |                                          |                              |
| 0                                                          | 18/77 (23.4%)                            | (14.5, 34.4)                 |
| 1                                                          | 19/112 (17.0%)                           | (10.5, 25.2)                 |
| 2                                                          | 10/54 (18.5%)                            | (9.3, 31.4)                  |
| x=3                                                        | 5/22 (22.7%)                             | (7.8, 45.4)                  |
| TIMEFROMCOMPIETIONOFMOSTRECENTPRIORREGIMENTOSTUDYTRFATMENT |                                          |                              |
| 3MONTHS                                                    | 18/110 (16.4%)                           | (10.0, 24.6)                 |
| 3-< 6 MONTHS                                               | 14/70  (20.0%)                           | (11.4, 31.3)                 |
| >= 6 MONTHS                                                | 20/85 (23.5%)                            | (15.0, 34.0)                 |
| NUMBEROFBELIMUNTRISKFACTORS                                |                                          |                              |
| 0                                                          | 24/96 (25.0%)                            | (16.7, 34.9)                 |
| 1                                                          | 21/109 (19.3%)                           | (12.3, 27.9)                 |
| 2                                                          | 6/45 (13.3%)                             | (5.1, 26.8)                  |
| 3                                                          | 1/15 5 (6.7%)                            | (0.2, 31.9)                  |
| BASELINE CRFATININE CIEARANCE                              |                                          |                              |
| <30 ML/MIN                                                 | 1/5 (20.0%)                              | (0.5, 71.6)                  |
| 30-<60ML/MIN                                               | 20/99 (20.2%)                            | (12.8, 29.5)                 |
| >=60 ML/MIN                                                | 30/160 (18.8%)                           | (13.0, 25.7)                 |
| NOT REPORTED                                               | 1/1 (100.0%)                             | (2.5, 100.0)                 |
| SUBSET OF INITIAL TUMOR ORIGIN                             |                                          |                              |
| URINARYBLADDER                                             | 41/190 (21.6%)                           | (16.0, 28.1)                 |
| RENALPELVIS，URETER                                         | 7/65 (10.8%)                             | (4.4, 20.9)                  |

(a) CR+PR as per RECIST 1.1 criteria confirmation of response erequired (BIRC Assessment), confidenceintervalbased on theClopper and Pearson method.

Source:Table7.2.1.3-1oftheCA209275CSR

Treated subjects from Japan enrolled after main enrollment period are excluded.

## · Overall Survival in pre-defined subsets

Table 23: Overall Survival and survival rates in pre-defined subsets - Summary - All treated subjects

|                                                         | Overall Suuvival in Pre-Defined Subsets Summary All Treated Subjects   | Overall Suuvival in Pre-Defined Subsets Summary All Treated Subjects   | Overall Suuvival in Pre-Defined Subsets Summary All Treated Subjects   |
|---------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
|                                                         | PD-L1<1 N = 146                                                        |                                                                        | PD-L1 >=1 N = 124                                                      |
| BASELINEEOOGFERFORMANCESTATUS                           |                                                                        |                                                                        |                                                                        |
| 0 EVENIS/# SUBJECTS() MEDIAN OS(MONIHS)(1)(95% CI)      | 31/13 (58:37,                                                          | N.A.)                                                                  | 30/73 (41.1) N.A.(9.69,N.A.)                                           |
| EVENIS/SUBJECTS.（8） MEDIAN OS (MONIHS) (1)(95% CI)      | 56/73 (76.7) 3.15 (2.76,                                               | 4.17)                                                                  | 31/51 (60.8) 9.10(4.80, 11.63)                                         |
| BASELINE LIVER METASTASES (IRC)                         |                                                                        |                                                                        |                                                                        |
| YES EVENIS/# SUBJECTS.(8) MEDIAN OS (MONIHS)(1)(95% CI) | 36/45 (80.0) 2.92(2.23)                                                | 3.15)                                                                  | 21/32 (65.6) 9.33(2.04,12.94)                                          |
| NO #EVENIS /# SUBJECTS(%) MEDIAN OS (MONIHS)(1)(95% CI) | 57/101 (56.4) 8.74 (6.11,N.A.)                                         |                                                                        | 40/92 (43.5)                                                           |

<div style=\"page-break-after: always\"></div>

BASELINE VISCERAL METASTASES (IRC)

YES

(10 8S6),(T) (SHINON SO NNIOGN

#EVENIS /# SUBJECTS.(8)

NO

MEDIAN OS (MONIHS) (1) (95% CI)

EVENIS/SUBJECTS（名）

BASELINE LYMFH NOIE ONLY (IRC)

YES

MEDIAN OS (MONIHS) (1) (95% CI)

EVENIS/SUBJECTS.（）

NO

MEDIAN OS (MONIHS)(1)(95% CI)

EVENIS/SUBJECTS（8)

&lt; 3 MONIHS

MEDIAN OS (MONIHS) (1) (95% CI)

# EVENIS / # SUBJECTS ()

3-&lt;6MONIHS

MEDIAN OS (MONIHS) (1) *(95% CI)

#EVENIS / # SUBJECTS ()

=6 MONIHS

MEDIAN OS (MONIHS) (1)(95% CI)

# EVENIS / + SUBJECTS (8)

NUMBER OF BELIMINT RISK FACTORS

0

2

3

EVENIS/SUBJECTS

(108S6).(T)(SHINON)SO NIOGN

EVENIS/SUBJECTS（8）

MEDIAN OS (MONIHS)(1)(95% CI)

EVENIS/SUBJECIS（8)

MEDIAN OS (MONIHS)(1)(95% CI)

#EVENIS / # SUBJECTS、(8)

MEDIAN OS (MONIHS)(1)

(95% CI)

<!-- image -->

## Overall Survival in Pre-Defined Subsets Summary All Treated Subjects

PD-L1&lt;18

N = 146

84/123 (68.3)

4.96 ( 3.94,6.74)

N2: (P%:4h, N.A.)

N/2: (7%:43, N.A.)

84/123 (68.3)

PD-L1 &gt;=1&amp;

N = 124

18.1 (852, N.a.)

6/23 (26.1)

6/23 (26.1)

N.A.

55/101 (54.5)

4.96(3.94,6.74)

10.87 (6.31, N.A.)

Overall Suuvival\\_in Pre-Defined Subsets Summary All Treated Subjects

PD-L1 &lt;1

N = 146

40/58 (69.0)

4.53('3.15)

31/45 (68.9)

4.96('3.65)

7.85)

8.08)

22/43 (51.2)

PD-L1 &gt;1

N = 124

33/54 (61.1)

6.31 (4.60, 12.94)

N/28 (1:8, 1.a.)

11.10( 4.63,N.A.)

20/42 (47.6)

N.A.(5.85,

N.A.)

Overall Survival in Pre-Defined Subsets Summary

PD-L1 &lt;1

N = 146

19/48

(39.6)

N.A. ( 9.00,

N.A.)

32427 (486),。 8.57)

25/31 (80.6)

3.15 (2.20,

3.32)

10/10,(100.0)

All Treated Subjects

PD-L1 &gt;=1

N = 124

15/49 (30.6)

N.A.

354 (9.8, 12.94)

10/16 (62.5)

10.20 ( 1.45, N.A.)

2/. (60.0)0

<!-- image -->

2.27(0.30,3

3.12)

PD-L1&lt;1

PD-L1&gt;=1

Survival Rate (95号 CI)

(N=146)

(N=124)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| BASELINEHEMOGLOBIN <10 G/DL            | BASELINEHEMOGLOBIN <10 G/DL   |             |                                  |
|----------------------------------------|-------------------------------|-------------|----------------------------------|
| EVENIS / # SUBJECIS ()                 | 26/30_ (86.7) 66.7 46.9       | 80.51       | 10/18, (55.6)                    |
| 3-MONIH                                |                               |             | 61.1 35.3. 79.2)                 |
| HINONH-9                               | 24.6                          |             | 50.0 78:3                        |
| HINOIH-6                               | 17.5                          |             | 50.0                             |
| 12-MONTH                               | 9.4 1.                        | 24.1)       | 37.5 12.7, 62.8)                 |
| >=10 G/DL                              |                               |             |                                  |
| EVENTS / # SUBJECIS ()                 | 67/116 (57.8)                 |             | 51/106 (48.1)                    |
| 3-MONTH                                | 73.2                          |             | 83.0 74.4. 88.91                 |
| 6-MONIH                                | 55.6 4663                     |             | 67.7 34                          |
| HINOW-6                                | 45.8                          |             | 11                               |
| 12-MONTH                               | 40.4                          |             | 4.96                             |
| BASELINE EOOG FERFORMANCE STATUS 0     |                               |             |                                  |
| EVENIS / # SUBJECIS()                  | 36/72 (50,2)                  | %:31        | 30/73_(41 .1) 83.                |
| 3-MONIH 6-MONIH                        |                               |             | 28:81                            |
| 9-MONTH                                | 55.1                          |             | 65.8                             |
| 12-MONTH                               | 8.87                          | 128         | 59.4                             |
| 1                                      |                               |             |                                  |
| EVENIS /# SUBJECIS()                   | 56/73_ (76.7)                 |             | 31/51 (60.8)                     |
| 3-MONIH                                | 58.5 2.96                     |             | 74.5 58.4                        |
| 6-MONIH                                |                               | 11          |                                  |
| 9-MONIH                                |                               |             |                                  |
| 12-MONTH                               | 19.2 10.4,                    | 30.0)       | 50.3 36.0 22.5, 49.8)            |
| BASELINE LIVER METASTASES (IRC) YES    |                               |             |                                  |
| EVENIS / # SUBJECIS (8) 3-MONIH        | 36/45 (80.0) 48.2( 32.9,      | 61.9)       | 21/32 (65.6) 65.6 6( 46.6, 79.3) |
| 6-MONIH                                | 22.9 11.9,                    | 36.1)       | 56.3 37.6, 71.31                 |
| 9-MONTH 12-MONIH                       | 18.4 18.4                     | 18:18       | 53.1 34.0                        |
| NO                                     |                               |             |                                  |
| #EVENIS / # SUBJECTS ()                | 57/101（ (56.4)                |             | 40/92 (43.5)                     |
| 3-MONIH                                | 88.3                          | 88:3        | 38:3                             |
| 6-MONIH                                |                               |             | 016                              |
| 9-MONIH 12-MONTH                       |                               | 58:93       | 12-62                            |
| BASELINE VISCERAL METASTASES (IRC) YES |                               |             |                                  |
| #EVENIS /# SUBJECTS()                  |                               |             | 55/101 154. 5                    |
|                                        | 44.6                          | 77.81       |                                  |
| 3-MONIH                                | 70.6                          |             |                                  |
| 12-MONIH                               | 28.6                          |             |                                  |
|                                        | 84/123 (68. 31                |             | moom 43.3                        |
| NO #EVENIS / # SUBJECIS ()             | 139.                          |             | (26.                             |
| 6-MONIH HINOWH-6                       | 35.3                          |             |                                  |
|                                        | 15548 4omm                    |             | 6m1                              |
| 0                                      |                               |             |                                  |
| 6-MONIH                                |                               |             |                                  |
| HINONHC                                |                               | 88:3        |                                  |
| HINOWH-6                               |                               |             |                                  |
|                                        |                               |             | joioibo                          |
| 12-MONTH                               |                               | 186         |                                  |
| NUMBER OF BELIMINT RISK FACIORS        |                               |             |                                  |
| #EVENIS / # SUBJECIS ()                | 19/48 (39.                    |             | 15/49_(                          |
| 3-MONIH 6-MONIH                        | 9.68                          |             | 89.8                             |
| 9-MONIH                                | 1                             | 17          | 11                               |
| 12-MONIH                               | 58.8 43.1                     |             | 69.4 80.3)                       |
| 1                                      |                               |             |                                  |
| #EVENIS / # SUBJECTS ()                | 39/57_ (68.4)                 |             | 33/54_(61.1) 2.                  |
| 3-MONIH 6-MONTH                        | 73.7 47.4                     | 8:31        | 98.31 mi                         |
| 9-MONIH                                | 36.6                          |             | 63.6                             |
| 12-MONTH                               | 8.63                          |             | 23.2, 51.61                      |
| 2                                      |                               |             |                                  |
| #EVENIS / # SUBJECIS ()                | 25/31_ (80.6)                 |             | 10/16 (62.5)                     |
| 3-MONTH                                | 53.7 34.6                     | .5          | 68.8                             |
| 6-MONIH HIN0WH6                        |                               |             |                                  |
| 12-MONIH                               | 13.4 3.9,                     | 33.71 29.0) | 928 25.0                         |

<div style=\"page-break-after: always\"></div>

## · Subgroup analysis by Bellmunt risk factors (pre-defined subsets)

Established poor prognostic factors in patients with advanced urothelial carcinoma who have failed platinum-containing regimens include ECOG performance status (PS) more than 0, Hb level &lt; 10 g/dL, and the presence of liver metastasis. A scoring system which groups patients into four categories representing the presence of 0, 1, 2, and 3 of these Bellmunt risk factors has also been established.

<div style=\"page-break-after: always\"></div>

Table 24: Efficacy by Bellmunt risk Factors - all treated subjects CA209275 (updated analysis DBL 2 Sept 2016)

|   Number' ofBellmunt Risk Factors | ORR (%) 95% CI N=270        | Median PFS (months) 95% CI N=270   | Median OS (months) 95% CI N=270   |
|-----------------------------------|-----------------------------|------------------------------------|-----------------------------------|
|                                 0 | 26/97 (26.8%) (18.3, 36.8)  | 3.65 (2.10, 5.32)                  | NA                                |
|                                 1 | 20/111 (18.0%) (11.4, 26.4) | 1.91 (1.81, 2.23)                  | 7.03 (5.42, 9.69)                 |
|                                 2 | 7/47 (14.9%) (6.2, 28.3)    | 1.87 (1.58, 3.02)                  | 3.22 (2.66, 5.03)                 |
|                                 3 | 1/15 (6.7%) (0.2, 31.9)     | 1.07 (0.46, 1.81)                  | 2.23 (0.69, 3.12)                 |

Abbreviations: ORR: objective respoonse rate; PFS: progression-free survival; OS: overall survival; CI: confidence inteival; NA: not available

Source: Table S.5.13, Table S.5.14, and Table S.5.23 of Addendum 01 of the CA209275 CSR

- Subgroup analysis for prior regimens in metastatic setting and time from prior regime (pre-defined subset)

Table 25 Subgroup analyses for prior regimens in metastatic setting and time from prior regime for ORR, PFS and OS (study CA20275)

|                                                                                        | ORR                                                                                    | PFS                                                                                    | OS                                                                                     |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| The influence of time from completion of most recent prior regimen to study treatment. | The influence of time from completion of most recent prior regimen to study treatment. | The influence of time from completion of most recent prior regimen to study treatment. | The influence of time from completion of most recent prior regimen to study treatment. |
| < 3 months (n=110)                                                                     | 16.4 (CI 10-24.6)                                                                      | 1.87 (CI 1.77-2.04)                                                                    | 5.95 (CI 4.30-8.74)                                                                    |
| 3-6 months (n=70)                                                                      | 20.0 (CI 11.4-31.3)                                                                    | 3.52 (CI 1.81-3.71)                                                                    | 9.49 (CI 6.24- NA)                                                                     |
| ≥ 6 months (n=85)                                                                      | 23.5 (CI 15-34)                                                                        | 2.79 (CI 1.91-3.65)                                                                    | 11.30 (CI 5.85-NA)                                                                     |
| Number of prior regimens in metastatic setting                                         | Number of prior regimens in metastatic setting                                         | Number of prior regimens in metastatic setting                                         | Number of prior regimens in metastatic setting                                         |
| 0 (n=77)                                                                               | 23.4 (CI 14.5-34.4)                                                                    | 1.97 (CI 1.77-3.15)                                                                    | 7.62 (CI 4.63-NA)                                                                      |
| 1 (n=112)                                                                              | 17.0 (CI 10.5-25.2)                                                                    | 2.00 (CI 1.87-3.45)                                                                    | NA (CI 5.68-NA)                                                                        |
| 2 (n=54)                                                                               | 18.5 (CI 9.3-31.4)                                                                     | 1.97 (CI 1.77-3.71)                                                                    | 9.63 (CI 5.03-NA)                                                                      |
| ≥ 3 (n=22)                                                                             | 22.7 (CI 7.8 -45.4)                                                                    | 2.02 (CI 1.64-5.78)                                                                    | 6.47 (CI 4.30 -NA)                                                                     |

## · OS rates (per BIRC) (post-hoc analysis)

Additional analyses were conducted to further examine survival rates in key subgroups of patients within PD-L1 expression subgroups (02-Sep-2016 database lock).

<div style=\"page-break-after: always\"></div>

Table 26: Overall Survival rates - all responders per BIRC

| Overall Survival Rates (All Responders per BIRC)   | Overall Survival Rates (All Responders per BIRC)   | Overall Survival Rates (All Responders per BIRC)   | Overall Survival Rates (All Responders per BIRC)   | Overall Survival Rates (All Responders per BIRC)   | Overall Survival Rates (All Responders per BIRC)   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Survival Rate (95% CD)                             | PD-L1 ≤1% N=23                                     | PD-L1≥1% N=31                                      | PD-L1=5%6 N=29                                     | PD-L1≥ 5% N=25                                     | All Treated Subjects N=54                          |
| 3 month                                            | 100.0 (100.0, 100.0)                               | 100.0 (100.0, 100.0)                               | 100.0 (100.0, 100.0)                               | 100.0 (100.0, 100.0)                               | 100.0 (100.0, 100.0)                               |
| 6 month                                            | 95.7 (72.9,99.4)                                   | 96.8 (79.2, 99.5)                                  | 93.1 (75.1, 98.2)                                  | 100.0 (100.0, 100.0)                               | 96.3 (86.0, 99.1)                                  |
| 9 month                                            | 95.7 (72.9, 99.4)                                  | 96.8 (79.2, 99.5)                                  | 93.1 (75.1, 98.2)                                  | 100.0 (100.0, 100.0)                               | 96.3 (86.0, 99.1)                                  |
| 12 month                                           | 95.7 (72.9, 99.4)                                  | 92.6 (73.1, 98.1)                                  | 93.1 (75.1, 98.2)                                  | 94.7 (68.1, 99.2)                                  | 93.9 (82.1, 98.0)                                  |

Souuce:Table S.5.2EUB of Appendix 1

## Exploratory Endpoints

- Baseline PD-L1 Expression and Efficacy

The protocol defines two PD-L1 expression cutoffs (1% and 5%).

Ad-hoc exploratory analyses were performed to further explore the effect of baseline PD-L1 expression on confirmed response per BIRC as continuous variable from 0% to 100%. The receiver operating characteristics (ROC) curve based on response showed that there was no optimal cutoff for PD-L1 expression. The logistic regression model with response and PD-L1 expression was consistent with previous observations, i.e. the predicted probability of response was clinically meaningful across the range of PD-L1 expression value.

<!-- image -->

AreaUnder the Curve:0.5841

Figure 8 Receiver Operating Characteristic (ROC) Curve Based on Confirmed Response per BIRC - All Treated Subjects (study CA20275)

<div style=\"page-break-after: always\"></div>

The association between other biomarker measures and BOR assessed in study CA209275 is presented below.

Table 27 Tumour PD-L1 and Qualitative PD-L1 Immune Cell Staining Scores and ORRCA209275

| PD-Ll expression category                             | ORR Tumow' PD-L1 -1%6   | ORR Tumour PD-L1 ≥1%   | ORR Tumour PD-L1-5%   | ORR Tumour PD-L1≥5%   |
|-------------------------------------------------------|-------------------------|------------------------|-----------------------|-----------------------|
| ORR regardless of immume PD-L1 expression, n/N (%)    | 23/143 (16.1%)          | 29/122 (23.8%)         | 29/184 (15.8%)        | 23/81 (28.4%)         |
| No immume cells orno PD-L1+ immmue cells present      | 0/7 (0%)                | 0/0 (0%)               | 0/7 (%0)              | 0/0 (0%)              |
| Rare PD-L1+ immume cells - responders, n/N (%)        | 4/50 (8.0%)             | 6/23 (26.1%)           | 5/53 (9.4%)           | 5/20 (25.0%)          |
| IntermediatePD-L1+imumme cells -- responders, n/N (%) | 15/65 (23.1%)           | 13/68 (19.1%)          | 18/92 (19.6%)         | 10/41 (24.4%)         |
| Numerous PD-L1+ immume cells --responders, n/N (%)    | 4/21 (19.0%)            | 10/31 (32.3%)          | 6/32 (18.8%)          | 8/20 (40.0%)          |

RNA/Gene expression was assessed in available pre-treatment tumour tissue by EdgeSeq technology (n = 204 subjects with evaluable gene expression data). A gene signature composed of 25 IFN ɣ related genes was tested for association with nivolumab response per BIRC. An IFN ɣ signature score for each evaluable sample was calculated as the sum of z-scores for each gene in the signature based on the normalized data generated by EdgeSeq technology (HTG Molecular Diagnostics Inc).

Figure 9 Expression Levels of INF γ Genes and Correlation with Response in all subjects and subjects with tumour PD-L1 ≥ 1%.

<!-- image -->

In CA209275, the MDSC (% of CD14+ LIN-) abundance in the circulation was measured using freshly collected blood (within 24 h of collection).

<div style=\"page-break-after: always\"></div>

Figure 10 Relative Abundance of MDSCs and Correlation with Response - All Treated Subjects CA209275

<!-- image -->

Tumour infiltrating lymphocytes have been measured by immunohistochemistry (IHC). The presence of CD8+ and FOXP3+ tumour infiltrating lymphocytes (TILs) was assessed in the pre-treatment tumour samples. CD8+ and FOXP3+ cells were enumerated by digital image analysis in regions of interest within the tumour tissue sections and the percentage of CD8+ and FOXP3+ of total number cells was estimated. Regions of interest were circled by a pathologist around tumour areas that may have included intervening stroma.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Response Status

Figure 11 Relative Abundance of FoxP3+ Cells across Response Categories -CA209275; Relative Abundance of CD8+ Cells by Response Category - CA209275; Relative Abundance of the Ratio of CD8+ / FoxP3+ Cells Across Response Categories - CA209275

The expression of PD-L2 in pre-treatment tumour tissue of patients from the CA209275 study was assessed by IHC, using a mouse monoclonal anti-PD-L2 Ab clone.

<div style=\"page-break-after: always\"></div>

## Table 28 Objective Response Rate per BIRC by PD-L2 Status within PD-L1 expression subgroups - CA209275 (updated analysis, DBL 2 Sept 2016)

|                                                                   | PD-L1 <1& (N=146)           | PD-L1 >=1 (N=124)             | PD-L1 <5 (N=187)             | PD-L1 >=5 (N=83)           | ALLTREATED SUBJECTS (N=270)   |
|-------------------------------------------------------------------|-----------------------------|-------------------------------|------------------------------|----------------------------|-------------------------------|
| PD-L2STATUS(TUMORCELLS-MEMBRANE) (A) PD-L2 FOSITIVE PD-L2NEGATIVE | 8 (5.5) 126 (86.3) 12 (8.2) | 10 (8.1) 101 (81.5) 13 (10.5) | 11 (5.9) 164 (87.7) 12 (6.4) | 7 (2.6) 63 (23.3) 13 (4.8) | 18 (6.7) 227 (84.1) 25 (9.3)  |
| PD-L2STATUS（TUMORCELLS-MEMBRANEOrCYTOPLASMIC) (B) PD-L2 POSITIVE  |                             | 30 (24.2)                     | 25 (13.4)                    |                            | 47 (17.4)                     |
| NOTREFORTED/EVALUABLE                                             |                             |                               |                              |                            |                               |
| PD-L2NEGATIVE                                                     | 17 (11.6) 117 (80.1)        | 81 (65.3)                     | 150 (80.2)                   | 22 (8.1) 48 (17.8)         | 198 (73.3)                    |
|                                                                   |                             | 13 (10.5)                     |                              |                            |                               |
| NOTREFORTED/EVALUABLE                                             | 12 (8.2)                    |                               | 12 (6.4)                     | 13 (4.8)                   | 25 (9.3)                      |

(A)Positive if locationis MEMBRANE or CYTOPLASMIC/MEMBRANE andIHC SCore is 1+，2+ or 3+ (B）Positive if location is MEMBRANE or CYTOPLASMIC/MEMBRANE and IHC sCore is1+，2+or 3+orif locationis CYTOPLASMICandIHCSCOreis2+or3+

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 29 Summary of Efficacy for trial CA209275

| Title: A Phase 2 Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment with a Platinum Agent   | Title: A Phase 2 Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment with a Platinum Agent   | Title: A Phase 2 Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment with a Platinum Agent   | Title: A Phase 2 Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects with Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment with a Platinum Agent   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                               | BMS-936558                                                                                                                                                                                                     | BMS-936558                                                                                                                                                                                                     | BMS-936558                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                         | Single arm trial                                                                                                                                                                                               | Single arm trial                                                                                                                                                                                               | Single arm trial                                                                                                                                                                                               |
| Design                                                                                                                                                                                                         | Duration of main phase: Duration of run-in phase: Duration of extension phase:                                                                                                                                 | Duration of main phase: Duration of run-in phase: Duration of extension phase:                                                                                                                                 | On going not applicable not applicable                                                                                                                                                                         |
| Hypothesis                                                                                                                                                                                                     | The primary objective was to estimate ORR per BIRC                                                                                                                                                             | The primary objective was to estimate ORR per BIRC                                                                                                                                                             | The primary objective was to estimate ORR per BIRC                                                                                                                                                             |
| Treatment groups                                                                                                                                                                                               | Nivolumab                                                                                                                                                                                                      | Nivolumab                                                                                                                                                                                                      | 3 mg/kgQ2W.                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                               | ORR                                                                                                                                                                                                            | ORR based on BIRC assessment in subjects with tumor expressing PD-L1 (membranous staining in ≥ 5% and ≥ 1% tumor cells) and in overall treated subjects                                                        |
| Endpoints and definitions                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                             | PFS by BICR                                                                                                                                                                                                    | Time from first dosing date to the date of the first documented tumor progression, based on BIRC assessments (per RECIST 1.1), or death due to any cause.                                                      |
| Endpoints and definitions                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                             | OS                                                                                                                                                                                                             | Time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive                                                                                         |
| Database lock                                                                                                                                                                                                  | 02-Sep-2016                                                                                                                                                                                                    | 02-Sep-2016                                                                                                                                                                                                    | 02-Sep-2016                                                                                                                                                                                                    |
| Results and analysis                                                                                                                                                                                           | Results and analysis                                                                                                                                                                                           | Results and analysis                                                                                                                                                                                           | Results and analysis                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Primary analysis                                          | Primary analysis                                          |
|-------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Analysis population and time point description  | All subjects who received at least one dose of nivolumab. | All subjects who received at least one dose of nivolumab. |
| Descriptive statistics and estimate variability | Treatment group                                           | Nivolumab                                                 |
| Descriptive statistics and estimate variability | Number of subjects                                        | 270                                                       |
| Descriptive statistics and estimate variability | ORR by BICR (%)                                           | 20.0                                                      |
| Descriptive statistics and estimate variability | CI95%                                                     | 15.4-25.3                                                 |
| Descriptive statistics and estimate variability | DOR by BIRC (median)                                      | 10.35                                                     |
| Descriptive statistics and estimate variability | CI 95%                                                    | 7.52-N.A                                                  |
| Descriptive statistics and estimate variability | PFS by BICR (median)                                      | 2.00 months                                               |
| Descriptive statistics and estimate variability | CI 95%                                                    | 1.87-2.63                                                 |
| Descriptive statistics and estimate variability | OS (median)                                               | 8.57 months                                               |
| Descriptive statistics and estimate variability | CI 95%                                                    | 6.05-11.27                                                |

## Supportive study

## Study CA209032

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

CA209032 is a multicenter Phase 1/2, open label, randomised study of nivolumab monotherapy or nivolumab combined with ipilimumab designed to evaluate the efficacy and safety of nivolumab as monotherapy or in combination with ipilimumab in subjects with 6 different tumour types including UC. Subjects with UC originating in the renal pelvis, ureter, bladder or urethra with tumour progression or refractory disease and at least 1 platinum-containing chemotherapy regimen unless the subject actively refused chemotherapy were treated with one of following 3 regimens: nivolumab monotherapy 3 mg/kg, nivolumab 3 mg/kg + ipilimumab 1 mg/kg, and nivolumab 1 mg/kg + ipilimumab 3 mg/kg.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note:The focus of this interim CSR is subjects treated with nivolumab monotherapy(Arm N).The 2 combination armswillbereportedseparatelyatalaterdate.

Figure 12 Design Schematic for Urothelial Carcinoma Cohort (study CA209032)

Treated subjects were evaluated for response according to RECIST v1.1 at baseline and then at 6 weeks after first dose and continuing every 6 weeks for the first 24 weeks, and then every 12 weeks until disease progression (investigator-assessed RECIST v1.1-defined progression) or treatment discontinuation, whichever occurred later. Subjects were treated until progression, unacceptable toxicity, or other protocol-defined reasons. Treatment beyond initial investigator-assessed RECIST v1.1-defined progression was permitted if the subject had an investigator-assessed clinical benefit and was tolerating study drug.

Subjects treated with nivolumab monotherapy who had a confirmed progression were subsequently allowed to cross over to nivolumab 3 mg/kg + ipilimumab 1 mg/kg combination.

The clinical data base lock for this analysis occurred on 24-Mar-2016.

Pre-treatment tumour tissue (archival or fresh biopsy specimen) was systematically collected in order to conduct pre planned analyses of efficacy according to baseline PD-L1 expression status. Subjects were treated, regardless of baseline tumour PD-L1 expression status. Archived tissue could be from prior biopsy of unresectable or metastatic disease or from prior surgical resection. Database lock was 24-Mar2016.

## · Sample Size and Power

An ORR of 10% or less was considered not of clinical value, and an ORR of 25% or greater was considered of strong clinical interest. The sample size 60 - 105 provided 90% to 97% power to reject the null hypothesis of 10% response rate if the true response rate was 25% with a two-sided Type I error rate of 5%.

## · Efficacy Endpoints

The primary endpoint for the nivolumab monotherapy treated UC cohort was to assess the investigatorassessed ORR. The ORR was defined as the proportion of treated subjects with a confirmed BOR of CR or PR according to RECIST 1.1.

Additional efficacy assessments included investigator-assessed DOR and PFS according to RECIST v1.1; OS; association between tumour PD-L1 expression and efficacy; HRQoL as assessed by the EQ-5D.

- Baseline characteristics

<div style=\"page-break-after: always\"></div>

Table 30 Baseline Disease Characteristics and Tumor Assessments - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

|                                         | Nivolumab N = 78   |
|-----------------------------------------|--------------------|
| PERFORMANCE STATUS(ECOG)[%]             |                    |
| 0                                       | 42 (53.8)          |
| 1                                       | 36 46.2)           |
| NUMBEROFBELIMUNTRISKFACIORS             |                    |
| 0                                       | 7.39 34.6)         |
| 12                                      | 50.07              |
|                                         | 8 10.3)            |
| 3                                       | 4 5.1)             |
| SMOKINGSTATUS                           |                    |
| CURRENT/FORMER                          | 48 61.5)           |
| NEVER SMOKER                            | 29 37.2)           |
| UNKNOWN                                 | 1 i 1.3)           |
| BASELINE LIVER METASTASIS               |                    |
| YES NO                                  | 38 1 3强:8]         |
| BASELINE VISCERAL METASTASIS (A)        |                    |
| YES                                     | 66 (84.6)          |
| NO                                      | 12 ( 15.4)         |
| BASELINE LYMPH NODE ONLY                |                    |
| YES                                     | 皆 (器:3             |
| NO                                      |                    |
| BASELINEHEMOGLOBIN                      |                    |
| <10G/DL >10 G/DL                        | (器:3               |
| BASELINECREATININECTFARANCE             |                    |
| <30ML/MIN                               | 0                  |
| 30-<60ML/MmN                            | 25 (32.1)          |
| >=60 ML/MMN                             | 53 ( 67.9)         |
| CURRENT (STUDY ENIRY) DISEASE STAGE (%) |                    |
| STAGE 工                                 |                    |
| STAGE II                                |                    |
| STAGE III STAGE IIIA                    | 6.4)               |
| STAGE IIIB                              | 005011 1.          |
| STAGE IIIC                              |                    |
| STAGE IV                                | 71 91.0)           |

Most (84.6%) subjects received prior systemic cancer treatments in the metastatic setting. Percentages of subjects receiving prior systemic cancer treatments in the neoadjuvant and adjuvant settings were 17.9% and 42.3%, respectively. Nearly all (96.2%) subjects received prior platinum-containing therapy in any setting with the majority (75.6%) receiving the therapy in the metastatic setting. The most frequent prior platinum-containing therapy was cisplatin followed by carboplatin. Prior platinumcontaining therapy was associated with recurrence/progression in 92.3% of the subjects. Nearly all subjects progressed within 12 months of their most recent platinum regimen, with nearly two-thirds (59.7%) progressing within 3 months.

- Results

The enrollment period for nivolumab monotherapy UC cohort lasted approximately 11 months (June 2014 to May-2015). The last patient's first treatment date was 08-May-2015, and the last patient last visit date (clinical cut-off) was 11-Feb-2016, providing a minimum follow-up of approximately 9 months. The clinical data base lock occurred on 24-Mar-2016. 86 subjects with advanced or metastatic UC were enrolled in the nivolumab monotherapy treatment arm at 16 sites in 5 countries. Across the 16 sites, 78 (90.7%) of these enrolled subjects were treated with nivolumab monotherapy. Among these treated subjects, 19 (24.4%) were in Europe (Finland, Germany, Spain, and United Kingdom), and 59 (75.6%) were in the US.

76.9% of all treated subjects were no longer continuing in the treatment period (Table 31). The primary reason for treatment discontinuation was disease progression. 18 (23.1%) subjects crossed from nivolumab monotherapy over to nivolumab 3 mg/kg + ipilimumab 1 mg/kg combination regimen, of whom 15 (83.3%) were no longer continuing in the treatment period; the primary reason for treatment discontinuation was disease progression.

<div style=\"page-break-after: always\"></div>

## Table 31 End of Treatment Subject Status Summary - All Treated Nivolumab Monotherapy Urothelial Carcinoma Subjects (study CA209032)

|                                                                                                                                                                                                                                                                | Nivolumab                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| SUBJECTS                                                                                                                                                                                                                                                       | 78                                       |
| SUBJECTSOONTINUINGIN THE TRFATMENT PERIOD(%)                                                                                                                                                                                                                   | 18 ( 23.1)                               |
| SUBJECTSSWITCHINGTOCROSSOVER PERIOD()                                                                                                                                                                                                                          | 18 ( 23.1)                               |
| SUBJECTSNOTCONTINUINGINTHETRFATMENTPERIOD(%)                                                                                                                                                                                                                   | 60 (76.9)                                |
| REASON FORNOT CONTINUINGIN THETREAIMENTFERIOD(%) DISFASEPROGRESSION SIUDYDRUG TOXICITY ADVERSEEVENTUNRELATPDTOSIUDYDRUG SUBJECTREQUESTTODISCONTINUESTUDYTREATMENT FOOR/NON-COMPLTANCE SUBJECTNOIONGERMEEISSTUDYCRITERIA SUBJECTSCONTINUINGTOBEFOLIOWED(）(A)(B) | 50 64.1) 24 2.6) 5.1) 2 2.6) 1 1.3) 1.3) |
|                                                                                                                                                                                                                                                                | 53 ( 67.9)                               |
| SUBJECTSNOTCONTINUINGTOBEFOLIOWED(%）(B)                                                                                                                                                                                                                        | 7(9.0)                                   |
| REASONFORNOTCONTINUINGTOBEFOLIOWED(%) SUBJECTWITHDREWOONSENT DEATH OTHER                                                                                                                                                                                       | 2 2.6) 4 5.1) 1.3)                       |

Percentages basedonsubjectsenteringperiodorcantinuingstudy

(B)Subjectstatusatendoftreatment;crossover subjectsare notcounted.

(A)Includes subjects stiil on treatment and subjects off treatment continuing in the Follow-up period

## · Outcomes

## Table 32 Summary of Efficacy Results - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

| Endpoint                                                            | Nivolumab3mg/kg(N=78)   |
|---------------------------------------------------------------------|-------------------------|
| PRIMARYENDPOINT                                                     |                         |
| ConfirmedObjectiveResponseRate(ORR,CR+PR)                           |                         |
| Responders,n (%)                                                    | 19 (24.4)               |
| 95%confidenceinterval(C1)                                           | (15.3, 35.4)            |
| SECONDARYENDPOINTS                                                  |                         |
| Duration ofResponse(DoR)                                            |                         |
| Ongoingresponder(asof the last available tumor assessment), n/N (%) | 13/19 (68.4)            |
| Median (95%C1),months                                               | NA (9.92, NA)           |
| Min, Max                                                            | 4.4, 16.6+              |
| Progression-freeSurvival (PFS)                                      |                         |
| Events, n (%)                                                       | 60 (76.9)               |
| Median(95%C1),months                                                | 2.78 (1.45, 5.85)       |
| Rate at6 months (95%C1),%                                           | 38.0 (27.1, 48.7)       |
| OverallSurvival (OS)                                                |                         |
| Events,n (%)                                                        | 46 (59.0)               |
| Median (95%C1),months                                               | 9.72 (7.26, 16.16)      |
| Rate at 6 months (95% Cl),%                                         | 69.2(57.7,78.2)         |
| Rate at12months(95%C1)%                                             | 45.6 (34.2, 56.3)       |
| EXPLORATORYENDPOINTS                                                |                         |
| EfficacybyBaselinePD-L1Expression (1%tumorcellmembraneexpression)   |                         |
| Subjectswith≥1%PD-L1Expression(n=25)                                |                         |
| Confimed ORR(95%C1)                                                 | 24.0 (9.4,45.1)         |
| MedianPFS(95%C1),months                                             | 5.45 (1.41, 11.17)      |
| Median OS (95%CI),months                                            | 16.16 (7.59, NA)        |
| Subjectswith<1%PD-L1Expression(n=42)                                |                         |
| ConfimedORR(95%C1)                                                  | 26.2 (13.9,42.0)        |
| MedianPFS(95%C1),months                                             | 2.76(1.41,6.51)         |
| MedianOS(95%C1),months                                              | 9.89 (7.03, NA)         |

Best overallresponsewas based on tumor assessment bythe investigator usingRECISTvl.1.

Medians and associated95%CIsforDOR,PFS,and OSwere calculatedusingKaplan-Mcier method.

Confidence interval for confirmed ORR was computed using the Clopper-Pearson method.

PFSandOSratesandassociated95%CIswerecalculatedusingKaplan-Meiermethod.

Symbol+indicates a censoredvalue.

Therewere1lsubjectswithoutPD-Llquantifiableatbaseline.

## Primary endpoint

<div style=\"page-break-after: always\"></div>

## Table 33 Best Overall Response per Investigator - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

<!-- image -->

## Secondary endpoints

Table 34 Time to Response and Duration of Response per Investigator - All Nivolumab Monotherapy Treated Urothelial Carcinoma Responders (study CA209032)

<!-- image -->

(A) Symbol + indicates a censored value.

(C）

(B)Median camputedusingKaplan-Meiermethod.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Symbolsrepresentcensoredobservalions. RECiST1.1ResponseCrileriawhereconfimalionofresponse isreauired.

Figure 13 Kaplan-Meier Plot of Progression Free Survival per Investigator - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

A pre-specified sensitivity analysis was performed for PFS in which there was no censoring for systemic anti-cancer therapy prior to a progression event. The results of this sensitivity analysis (median PFS: 2.76 [95% CI: 1.45, 5.52] months) were consistent with the PFS analysis using the primary definition.

As highlighted in the Kaplan-Meier plot in

Figure 14 , The median OS was 9.72 months and the OS rates (95% CI) were 78.2% (67.3, 85.8) at 3 months, 69.2% (57.7, 78.2) at 6 months, and 45.6% (34.2, 56.3) at 12 months.

Figure 14 Kaplan-Meier Plot of Overall Survival - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

<!-- image -->

Symbolsrepresentcensoredobservations

<div style=\"page-break-after: always\"></div>

An ad-hoc sensitivity analysis to assess the impact of planed treatment crossover on OS was conducted using Kaplan-Meier method. The 18 subjects who received planned crossover treatment with nivolumab + ipilimumab combination were separated from the remaining subjects who did not receive planned crossover treatment in the OS analyses. In subjects who did not receive planned crossover treatment, the median OS was 7.89 months (95% CI: 5.29, 16.16); the OS rate (95% CI) was 61.7% (48.2, 72.6) at 6 months and 43.3% (30.6, 55.3) at 12 months.

PD-L1 expression and efficacy results are shown in Table 35

Table 35 Frequency of PD-L1 Expression Status - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

| PD-L1ExpressionStatus                                                                                                                         | NUMBER OF SUBJECTS(%) Nivolumab   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
|                                                                                                                                               | N = 78                            |
| SUBJECTSWITHTUMDRTISUUESAMPLESCOLLECTEDATBASELINE                                                                                             | 71 (91.0)                         |
| SUBJECTSWITHPD-L1OUANTIFIABLEATBASELINE(A)                                                                                                    | 67 (85.9)                         |
| >= 1 <1%                                                                                                                                      | 25 (37.3) 42 ( 62.7)              |
| >=5% <5%                                                                                                                                      | 14 ( 20.9) 53 (79.1)              |
| SUBJECTSWITHOUTPD-L1QUANTIFIABIEATBASELINE                                                                                                    | 11 ( 14.1)                        |
| SUBJECTSWITHOUTTUMORTISSUESAMPLE(B) SUBJECISWITHTUMDRTISSUESAMPLEOOLIECTEDONSIUDYONLY(C) SUBJECISWITHINDETERMINATEPD-L1EXPRESSIONATBASELINEOR | 7(9.0) 0                          |
| WITH PD-L1 EXERESSION AT BASELINE NOT EVALUABLE (D)                                                                                           | 4( 5.1)                           |

(A）Subjectswithatleastonetumorsamplecollectedatbaseline，withnumberviabletumor (B)+(C)+(D):SubjectswithoutquantifiabletumorPD-L1expressionatbaseline Source:Table7.4.1.1-1of theCA209032CSR

<div style=\"page-break-after: always\"></div>

Table 36 Best Overall Response and Objective Response per Investigator for each PD-L1 Expression Status Group - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

| PD-Ll Expression Result Group at Baseline                                                  | Niwolumab N = 78      |
|--------------------------------------------------------------------------------------------|-----------------------|
| SUBJECTSWITHBASELINEPD-L1EXPRESSION >=5%                                                   | 14 ( 17.9)            |
| BEST OVERAIL RESPONSE (A):                                                                 |                       |
| COMPLETE RESFONSE  (OR)                                                                    | 2 (14.3)              |
| PARTIAL RESFONSE (PR)                                                                      | 2 (14.3)              |
| STABLE DISEASE (SD)                                                                        | 6 (42.9)              |
| PROGRESSIVE DISEASE (PD)                                                                   | 3 ( 21.4)             |
| UNABLE TO DEIERMINE (UID)                                                                  | 17.7.1)               |
| OBJECTIVE RESPONSE RATE (1)                                                                | 4/14( 28.6%)          |
| (95% CI)                                                                                   | (8.4,58.1)            |
| SUBJECTS WITH BASELINE FD-L1EXPRESSION < 5%                                                | 53 ( 67.9)            |
| BEST OVERAIL RESPONSE (A):                                                                 |                       |
| COMPLETE RESFONSE  (OR) PARTIAL RESFONSE (FR) STABLE DISEASE (SD) PROGRESSIVE DISFASE (PD) | 3( 5.7)               |
|                                                                                            | 10 (18.9)             |
|                                                                                            | 13 (24.5) 23 ( 43.4)  |
| UNABLE TO DETERMINE (UID)                                                                  | 4( 7.5)               |
| OBJECTIVE RESFONSE RATE (1)                                                                | 13/53 ( 24.5%)        |
| (95% CI)                                                                                   | (13.8, 38.3)          |
| SUBJECTSWITHBASELINEFD-L1EXPRESSION>=18                                                    | 25 ( 32.1)            |
| BEST OVFRAIL RESPONSE (A): COMPLETE RESFONSE (CR)                                          | 4 ( 16.0)             |
| PARTIAL RESFONSE (PR)                                                                      | (8.0)                 |
| STABLE DISEASE (SD)                                                                        | 8( 32.0)              |
| PROGRESSIVE DISFASE (PD)                                                                   | 8( 32.0)              |
| UNABLE TO DETERMINE(UTD)                                                                   | 3 ( 12.0)             |
| OBJECTIVE RESFONSE RATE (1)                                                                | 6/25(24.0%)           |
| (95% CI)                                                                                   | (9.4,45.1)            |
| SUBJECTS WITH BASELINE FD-I1 EXPRESSION < 18                                               | 42 ( 53.8)            |
| BEST OVERAIL RESFONSE (A): COMPLETE RESFONSE (CR)                                          | 1 (.2.4)              |
| PARTIAL RESFONSE (PR)                                                                      | 10 ( 23.8)            |
| STABLE DISEASE (SD)                                                                        | 11 ( 26.2) 18 ( 42.9) |
| PROGRESSIVE DISFASE (PD)                                                                   |                       |
| UNABLE TO DEIERMINE (UTD)                                                                  | 2.(4.8)               |
| OBJECTIVE RESFONSE RATE (1)                                                                | 11/42 ( 26.2%)        |
| (95%CI)                                                                                    | (13.9,42.0)           |
|                                                                                            | 11 ( 14.1)            |
| SUBJECTSWITHOUTPD-L1OUANTIFIABIEATBASELINE                                                 |                       |
| BEST OVERAIL RESFONSE (A):                                                                 | 0 2 (18.2)            |
| COMPLETE RESFONSE  (OR) PARTIAL RESFONSE (PR) STABLE DISEASE (SD)                          | 3 (27.3)              |
| PROGRESSIVE DISFASE (PD)                                                                   | 4( 36.4)              |
| UNABLE TO DETERMINE (UTD)                                                                  | 2 (18.2)              |
| OBJECTIVE RESFONSE RATE (1)                                                                | 2/11 ( 18.2%)         |
| (95% CI)                                                                                   | (2.3, 51.8)           |

a Using RECIST 1.1 criteria.

CR+PR, Confidenoe interval based on the Clopper-Pearson method

<div style=\"page-break-after: always\"></div>

Table 37 Time to Response and Duration of Response per Investigator by PD-L1 Status at Baseline - All Nivolumab Monotherapy Treated Urothelial Carcinoma Responders (study CA209032)

|                                                            | PD-L1 >= 1% N=6   | PD-L1 <1% N = 11   | INDETERMINATE/ NOT EVALUABLE/ MISSING N=2   |
|------------------------------------------------------------|-------------------|--------------------|---------------------------------------------|
| TIMETORESPONSE(MONTHS)                                     |                   |                    |                                             |
| NUMBER OFRESPONDERS                                        | 6                 | 11                 | 2                                           |
| MEAN                                                       | 3.87              | 2.56               | 2.10                                        |
| MEDIAN                                                     | 3.42              | 1.48               | 2.10                                        |
| MIN, MAX                                                   | 1.0, 8.3          | 1.2, 5.3           | 1.3, 2.9                                    |
| Q1,Q3                                                      | 1.18, 5.91        | 1.35, 4.11         | 1.31, 2.89                                  |
| STANDARDDEVIATION                                          | 3.145             | 1.544              | 1.115                                       |
| DURATION OFRESPONSE(MONTHS)                                |                   |                    |                                             |
| MIN, MAX (A)                                               | 8.3+, 13.5+       | 4.4, 16.6+         | 5.2,8.0+                                    |
| MEDIAN(95%CI）(B)                                           | 12.48(9.92,N.A.)  | N.A. (5.55, N.A.)  | N.A. (5.22, N.A.)                           |
| NEVENT/N RESP(%)                                           | 2/6 (33.3)        | 3/11 (27.3)        | 1/2 (50.0)                                  |
| NUMBER OF SUBJECIS WITH DURATION OF RESFONSE OFAT LEAST(%) |                   |                    |                                             |
| 3 MONTHS                                                   | 6 (100.0)         | 11 (100.0)         | 2 (100.0)                                   |
| 6 MONTHS                                                   | (100.0)           | 7 (63.6)           | 1 ( 50.0)                                   |
| 12 MONTIS                                                  | 2 (33.3)          | 3 (27.3)           |                                             |
| 18 MONTHS                                                  | 0                 | 0:0                | 0:0                                         |
| 24 MONTHS                                                  | 0                 |                    | 0                                           |
| NUMBER OF SUBJECTS ACHIEVED PR OR CR (%)）(C)               |                   |                    |                                             |
| WITHIN THE FIRST 9WEEKS                                    | 3 (12.0)          | 6 14.3)            | 1 9.1)                                      |
| WITHIN THE FIRST 4MONTHS                                   | 3 12.0)           | 7 16.7)            | 18.2)                                       |
| WITHIN THE FIRST 6 MONTHS                                  | 5 20.0)           | 11 26.2)           | 18.2)                                       |
| WITHIN THE FIRST 8MONTHS                                   | 5 20.0)           | 11 26.2)           | 2222 18.2)                                  |
| WITHIN THE FIRST 12 MONTHS                                 | 6 24.0)           | 11 26.2)           | 18.2)                                       |
| WITHIN THE FIRST 18 MDNTHS                                 | 6 (24.0)          | 11 26.2)           | 18.2)                                       |

Symbol + indicates a censored value.

C Denominator based on All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects in Corresponding PD-L1 Subgroup Subjects\\_who progressed before achieving objective response are excluded from the calculation of time to response.

(B) Median camputed using Kaplan-Meier method.

<!-- image -->

Figure 15 Kaplan-Meier Plot of Progression Free Survival by PD-L1 Status at Baseline (1 Percent Cutoff) - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

<div style=\"page-break-after: always\"></div>

<!-- image -->

- - PD-L1 expression &lt; 1% (events: 25/42), median and 95% Cl: 9.89 (7.03. N.A.)
- No Quantifiable PD-L1 (events: 8/11). median and 95% Cl: 6.51 (1.91, N.A.)

Figure 16 Kaplan-Meier Plot of Overall Survival by PD-L1 Status at Baseline (1 Percent Cutoff) - All Nivolumab Monotherapy Treated Urothelial Carcinoma Subjects (study CA209032)

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

This application in bladder cancer is based on two ongoing clinical studies: one pivotal Phase 2 study in metastatic or unresectable urothelial cancer (CA209275) and one supportive Phase 1/2 study in multiple tumour types, including unresectable locally advanced or metastatic UC (CA209032), both conducted in patients who has progressed on or after to at least 1 platinum-containing chemotherapy regimen.

Both studies are single arm trials hampering any discussion about relative efficacy of nivolumab versus chemotherapy. Previously reported data on therapy for relapse in metastatic and advanced UC are highly variable with results being vastly dependent on patient selection; therefore there is a risk that the outcomes of these two studies are overestimated (see discussion on efficacy data).

Patients intended to be recruited, according to the inclusion/exclusion criteria, were subjects with histological or cytological evidence of metastatic or surgically unresectable urothelial carcinoma originating in the bladder, urethra, ureter, or renal pelvis. They must have progression or recurrence after treatment with at least 1 platinum-containing chemotherapy regimen for metastatic or surgicallyunresectable locally advanced urothelial cancer, or within 12 months of peri-operative (neo-adjuvant or adjuvant) treatment with a platinum- containing chemotherapy in the setting of cystectomy for localised muscle- invasive UC. These inclusion criteria can be considered representative of the claimed indication,

<div style=\"page-break-after: always\"></div>

i.e. patients with locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum- containing therapy.

The primary endpoint for both studies was confirmed ORR (BICR assessment and investigator assessment in CA209275 and CA209032 respectively). TTR, DoR, PFS and OS were secondary endpoints. The use of ORR as primary endpoint is acceptable for phase I/II studies, although cannot be used on its own to demonstrate the clinical benefit to patients. Long term clinical outcomes like PFS and OS have been provided as secondary endpoints, which are considered appropriate in such trial designs.

## Efficacy data and additional analyses

In the Study CA209275, 386 subjects were enrolled at 63 sites in 11 countries. Of them 265 were considered the efficacy population, given the requirement of a minimum follow up of 6 months from the global enrolment last patient first treatment date. The main reason for not treating patients was that subject no longer met the inclusion criteria. Patients included were mainly white (85.6%) and male population (78.1%) with urinary bladder as tumour type (73%). Only 3.3% were locally unresectable. Almost 28% of patients had liver metastasis and 84% with visceral metastases. There were no patients but one with CNS metastases. Regarding the previous treatment received, 71.5% had received previous treatment in the metastatic setting. All patients had received platinum treatment, with almost 66% of patients with the most recent platinum regimen in the metastatic setting. Of note, 59% of patients progressed in less than 3 months from the last platinum treatment. Subjects with ECOG &gt;1 were not included (except for 1 protocol deviation). Results from these patients can not necessarily be extrapolated to patients who have a ECOG performance status of 2 or higher, which comprise almost 40-50% of the advanced and metastatic urothelial carcinoma patients.

Most baseline demographics and disease characteristics were balanced between PD-L1 cohorts, except for the distribution of baseline poor prognostic factors, most apparent when using the 1% cut-off for PD-L1 expression.

Overall, the patients recruited in study CA209275 seem to have a poor prognosis, especially when considering the percentage of patients with visceral metastasis and the treatment free interval. Study CA209032 reveals a similar population in regard to baseline characteristics, though with a smaller number of treated patients (78).

At the time of initial submission, outcomes from the pivotal trial (study CA209275) in terms of ORR by BICR showed a response rate of 19.6% in all treated patients (23% by investigator assessment), with a median of duration of response not reached yet but with the lower bound of 7.43 months (77% of patients were in response at the database lock) and with a time to objective response of around 2 months. This antitumor activity could be translated into a life expectancy of 8-9 months in terms of median, even though the percentage of events was 51%. Two pre-specified sensitivity analyses were performed for BIRC-assessed BOR and the results of these analyses were consistent with those of the primary analysis.

Median PFS was around 2 months with 76% of events. These results are supported by those from the study CA209032, where the ORR were 24% (investigator assessment) and similar PFS and OS results were achieved (median PFS 2.78 months and 9.72 months of OS).

Updated efficacy data submitted during the review, from study CA209275 with a clinical cut-off of 21 July 2016, showed similar results: ORR of 20.0% (95% CI: 15.4, 25.3) in all treated subjects and a median OS of 8.57 months (95% CI: 6.05, 11.27). The median DOR per BIRC was 10.35 months in all treated subjects;  however this  seemed to  be  reflective  of  1  subject  experiencing  a  late  event  and  which  may change with longer follow-up. More than half (34/54, 63.0%) of the responders had ongoing response at the time of the clinical cut-off for this analysis.

<div style=\"page-break-after: always\"></div>

Twenty  percent  of  the  subject  received  subsequent  cancer  therapies  in  the  pivotal  trial  and  30%  of patients  in  the  study  CA209032.  The  MAH  was  requested  to  discuss  the  potential  impact  of  postprogression therapies on OS. The use of subsequent therapies seemed to have an important impact on the  OS  data.  Despite  only  54  (20%)  subjects  received  subsequent  therapy  with  28  (10.4%)  receiving systemic  anticancer  therapy,  when  these  patients  were  excluded  from  the  analysis,  the  median  OS decreased to 6.47 (95% CI: 4.76, 9.99) months from the 8.57 months in whole population (95% CI: 6.05, 11.27). On the other hand, this decrease in the median did not have a great impact in the long term survival, since the 1-year survival rate appeared to be identical. Similar conclusions were observed in  the  study  CA209032.  In  any  case,  the  OS  data  in  whole  population  and  especially  in  PD-L1&gt;1% patients, appeared overall superior to those described with chemotherapy, with higher survival rates at 12  months.  However,  in  the  PD-L1&lt;1%  subgroup,  when  only  subjects  without  subsequent  anticancer therapy were analysed, the 12-month survival rate decreased to 33.5%, which appeared similar to those described in larger trials with single-agent chemotherapy (25%-30%). The lack of comparator hampered further discussion on this issue.

As expected, results in those subgroups of patients with poorer prognosis (visceral and hepatic metastasis, high ECOG) obtained lower ORR. Of note, the response rate according to the different age groups showed that older subgroups had better results.

In the pivotal study, similar PFS and OS results were observed for subgroups with different numbers of prior regimens in the metastatic setting. Patients with a shorter time from the most recent prior regimen, which could represent those who have experienced rapidly progressing disease, had worse OS and ORR results than patients with longer time since prior treatment, who may have had more indolent disease. The median TTR was 1.87 months. It is possible that patients with rapidly progressing tumours have insufficient time to experience benefit from treatment with nivolumab. Nevertheless, the nivolumab treated group seems to experience a better response than what is expected for chemotherapy and in the subgroup designated as PD-L1&lt;1%, the responses are considered superior to the standard of care. Therefore, while it is possible that patients may experience a delay in the onset of response to nivolumab as observed in other indications, because of the lack of a control arm it is not possible to elucidate whether the survival curve of nivolumab would be below chemotherapy at the beginning of the treatment.

The design of the studies as single arm trials is considered an important drawback as it hampers the interpretation of the results in a heterogeneous patient population. According to the bibliography in metastatic bladder cancer, the therapeutic landscape after a first treatment of platinum (vinflunine, taxanes, gemcitabine and pemetrexed) offers ORRs in monotherapy that range between 10-15% with a median OS of 7-9 months, with the exception of gemcitabine that as single agent has demonstrated ORRs of 11-29%, with median OS that ranged from 5 to 13 months, as second-line therapy in small Phase 2 studies (N&lt;50) 8,9,10,11 . With taxane-based combination chemotherapies, ORRs increase up to 30-70%, with 11-13 months of OS, however these regimens are not frequently used due to their toxicity 12 .

In both studies CA209275 and CA209032, in the subset of patients with high tumour PD-L1 expression i.e. &gt;1%, treatment with nivolumab showed consistently higher rates of tumour responses (over 24%) and a trend  for  higher  OS  when  compared  to  what  has  been  reported  in  the  literature.  These  results

8 Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the

urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998;34:1208-12. 9 Gebbia V, Testa A, Borsellino N, et al. Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial

carcinoma: a phase II study. Clin Ter. 1999;150:11-5.

10 Albers P, Siener R, Hartlein M, et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie. 2002;25:47-52.

11 Akaza H, Naito S, Usami M, et al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol. 2007;37:201-6.

12  Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C, Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016 Feb;195(2):25463. doi: 10.1016/j.juro.2015.06.115. Epub 2015 Sep 26.

<div style=\"page-break-after: always\"></div>

support a trend for a greater benefit in patients that have tumours that express PD-L1. Similar results were  provided  by  the  study  CA209032.  These  promising  results  in  patients  with  high  tumour  PD-L1 expression  are  very  much  in  line  with  those  reported  for  other  immunotherapeutic  medicinal  products with a similar mechanism of action and add further to the biological plausibility to the observed results.

In the pivotal study CA209275, patients with tumour PD-L1 expression≥1% and 5% obtained ORRs of 25% and 30% respectively, while patients with tumour PD-L1 expression&lt;1% had an ORR of 16%. Both PFS  and  OS  were  longer  for  patients  with  high  tumour  PD-L1  expression  (median  OS  11.6  and  12.9 months in PD-L1 ≥1% and PD-L1 ≥5% respectively vs. 6 months in PD-L1 &lt;1% and PD-L1 &lt;5%; median PFS 3.55 months in PD-L1 ≥1% and 3.71 months in PD-L1 ≥5% and 1.9 months in PD-L1 &lt;1% and PDL1  &lt;5%).  The  largest  baseline  differences  between  the  two  PD-L1  subgroups  (&lt;1%  and  &gt;1%) encompassed  smoking  status  and  Bellmunt  Risk  Factors.  The  percentage  of  never  smokers  was  10% higher  in  the  PD-L1&lt;1%  (29.5  vs  19.4%).  On  the  other  hand,  there  were  more  patients  with  2-3 Bellmunt Risk Factors in the PD-L1&lt;1% than in the &gt;1% subgroup (28% vs. 16.1%). To what extent these imbalances influenced the results is not totally clear. Among the rest of baseline characteristics, the differences were judged as not to have strongly impacted on the survival. It was notable that for patients with tumour PD-L1&lt;1% a shorter median OS was observed in the vast majority of subsets, in particular for patients with poor prognostic factors.

In the supportive study CA209032, ORR did not seem to be affected by tumour PD-L1 expression, with ORR of 24% and 26% for patients with above 1% expression and below 1% expression, respectively. Of importance  is  that  durable  responses  were  observed  across  all  PD-L1  subgroups.  The  duration  of response  (DoR)  reached  with  nivolumab  appeared  better  than  DoRs  described  for  all  other  available therapies  (including  combination-chemotherapy),  even  in  the  subgroups  with  PD-L1  expression  below 1%. Therefore, while the response rates achieved with nivolumab in subgroups with PD-L1&lt;1% were not very high, the responses were durable which is considered clinically relevant.

Whilst the median of OS with nivolumab in patients with PD-L1 &lt;1% and with presence of 2 Bellmunt factors was 3.15 months, the OS rates at 1 year was 13.4% (Table 23) which appear to be similar to chemotherapy (i.e. &lt;10%) 13 . The 1 year survival rate in the overall population of patients PD-L1&lt;1% provided similar results to chemotherapy (i.e. 34% reported with nivolumab in study CA209275 (Table 18)  versus  31%  reported  with  chemotherapy  in  study  KEYNOTE-45) 14 and  the  1-year  survival  rate  in those patients in response, was close to 96%, which is considered clinically meaningful. Therefore, it is considered reasonable to assume that the use of nivolumab, also in patients with PD-L1 &lt;1% for second line treatment of UC, will provide comparable rates of response to chemotherapy. Also, these responses are more durable than achieved with any other therapy, and the survival benefit is very much in line to that reported for chemotherapy.

The SmPC has been updated to reflect that results from post-hoc, exploratory analyses indicate that in patients with low (e.g. &lt;5%) to no tumour PD-L1 expression, other patient characteristics (e.g. liver metastases, visceral metastases, baseline haemoglobin &lt;10g/dL and ECOG performance status = 1) might contribute to the clinical outcome (see SmPC section 5.1).

The ROC curve based on response showed that there was no optimal cut-off for PD-L1 expression. Additional analyses requested by the CHMP showed that some biomarkers analysed were not predictive of response of nivolumab, being Interferon-gamma gene (RNA) expression signature using the provided assay, myeloid-derived suppressor cells (MDSCs; % of CD14+LIN-) abundance, percentage of CD8+ T cells infiltrate in tumour and the ratio of CD8+ T cells to FOXP3+ cells (T regulatory cells). No firm conclusions could be drawn regarding PD-L2 tumour expression, due to the low number of tumour cells expressing PD-L2. The combination of PD-L1 expression on immune cells and PD-L1 on tumour cells

13 J Clin Oncol. 2010 Apr 10;28(11):1850-5

14 Bellmunt et al. NEJM 2017

<div style=\"page-break-after: always\"></div>

might be helpful in identifying which patients have limited chance of responding to therapy (Table 27). Few responders to nivolumab (RR 7-8%) were observed among patients with both no/rare PD-L1 expression on immune cells and PD-L1&lt;1% or &lt;5% expression on tumour cells, however no quantitative method was used as currently no validated assays and methods exists. Therefore, PD-L1 expression on both immune cells and tumour cells should be assessed in predicting treatment response and survival in a prospective manner and using validated assays and methods where possible. Other biomarkers such as other gene signatures, mutational load, PD-L1 and PD-L2 on mRNA remain to be evaluated, however, tissue inventory limitations have to be taken into account. Annex II has been updated accordingly. In particular the MAH will further explore in UC patients the early identification of those who do/do not respond to treatment with nivolumab, as well as evaluate the association between improved clinical outcomes to nivolumab and the presence of mutational and neoantigen load and of PD -L1 expression on tumour- and tumour associated immune cells using validated approaches as feasible. These biomarker assessments will be exploratory for study CA209275, however they should be prospectively assessed in future UC studies with nivolumab.

Furthermore,  in  melanoma  a  high  level  of  LDH  seems  to  be  a  predictor  of  low  nivolumab  benefit. Unfortunately, very few UC patients (3.7%) had a baseline LDH of &gt; 2*ULN, so no firm conclusions can be drawn from the 2*ULN cut-off. Though there are differences observed in efficacy outcomes between those with elevated LDH and those with normal LDH levels, there are still responders among patients with elevated LDH level and thus this cannot be used to exclude patients from treatment. When combined with subgroups  stratified  for  PD-L1  expression,  the  LDH  level  provides  no  additional  value  for  treatment selection.

## 2.4.4. Conclusions on the clinical efficacy

Nivolumab has shown a clinically meaningful result in terms of ORR and OS in two single arm trials.  In patients with PD-L1 expression below 1%, response rates and OS were very much in line to those expected from chemotherapy, also the responses were more durable than achieved with current standard of care.

No useful clinical risk factor or biomarker predictive of treatment response was identified. Based on the above, the CHMP considers the following measures necessary to address issues related to efficacy (Annex II condition):

The value of biomarkers to predict the efficacy of nivolumab therapy should be further explored in patients with urothelial carcinoma:

- To further investigate the value of biomarkers other than PD-L1 expression status at tumour cell membrane level by IHC (e.g., other genomic-based methods / assays, and associated cut-offs, that might prove more sensitive and specific in predicting response to treatment based on PD-L1, PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA signature, expression of components of antigen-presentation complexes and/or other inhibitory checkpoint receptors/ligands within tumour, etc.) as predictive of nivolumab efficacy. This will be provided for urothelial carcinoma studies CA209275 and CA209032: by 30 June 2018
- To further explore in UC patients the early identification of those who do/do  not respond to treatment with nivolumab, as well as to evaluate the association between improved clinical outcomes to nivolumab and the presence of:
- o Mutational and neoantigen load, and PD -L1 expression on tumour- and tumour associated immune cells using validated approaches as feasible: by 30 June 2018

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The MAH provided a summary of clinical safety (SCS) that was an integrated view of the safety data from the nivolumab clinical development program supporting the recommended dose schedule for nivolumab monotherapy (3 mg/kg IV Q2W) and the labelling information for an indication in subjects with locally advanced or metastatic  urothelial  carcinoma  (UC)  who  have  disease  progression  during  or  following  a platinum-containing  chemotherapy  or  within  12  months  of  neoadjuvant  or  adjuvant  treatment  with  a platinum-containing therapy.

It included safety and tolerability data from 1 Phase 2 study, CA209275: a single arm study of nivolumab (270  treated  subjects)  in  subjects  with  metastatic  or  surgically  unresectable  urothelial  carcinoma  who have progressed or recurred following treatment with a platinum agent and the 1 supportive Phase 1/2 study,  CA209032,  an  open-label  study  of  nivolumab  monotherapy  or  nivolumab  combined  with ipilimumab  in  subjects  with  advanced  or  metastatic  solid  tumors  (78  treated  subjects  in  nivolumab monotherapy UC cohort). A final CSR for  CA209275 based on the 30-May-2016 database lock and an interim CSR for CA209032 based on the 24-Mar-2016 database lock.

Integrated safety data were presented for 348 UC subjects from CA209275 and CA209032 (nivolumab monotherapy UC cohort), hereafter referred to as the 'Integrated UC Population'. Both studies included a nivolumab 3 mg/kg Q2W dosing regimen and the same method of safety data collection. The Integrated UC Population was the population for presentation of safety of nivolumab monotherapy in UC.

<div style=\"page-break-after: always\"></div>

|                                                             | CA209275@N=270)             | CA2090321CA209275（N=348)   | CA2090321CA209275（N=348)   | CA2090321CA209275（N=348)            |
|-------------------------------------------------------------|-----------------------------|----------------------------|----------------------------|-------------------------------------|
| DEATHS                                                      | 138 51.1)                   |                            | 174 C 50.0)                |                                     |
| WITHIN 30 DAYS OFIASTDOSE WIIHIN 1OO DAYS OEIASTDOSE        | 53 19.6) 121 44.8)          | (a)                        | 60 17.2) 146 42.0) 4 1.1)  | (b)                                 |
| DUETOSIUDYDDGTOXICTTY                                       | 3 1.1)                      |                            |                            |                                     |
|                                                             | Nunber (8) Subjeots         | Nunber (8) Subjeots        | Nunber (8) Subjeots        | Nunber (8) Subjeots                 |
|                                                             | CA209275 (OLZ=N) Any Grade  | Grada3-4                   | CA209032 Any Gzade         | ICA209275(N=348) Grade3-4           |
| AILCAUSALTTYSAES DRUG-RSTATSDSAFS                           | 147 （54.4) 25 9.3)          | 99(36.7) 18 6.7)           | 183 33 (9.5)               | （52.6）122（35.1) 23 (6.6)            |
| ALLCAUSALITYAE'SLEADINGTODC DRUG-RETAIEDAESLEADINGTODC      | 56 （20.7） 13 4.8)           | 42 (15.6) 8 3.0)           | 62 17.8) 15 4.3)           | 46 (13.2) 10 2.9)                   |
| AILCAUEALTTYAES                                             |                             | （98.9)137（50.7)            |                            | （51.7)                              |
|                                                             | 267                         |                            | 345(99.1)                  | 180                                 |
| MostErequentAEs20oofAnyGradineithertreatmant FATIGUE NAUSEA | 87(32.2) 60（22.2) 59 (21.9) | graup) 7(2.6) 2 6 2.2)     | 129 0.7) 33 70 （20.1)      | (37.1) 10 2.9) （23.9) 3 0.9) 6 1.7) |
| DEOREASED APIETTTE DRUG-RELAIEDAES                          | 174(64.4)                   | 48 (17.8)                  | 239(68.7)                  |                                     |
| MostFrequentDzug-relatedAEs10afAnyGradeineither EATIGUE     | 45(16.7)                    | 5（ 1.9) 0                  | trsatmantgoup)             | 66(19.0) 7                          |
| ERURTTUS ALLCAUSAIITYSSTECTAES,BYCATHGORY ENDOORINE         | 25(9.3) 43 15.9)            | 1 0.4) 3.0)                | 73(21.0) 48（13.8)          | （2.0) 0                             |
| HEPATIC PULMONARY                                           | 33 12.2) 15                 | 8 5.6)                     | 52(14.9) 1                 | 0.3) 11                             |
| GASTROINTESTINAL                                            | 48 17.8)                    | 0.7)                       | 64(18.4)                   | 3.2) （5.5)                          |
|                                                             | 12 4.4)                     | 2 2.2)                     | 45(12.9) 19 14（ 4.0)       | 2 (0.6) 3.2)                        |
| RENAL                                                       | 28 10.4)                    | 6 1.5)                     | 50 (14.4)                  | 11 66 1.7)                          |
| SKTN                                                        | 73 27.0)                    | 4                          | 109 (31.3)                 |                                     |
| HYPERSENSITIVITY/IEUSIONREACTION                            | 1.9)                        | 1 0.4)                     | 8 2.3)                     | 1（ 0.3)                             |
|                                                             | 5                           |                            |                            |                                     |
| DRUG-RETATSDSST3CTAES,EYCATFGORY ENDOORINE                  |                             |                            |                            | 1 0.3)                              |
|                                                             | 39 (14.4)                   | 1 0.4)                     | 45 (12.9)                  | 7 2.0)                              |
|                                                             | 25 9.3)                     | 2.2)                       | 33 9.5)                    | 1.7)                                |
| GASTROINIESTINAL                                            | 10                          | 6                          |                            |                                     |
| HEPATIC                                                     | 3.7)                        | 5                          | C                          | 6                                   |
| EULMONARY RONAL                                             | 11 4.1)                     | (1.9)                      | 14 4.0)                    | 0.9)                                |
| SN                                                          | 3 1.1)                      | 3 1.1)                     | 13 3.7)                    | 3 2 0.6)                            |
|                                                             | 47（17.4)                    | 1 0.4)                     | 10 2.9) 80                 | 1.7)                                |
| HYPERSENSTTIVITY/INEUSIONREACTION                           |                             | 4 （ 1.5)                   | (23.0)                     | 6                                   |
|                                                             | 3(1.1)                      | 0.4)                       |                            | 0.3)                                |
|                                                             |                             | 1                          | 5（ 1.4)                    |                                     |
|                                                             |                             |                            |                            | 1                                   |

Table 38 Summary of Safety Results - All Treated Subjects in CA209275 and Integrated Population

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 39 Summary of Safety Results (CA209032, CA209275 and Pooled UC)

<!-- image -->

|                                                               | CA209032 (N=78) %   | CA209275 (N=270) 0%   | PooledUC CA20925275+CA209032 (N=348) %   |
|---------------------------------------------------------------|---------------------|-----------------------|------------------------------------------|
| All causality AEs, any grade, n (%)                           | 78 (100)            | 267 (98.9)            | 345 (99.1)                               |
| All causality AEs, Grade 3-4                                  | 43 (55.1)           | 137 (50.7)            | 180 (51.7)                               |
| Drug-related AEs, any grade n (%)                             | 65 (83.3)           | 174 (64.4)            | 239 (68.7)                               |
| Drug-related AEs, Grade 3-4                                   | 18 (23.1)           | 48 (17.8)             | 66 (19.0)                                |
| Drug-related SAEs, any grade, n (%)                           | 8 (10.3)            | 25 (9.3)              | 33 (9.5)                                 |
| Drug-related SAE, Grade 3-4                                   | 5 (6.4)             | 18 (6.7)              | 23 (6.6)                                 |
| Drug-related AEs leading to discontinuation, any grade, n (%) | 2 (2.6)             | 13 (4.8)              | 15 (4.3)                                 |
| Drug-related AEs leading to discontinuation, Grade 3-4, n (%) | 2 (2.6)             | 8 (3.0)               | 10 (2.9)                                 |
| Drug-related deaths, n (%)                                    | 2 (2.6)             | 3 (1.1)               | 4 (1.1)                                  |

## Patient exposure

The nivolumab monotherapy UC safety data from studies CA209275 and CA209032 were pooled for the SCS since both studies used the same dosing schedule and the study populations were comparable. The populations  are  not  comparable  enough  for  pooling  of  efficacy  due  to  differences  in  line  of  therapy. CA209275 and CA209032 are the only studies in which patients with metastatic or surgically unresectable UC  have  been  treated  with  nivolumab  in  accordance  with  International  Conference  on  Harmonisation (ICH) guidance provided in the M4E(R1).

The Study CA209275 is a single arm, open-label Phase 2 trial. Safety analyses were conducted in all 270 subjects  with  metastatic  or  surgically  unresectable  UC  who  have  progressed  or  recurred  following treatment with a platinum agent. At the time of database lock, 270 subjects were treated with nivolumab monotherapy. Safety analyses were conducted in all 270 treated subjects who received at least one dose of  study  drug.  Study  CA209032  was  a  multicenter,  open-label,  Phase  1/2  study,  only  data  from  the nivolumab monotherapy UC cohort is included in the safety analysis. At the time of database lock, 78 subjects  were  treated  with  nivolumab  monotherapy.  Safety  analyses  were  conducted  in  all  78  treated subjects who received at least one dose of study drug. Both studies included a nivolumab 3 mg/kg Q2W dosing regimen and the same method of safety data collection.

In  the  Integrated  UC  Population  (Table  40)  the  majority  of  subjects  (80.2%)  received  ≥  90%  of  the planned  nivolumab  dose  intensity,  the  median  number  of  nivolumab  doses  received  was  7.0  and  the median duration of therapy was 3.25 months with 52.6%, 33.3%, 15.8%, and 5.2% of subjects treated for more than 3, 6, 9, or 12 months, respectively.

<div style=\"page-break-after: always\"></div>

Compared with CA209275 and the Integrated UC Population, subjects in CA209032 received a slightly higher median cumulative dose of nivolumab as a higher percentage of subjects were treated for more than 9 and 12 months.

Table 40 Cumulative Dose, Relative Dose Intensity, and Duration of Therapy Summary- All Treated Subjects

<!-- image -->

|                                                                          | CA209032 N-78                         | OA209275 N-270                           | CA209032+CA209275 N = 348                  |
|--------------------------------------------------------------------------|---------------------------------------|------------------------------------------|--------------------------------------------|
| MMEEROF DOSES RECETVED MEAW (SD) MEDIAN MIN-MAX)                         | 13.6(12.24) 8.5(1-46)                 | 9.3(7.15) 7.0（1-30）                      | 10.2(8.72) 7.0(1-46)                       |
| CUMUTATTVE DOSE(MG/KG) MEAN (SD) MEDIANIN-MAX                            | 40.55(36.241) 25.88(3.0-138.1)        | 27.82(21.310) 21.06 (3.0-89.0)           | 30.67(25.918) 21.44(3.0-138.1)             |
| RELATIVE DOSEINTENSTTY 110 9020<110 70T0 908 50.20<70 50%                | D 68                                  | 0 211 51 78.1) 18.9)                     | 0 279 60 17.2 80.2) 0.9                    |
| DURATICNCETHERAPY(MDNEHS) MIN,MAX (A) MEDIAN(95CT）（B) NCEETRT/ TREAED （） | 0.0,20.7 3.47（2.33， 5.09) 60/78(76.9) | 0.0,13.4+ 3.25（2.33, 3.48) 204/270(75.6) | 0.0,20.7+ 3.25.(2.73,3.48) 264/348(75.9)   |
| OTHERSTATISTTCS MEAN STANDARD DEVIATION >12MNIRS（） >6MNHS >9MDNS 3MDNRS  | 6.10 5.891 42 29 23 16 53.8) 37.2)    | 4.13 3.437 141 87 32 11 32               | 4.57 4.187 116 55 18 52.6) 33.3 15.8) 5.2) |

## Adverse events

## Common AEs

In the Integrated UC Population, the frequency, type, and severity of all-causality AEs (any grade and Grade 3-4) reported in subjects treated with nivolumab were consistent with the known safety profile of nivolumab.

In the Integrated UC Population, drug-related AEs consisted mainly of events in the general disorders and administration site conditions, skin and subcutaneous tissue disorders and GI disorders SOCs.

## Adverse Events (Regardless of Causality)

In  the  Integrated  UC  Population,  any-grade  AEs  (regardless  of  causality)  were  reported  in  99.1%  of subjects  treated  with  nivolumab  (Table 41).  The  most  frequently  reported  AEs  were:  fatigue  (37.1%), nausea (23.9%), anaemia (20.1%), decreased appetite (20.1%), and cough (17.8%).

In  the  Integrated  UC  population,  Grade  3-4  AEs  (regardless  of  causality)  were  reported  in  51.7%  of subjects  (Table  41).The  most  frequently  reported  Grade  3-4  AEs  were  anaemia  (6.9%),  urinary  tract infection  (5.7%),  malignant  neoplasm  progression  (4.3%),  dyspnoea  (3.7%),  asthenia  (3.2%),  and hyponatremia (3.2%)

<div style=\"page-break-after: always\"></div>

Table 41 AEs (All Causality) by Worst CTC Grade Reported within 30 Days of Last Dose in ≥10% of Treated Subjects - CA209275 and Integrated UC Population

| System Organ Class (8) Preferred Term (8)                                       | CA209275 N = 270                                      | CA209275 N = 270                           | CA209275 N = 270   | CA209032+CA209275 N = 348                              | CA209032+CA209275 N = 348                | CA209032+CA209275 N = 348   |
|---------------------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------|--------------------|--------------------------------------------------------|------------------------------------------|-----------------------------|
| System Organ Class (8) Preferred Term (8)                                       | Any Grade                                             | Grade 3-4                                  | Grade 5            | Any Grade                                              | Grade 3-4                                | Grade 5                     |
| TOTAL SUBJECTS WITH AN EVENT                                                    |                                                       | 267(98.9) 137 (50.7)                       | 31 (11.5)          |                                                        | 345(99.1)180(51.7)                       | 38 (10.9)                   |
| GENERAL DISORDERS AND ADMINISIRATION SITE                                       | 177 ( 65.6)                                           | 31 ( 11.5)                                 | 3 (1.1)            | 231 ( 66.4)                                            | 38 (10.9)                                | 3 (0.9)                     |
| CONDITIONS FATIGUE PYREXIA ASTHENIA OEDEMA PERIPHERAL                           | 47 87 32.2) 17.4) 38 14.1) 30 11.1)                   | 1 7 0.4) 2.6) 11 4.1) 0                    | 0 0 0 0            | 129 56 (37.1) 16.1) 43 12.4) 41 （ 11.8)                | 10 2 0.6) 2.9) 11 3.2) 0                 | 0 0 0 0                     |
| GASTROINIESTINALDISORDERS NAUSEA DIARRHOEA CONSTIPATION VOMITING ABDOMINAL PAIN | 151 55.9) 60 47 22.2) 17.4) 2 15.6) 32 11.9) 29 10.7) | 30 11.1) 2 7 0.7) 2.6) 1 0.4) 5 1.9 4 1.5) | 0 0 0 0 0 0        | 198 56.9) 83 60 17.2) 23.9) 56 16.1) 45 12.9) 43 12.4) | 39 11.2) 8 0.9) 2.3) 25 0.6) 1.4) 6 1.7) | 0 0 0 0 0 0                 |
| MUSCULOSKELETALAND                                                              | 114 1(42.2)                                           | 11 4.1)                                    | 0                  | 158 3(45.4)                                            | 15 ( 4.3)                                | 0                           |
| BACK PAIN ARTHRALGIA                                                            | 32 (11.9) 25 9.3)                                     | 3 1.1) 2 0.7)                              | 0 0                | 44 (12.6) 43 12.4)                                     | 4( 1.1) 3 0.9)                           | 0 0                         |
| RESPIRATORY，THORACIC AND MEDIASTINAL DISORDERS                                  | 101 ( 37.4)                                           | 18 6.7)                                    | 3( 1.1)            | 142 ( 40.8)                                            | 26 ( 7.5)                                | 1.1)                        |
| COUGH DYSPNOEA METABOLISM AND NUIRITION DISORDERS                               | 45 (16.7) 35 (13.0) 103 ( 38.1) 59 (21.9)             | 0 9 3.3) 9.3)                              | 0 0                | 62 (17.8) 52 (14.9)                                    | 0 13 3.7)                                | 0 0                         |
| DECREASED APPETITE                                                              |                                                       | 25 6( 2.2)                                 | 0                  | 136 ( 39.1) 70(20.1)                                   | 32 ( 9.2) 6( 1.7)                        | 0 0                         |
| INFECTIONS AND INFESTATIONS URINARY TRACT INFECTION                             | 103 38.1) 45 (16.7)                                   | 41 15.2) 17 6.3)                           | 0 0 0              | 133 (38.2) 55 (15.8)                                   | 51 14.7) 20 5.7)                         | 0 0                         |
| SKINANDSUBCUIANEOUSTISSUE                                                       | 93 (34.4)                                             | 2.2)                                       | 0                  | 133 (38.2)                                             | 9( 2.6)                                  | 0                           |
| DISORDERS PRURITUS RASH                                                         | 32 (11.9) 28 (10.4)                                   | 0 3 1.1)                                   | 0 0                | 56 (16.1) 33 9.5)                                      | 0 3( 0.9)                                | 0 0                         |
| System Organ Class (&) Preferred Term (%)                                       | CA209275 N = 270                                      | CA209275 N = 270                           | CA209275 N = 270   | CA209032+CA209275 N=348                                | CA209032+CA209275 N=348                  | CA209032+CA209275 N=348     |
| System Organ Class (&) Preferred Term (%)                                       | Any Grade                                             | Grade 3-4                                  | Grade 5            | Any Grade                                              | Grade 3-4                                | Grade 5                     |
| BLOODANDLYMPHATIC SYSTEM DISORDERS                                              | 61 (22.6)                                             | 23 （ 8.5)                                  | 0                  | 89 (25.6)                                              | 30 ( 8.6)                                | 0                           |
| ANAFMIA                                                                         | 46 5 (17.0)                                           | 18 6.7)                                    | 0                  | 70 ( 20.1)                                             | 24 6.9)                                  | 0                           |
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED(INCL CYSTS                          | 57 (21.1)                                             | 29 (10.7)                                  | 21 7.8)            | 67 (19.3)                                              | 30 （ 8.6)                                | 27（ 7.8)                    |
| AND POLYPS) MALIGNANT NEOPLASM PROGRESSION                                      | 5 (13.0)                                              | 14 （ 5.2)                                  | 20 （ 7.4)          | 42 (12.1)                                              | 15 （ 4.3)                                | 26 7.5)                     |

MedDRA Version: ：19.0 CIC Version 4.0

CA209032 consists of the nivolumab monotherapy urotheiial carcinoma (i.e. bladder) cohort of CA209032.

Includes events reported between first dose and 30 days after last dose of study therapy.

CA209032crossover subiects are truncated atthefirstdose date of crossover period.

Frequencies of all-causality AEs (any grade and Grade 3-4) for CA209032 tended to be higher than the Integrated UC Population (Table 42).

<div style=\"page-break-after: always\"></div>

Table 42 Summary of Any Adverse Events by Worst CTC Grade (Any Grade, Grade 3-4, Grade 5) - All Treated Subjects

|                                                                                                                           | CA209032 N = 78                                                  | CA209032 N = 78                                     | CA209032 N = 78   | CA209275 N= 270                                                                       | CA209275 N= 270                                        | CA209275 N= 270                 | CA209032 +_CA209275 N=348                                          | CA209032 +_CA209275 N=348                        | CA209032 +_CA209275 N=348                        | CA209032 +_CA209275 N=348                        |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------|-------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------|---------------------------------|--------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| System Organ Class (8) Preferred Term (%)                                                                                 | Any Grade                                                        | Grade 3-4                                           | Grade 5           | Any Grade                                                                             | Grade 3-4                                              | Grade5                          | Any Grade                                                          | Grade 3-4                                        | Grade 5                                          | Grade 5                                          |
| TOTAL SUBJECTS WITH AN EVENT                                                                                              | 78 (100.0)                                                       | 43 (55.1)                                           | （ 9.0)            | 267 （ 98.9)                                                                           | 137 (50.7)                                             | 31 （ 11.5)                      | 345 （ 99.1)                                                        | 180 （ 51.7)                                      | 38 (10.9)                                        | 38 (10.9)                                        |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS FATIGUE PYREXIA                                                      | 54 (69.2) 42 53.8) 11 5) 16.9                                    | ( 9.0) 1 3 8 00:000                                 | 0 0 o             | 177 （ 65.6) 87:38310171 87 17 32 .2) 11                                               | 31 (11.5) 2:3 4.1)                                     | 3 1.1)                          | 231 (66.4) 129 56 16. 37.1) 48                                     | 38 (10.9) 10                                     | 3（ 0.9) 3. ) 3.2)                                | 3（ 0.9) 3. ) 3.2)                                |
| ASTHENIA OEDEMA PERIPHFRAL PAIN CHILIS GENERAL PHYSICAL GASTROINTESTINAL DISORDERS NAUSEA DIARRHOFA CONSTIPATION VOMITING | 14.1) 15.4) 3.8) 47 （ 60.3) 23 29.5) 81 10.3) 1.3) 20 .3) 6.6 41 | 9 (11.5) 1 1 0:2 ( 2.6) 0 1 1.3) 1.3) 4（ 1 1 0000 8 | 0000 0 0          | 7) 11 4.1) 151 （ 55.9) 6072:3% 22.2) 17. 11.9) 29 10.7) L9 2.2) 2.6) 2(0: 114 ( 42.2) | 1.5) 8 ( 3.0) 30 （ 11.1) 71 2 0.7) 54 05 00 11 ( 32101 | ０００00０２ 0.7) 0 0 0 0 0 00 0 0 0 | 6. 3) 198 56.9) 8606153 23.9) 12. 9) 12.4) 14 4.0 2.3) 158 ( 45.4) | 3 0.3) 4.3) 0.9) 1.1) 0.3) o 0.3) 0.3) 7.5) 3.7) | 1.1) 0 2 0.6) 0 2.3) 0.9) 0 0 00 00 0 0 0 000000 | 1.1) 0 2 0.6) 0 2.3) 0.9) 0 0 00 00 0 0 0 000000 |
| PRODUCTIVE COUGH DECREASEDAPPETITE HYPERGLYCAEMIA DEHYDRATION HYPONATRAFMTA HYPERKALAFMIA HYPOMAGNESAFMTA                 | ( 3.8) 6.4) 33 11 14.1) 15 19. 7.7) 5.13 7.73                    | (10.3) 0 4100000 5.1) 1 7 0 4 03                    | 000000 0 00 0     | 1.1) 103 (38.1) 59 7 17 14 11                                                         | 25 6328 6) 4 0                                         |                                 | 43442314 12.6) 12.4 6.9) 6.91 6.6) 4.0)                            | 32 ( 9.2) 1.7 2. 0.                              | 00 o0                                            | 00 o0                                            |
| METABOLISM AND NUTRITION DISORDERS                                                                                        | 42.3) .2)                                                        | 9.0) 5.1) 3.8) 0:0                                  | 0 o 0:0           | 21.9 2. 6.3) 5.2) 4.1) 8 3.0)                                                         |                                                        |                                 | 136 72:221514                                                      | 1) 3 9 40                                        | 0 0000000                                        | 0 0000000                                        |
| HYPOKALAFMIA HYPOALBUMINAEMIA                                                                                             | 464664 7.73                                                      | 0 0                                                 | 0o o              | 2.6)                                                                                  | 1 0                                                    | 0:o                             | 13 10                                                              | 7) 3) 1 0                                        | 6) 1.1)                                          | 6) 1.1)                                          |
| INFECTIONS AND                                                                                                            | 5.1)                                                             | 10                                                  |                   | 76 103                                                                                | 41 （                                                   | 0                               |                                                                    |                                                  | 0                                                | 0                                                |
|                                                                                                                           | 30                                                               | (12.8)                                              | 0                 |                                                                                       |                                                        |                                 | 133 （3                                                             | 51                                               |                                                  |                                                  |
| URINARY TRACT                                                                                                             |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  | 0.3)                                             | 0.3)                                             |
| INFECTION UPPER RESPIRATORY TRACT INFECTION                                                                               |                                                                  |                                                     | 0                 | 45                                                                                    |                                                        |                                 |                                                                    | 8 ( 2.3) 39 (11.2)                               |                                                  |                                                  |
|                                                                                                                           | 38.5) 10                                                         | 1 1.3)                                              |                   |                                                                                       | 17                                                     | 0                               | 34:20 5. 7) 11 3.2)                                                | 39.1)                                            |                                                  |                                                  |
| MUSCULAR WEAKNESS AND MEDIASTINAL DISORDERS COUGH DYSPNOEA PLEURAL EFFUSION PNEUMONITIS NASALCONGESTION RHINORRHOEA       | 12.8) 7 9.0)                                                     |                                                     | 0 o 0 000 1       | 16.7) 11 4.1)                                                                         | 0                                                      | 0 0:0:                          | 1:3                                                                | 20 ( 5.7) 0                                      |                                                  |                                                  |
| CBSTRUCTION MUSCULOSKELETALAND CONNECTIVE TISSUE DISORDERS BACK PAIN ARTHRAIGIA MYALGIA PAIN IN EXTREMITY                 | 5:3) 44 ( 56.4) 15.4) .1                                         | 5.1)                                                |                   | 11.9) 39. 13 3.0)                                                                     | 10 1                                                   | 00000                           |                                                                    | 9:0 1.7)                                         |                                                  |                                                  |
| ABDOMINALPAIN DRY MOUTH SMALL INTESTINAL                                                                                  | 16.7 17.9) 16.7) 17.9)                                           |                                                     |                   |                                                                                       | 1.9) 1.5) 1.9)                                         |                                 |                                                                    | 1.4) 1.7)                                        | 0.6)                                             | 0.6)                                             |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    | 8256                                             |                                                  |                                                  |
| ABDOMINALDISTENSION                                                                                                       |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  |                                                  |                                                  |
| ABDOMINAL PAIN UPPER                                                                                                      |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    | 0 1                                              |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    | 15（                                              |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       | 4.1)                                                   |                                 |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   | 322516111                                                                             | 0.7) 0.4)                                              | 0                               |                                                                    | 431                                              |                                                  |                                                  |
| MUSCULOSKELETALPAIN                                                                                                       | 5.1) (52.6)                                                      |                                                     |                   | 66 33 10 3.7) 101 （ 37.4)                                                             | 0.4) 1 0.4) 18 (                                       | 3                               | (40.8)                                                             |                                                  |                                                  |                                                  |
| RESPIRATORY，THORACIC                                                                                                      |                                                                  |                                                     |                   |                                                                                       | 6.7)                                                   |                                 |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  | 4( 1.1)                                          | 4( 1.1)                                          |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    | 1 1 26                                           |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   | 1.3)                                                                                  |                                                        |                                 | 142                                                                |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     | 000：              | 16.7)                                                                                 | 3.3)                                                   | 1.1)                            | 17.8) 14.9                                                         |                                                  | 00020000 0.6)                                    | 00020000 0.6)                                    |
|                                                                                                                           | 17 21.8) 17 5２6335 21.8) 6.4) 6) 7.7)                            |                                                     | 10000             | 4. 1.1) 1.3) .1) 1. 9) 2                                                              | 094２0000 1.5) 0.7)                                     | OOOOTOOO 0.4)                   | 4. 967 2i 998 66                                                   | 1.4 0.6)                                         |                                                  |                                                  |
| OROPHARYNGEALPAIN                                                                                                         | 3.8)                                                             |                                                     | 0                 |                                                                                       |                                                        |                                 |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        | 0                               |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        | 0                               |                                                                    |                                                  | 0                                                | 0                                                |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       | 9.3) 0.7) 3.0)                                         | 0:00                            |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       | 1.5) 0.4)                                              |                                 | 20.                                                                |                                                  |                                                  | 0)                                               |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 | 6. 6. 5.                                                           |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   | 2.2)                                                                                  |                                                        |                                 | 4.                                                                 |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 | 4.0) 3.7 2.9) 38.2)                                                | 14.7)                                            |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       | 15.2)                                                  | 0 o                             |                                                                    |                                                  |                                                  |                                                  |
| INFESTATIONS                                                                                                              |                                                                  | 3                                                   |                   | 38.1)                                                                                 | 6.3)                                                   |                                 | 55 15.8)                                                           |                                                  | 0                                                | 0                                                |
| INFECTION                                                                                                                 |                                                                  | 3.8) 0 C 3.8)                                       | 0 00              |                                                                                       |                                                        |                                 | 18 5.2) 11                                                         | 2 C                                              | 0 0:0                                            | 0 0:0                                            |
| BRONCHITIS SEPSIS TISSUEDISORDERS                                                                                         | 414 5.1)                                                         | 31 1 ( C 1.33 3                                     | 0                 | 38                                                                                    |                                                        | 0 0                             | 9 CCC                                                              | (                                                | 0.6) 0                                           | 0.6) 0                                           |
|                                                                                                                           | 40 （                                                             |                                                     | 0                 | 1.9) 93 L 34.4)                                                                       |                                                        |                                 | 133                                                                | 9                                                |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       | 6                                                      |                                 |                                                                    | 2.6)                                             |                                                  |                                                  |
|                                                                                                                           |                                                                  | 1.3) 3.8)                                           |                   |                                                                                       | 0.4)                                                   |                                 | 38.2)                                                              |                                                  | 0                                                | 0                                                |
| PRURITUS                                                                                                                  |                                                                  |                                                     |                   |                                                                                       | 2.2)                                                   | 0                               |                                                                    | 0                                                |                                                  |                                                  |
| SKINANDSUBCUTANEOUS RASH RASH MACUIO-PAPULAR                                                                              | 51.3) 24 30.8)                                                   | 00                                                  | oo 0              | 2 10                                                                                  | 03                                                     | 0                               | 16.1) 9.5)                                                         | 2.6) 3 0.9) 3 0 0.9)                             | 0 0 0                                            | 0 0 0                                            |
| DRY SKIN                                                                                                                  | 6.4) 20.5) 9.0)                                                  | 20                                                  |                   | 11.9)                                                                                 |                                                        | 0                               | 63216:10                                                           |                                                  |                                                  |                                                  |
| HYPERHIDROSIS                                                                                                             |                                                                  |                                                     |                   | .4) 3.3) 3.3)                                                                         | 1.1) 0.4)                                              | 0 0                             |                                                                    |                                                  | 0 0                                              | 0 0                                              |
| DERMATITIS ACNEIFORM                                                                                                      | 1.3)                                                             | 2.6) 01 1.3)                                        |                   | 599142 0.4)                                                                           |                                                        | 0                               |                                                                    | 0                                                | 0                                                | 0                                                |
| ERYTHEMA                                                                                                                  | 5.1)                                                             |                                                     |                   |                                                                                       | 10:000                                                 |                                 | 6.0) 4.6)                                                          | 1                                                |                                                  |                                                  |
|                                                                                                                           | 71412                                                            | 0                                                   |                   | 1.5) 0.7)                                                                             |                                                        | 0                               | 554                                                                | 0                                                |                                                  |                                                  |
| ALOPECIA                                                                                                                  | 1.3)                                                             |                                                     | 0:0:00            |                                                                                       |                                                        | 0                               |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       | 0                                                      |                                 |                                                                    |                                                  | 0 0                                              | 0 0                                              |
|                                                                                                                           |                                                                  | 0                                                   |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           | 2.6)                                                             |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    | 0                                                |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    |                                                  | 0.3)                                             |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 | 1.1)                                                               |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 | 1.4)                                                               |                                                  |                                                  |                                                  |
|                                                                                                                           |                                                                  |                                                     |                   |                                                                                       |                                                        |                                 |                                                                    | 2.9) 1.4)                                        |                                                  |                                                  |

|                                           | CA209032 N = 78   | CA209032 N = 78   | CA209032 N = 78   | CA209032 N = 78   | CA209275 N = 270   | CA209275 N = 270   | CA209275 N = 270   | CA209032 +_CA209275 N= 348   | CA209032 +_CA209275 N= 348   | CA209032 +_CA209275 N= 348   |
|-------------------------------------------|-------------------|-------------------|-------------------|-------------------|--------------------|--------------------|--------------------|------------------------------|------------------------------|------------------------------|
| System Organ Class (%) Preferred Term (*) | Any ( Grade       | Grade 3-4         | Grade 5           | Any ( Grade       |                    | Grade 3-4          | Grade 5            | Any ( Grade                  | Grade 3-4                    | Grade 5                      |
| INVESTIGATIONS                            | 38 48.7)          | 13 (16.7)         | 0                 | 94 （ 34.8)        | 26                 | 9.6)               | 0                  | 132 37.9) 32                 | 39 (11.2)                    | 0                            |
| BLOODCREATININE INCREASED                 | 14 ( 17.9)        | 0                 | 0                 | 18                | 6.7) 2             | 0.7)               | 0                  | 9.2)                         | 2 0.6)                       | 0                            |
| WEIGHT DECREASED                          | 83                | 0                 | 0                 |                   | 7.%                |                    | 0 o                |                              |                              |                              |
| LIPASE INCREASED                          | 1 1.13            | 4 5 .1)           | 0                 |                   | 18:2 3.7)          | .9) 0.7)           | 281                |                              | 2.6)                         |                              |
| ALANINE AMINOTRANSFERASE INCREASED        | 7 9.0)            | 1                 | 0                 | 970               | 052                | 0                  |                    |                              | 093 0.9)                     | 00:0                         |

<div style=\"page-break-after: always\"></div>

L

| BLOOD AIKALINE                                                                                                                   | 6 7.7)                                              | 1 ( 1.3)                               | 0        | 11 4.1)                 | 4 1.5)                 | 0                               | 17             |                         | 4.9)                                | 5              | 1.4)                          | 0             |
|----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|----------------------------------------|----------|-------------------------|------------------------|---------------------------------|----------------|-------------------------|-------------------------------------|----------------|-------------------------------|---------------|
| PHOSPHATASE INCREASED AMYLASE INCREASED ASPARTATE AMINOTRANSFERASE                                                               | 9.%) 6.4)                                           | 41 1:33                                | 00       | 18 1 3:9)               | 823                    |                                 |                |                         | 15~ 4:3                             | 19 ~           | 2:8)                          | 0o            |
| INCREASED BLOOD BILIRUBIN INCREASED                                                                                              | 1 1.3)                                              | 0                                      | 0        | 10（ 3.7)                | 5( 1.9)                |                                 | 0              | 11 （                    | 3.2)                                |                | 1.4)                          | 0             |
| BLOOD THYROID STIMULATING HORMONE                                                                                                | 1( 1.3)                                             | 0                                      | 0        | 10（ 3.7)                | 0                      |                                 | 0              | 11 （                    | 3.2)                                | 0              |                               | 0             |
| INCREASED PLATELET COUNT                                                                                                         | 6 （ 7.7)                                            | 0                                      | 0        | 5 （ 1.9)                | 3 ( 1.1)               |                                 | 0              | 11 L                    | 3.2)                                | 3              | 0.9)                          |               |
| DECREASED LYMPHOCYTE OOUNT DECREASED                                                                                             | 5 6.4)                                              | 2 2.6)                                 | 0        | 4 1.5)                  | 3 ( 1.1)               |                                 | 0              | 9                       | 2.6)                                | 5              | 1.4)                          | 0             |
| NEUTROPHIL COUNT DECREASED                                                                                                       | 3 3.8)                                              | 2 2.6)                                 | 0        | 4 ( 1.5)                | 1 0.4)                 | 0                               |                | 7                       | 2.0)                                | 3              | 0.9)                          | 0             |
| WHITE BIOOD CELL COUNT DECREASED                                                                                                 | 4 5.1)                                              | 1 1.3)                                 | 0        | 3 1.1)                  | 1 0.4)                 | 0                               |                | 7                       | 2.0)                                | 2              | 0.6)                          | 0             |
| BLOOD THYROID STIMULATING HORMONE DECREASED                                                                                      | 0                                                   | 0                                      | 0        | 5 1.9)                  | 0                      | 0                               |                | 5                       | 1.4)                                | 0              |                               | 0             |
| BLOOD UREA INCREASED                                                                                                             | 5 6.4)                                              | 0                                      | 0        | 0                       | 0                      | 0                               |                | 5                       | 1.4)                                | 0              |                               | 0             |
| NERVOUS SYSTEM                                                                                                                   | 29 (37.2)                                           | 2 2.6)                                 | 0        | 70 ( 25.9)              | 8                      | 3.0) 0                          |                | 99                      | 28.4)                               | 10             | 2.9)                          | 0             |
| DISORDERS HEADACHE DIZZINESS PARAESTHESIA                                                                                        | 12 66 ( 10.3)                                       | 00000                                  | 00: 000  | 13370 4.8) 2.6)         | 01２0０ C                | 0.4) 0.7)                       | 00000          | 71598 89:363            | 8936                                | 01200 C        | 0.3) 0.6)                     | 00 0:0:0      |
| DYSGEUSIA PERIPHERALSENSORY NEUROPATHY BLOODANDLYMPHATIC                                                                         | 28 (35.9)                                           | 7                                      | 0        | 61 22.6)                | 23 18                  | 8.5)                            |                | 68                      | 3) 25.6)                            | 30 ( 6.9)      | 8.6)                          |               |
| SYSTEM DISORDERS ANAEMIA THROMBOCYTOPENIA LYMPHOPENIA NEUTROPENIA                                                                | ( 30.8) 8) 3) 3)                                    | 9.0) 10010 6 7.7) 1.3)                 | 000000   | 46 74431 17.0) 65 1. 5) | 11210                  | 6.7) 0.4) 0.4) 0 0 0 0.7) 0:0:0 | 0              | 705542                  | 20.1) . 9の 1. 41                    | 24 21220 C     | 0.5 0.3 63 0. (9              | 0 0 0 oo      |
| RENAL AND URINARY DISORDERS HAFMATURIA ACUTE KIDNEY INJURY DYSURIA HYDRONEPHROSIS URINARY INCONTINENCE URINARY TRACT OBSTRUCTION | 29 ( 37.2) 14 17.9) 82222 10.3) 2.6) 2.6) 2.6) 2.6) | 11 14.1) ４４０１０１ CC 5.1) 5.1) 1.3) 1.3) | 0 000000 | 51 18.9) 5.9) 1 4 1.5)  | 17 420204 26 5) 5)     | 6.3) 1.5) 0.7) 0.7) 1.5)        | 0 0 00000 7.8) | 08                      | 23.0) 8.6) 4.0) 2. 6) 1. 7) 1. 1.7) | 28 ８６０３０５      | 8.0) 2.3) 1.7) 0.9) 1.4) 27 （ | 0 0 0 o 0 0 0 |
| NEOPIASMS BENIGN, MALIGNANT AND UNSPECIFIED(INCL CYSTS AND POLYPS) MALIGNANT NEOPLASM                                            | 10 (12.8)                                           | 1 （ 1.3)                               | 6 ( 7.7) | 57 ( 21.1)              | 29 (10.7)              | 21                              |                | 67 (19.3)               | 30 （                                | 8.6)           |                               | 7.8)          |
| PROGRESSION PSYCHIATRIC DISORDERS                                                                                                | 7 9.0) 16.73                                        | 1 1.3) 1000 1.3)                       | 6 （ 7.7) | 35 （ 13.0) 17.          | 14 5.2) 1010 0.4) 0.4) | 20 0000                         | 7.4) 92888     | 42 ( 12.1) 8.53         | 15 20１0 （                           | 4.3) 0.6) 0.3) | 26 （ 00:00                    | 7.5)          |
| INSOMNIA ANXIETY DEPRESSION VASCULAR DISORDERS                                                                                   | 16.73 2.6) 11.5)                                    | 2.6) 1:3                               | 0:0:00   | 2 15.9) 1.9) (13.0)     | 8212, 0.7) 0.4)        | 2000 0                          | 0.7) Lπ8       | 16. 532 2.0) 38 1 7. 5) | 29 1)                               | 966 0. 9)      | 20000                         | 0.6)          |
| HYEOTENSION HYPERTENSION DEEP VEIN THROMBOSIS ENDOCRINE DISORDERS                                                                | 3 E 3:83 3                                          |                                        |          | 21  4:3                 | oo                     |                                 | 44             | 12.6)                   |                                     | 0.3)           |                               |               |
| HYPOIHYROIDISM                                                                                                                   |                                                     |                                        |          |                         |                        | oo                              |                |                         | 00                                  |                |                               |               |
| HYPERTHYROIDISM                                                                                                                  |                                                     |                                        | 0        |                         |                        |                                 |                |                         |                                     |                |                               |               |
|                                                                                                                                  |                                                     |                                        |          |                         |                        |                                 |                |                         |                                     |                |                               | 0:0           |
|                                                                                                                                  |                                                     |                                        | 0        |                         |                        |                                 |                |                         |                                     |                |                               |               |

|                                                                             | CA209032 N= 78              | CA209032 N= 78   | CA209032 N= 78   | CA209275 N = 270   | CA209275 N = 270   | CA209275 N = 270   | CA209032+ CA209275 N = 348   | CA209032+ CA209275 N = 348   | CA209032+ CA209275 N = 348   |
|-----------------------------------------------------------------------------|-----------------------------|------------------|------------------|--------------------|--------------------|--------------------|------------------------------|------------------------------|------------------------------|
| System Organ Class (*) Preferred Term ()                                    | Any Grade                   | Grade 3-4        | Grade 5          | Any Grade          | Grade 3-4          | Grade 5            | Any Grade                    | Grade 3-4                    | Grade 5                      |
| EYE DISORDERS VISION BLURRED LACRIMATION INCREASED CONJUNCTIVAL HAFMORRHAGE | 11 221 14.1) 2.6) 2.6) 1.3) | 0:0:0 1 （ 1.3)   | 0000             | 17 721 8.73 0.4)   | 00:00              | 00:00              |                              | 1 0:00 0.3)                  | 0:0 o:o:                     |
| CARDIAC DISORDERS TACHYCARDIA ATRIAL FIBRILLATION                           | 3 （ 3.8)                    | 00000            | 0:0:0 0 0        | 8.1)               | 8:49 1.9)          | 0.7)               | 25 7.2) 2. 0.9)              | 1.4)                         | ２０００００ 0.6)                  |
| SINUS BRADYCARDIA PALPITATIONS SINUS TACHYCARDIA                            | 0001 ( 1.3) 2 （             | 0                |                  | 1 1.1) 0.4)        | ５１２０００             | 200000             | 0.6) 0.6)                    | ５1２000                       |                              |
|                                                                             | 2.6)                        |                  | 0                |                    |                    |                    |                              | 5 (1.4)                      |                              |
| HEPATOBILIARYDISORDERS                                                      |                             | 1（               |                  |                    | 1.5)               | 0                  | 4.0)                         |                              |                              |
|                                                                             | 1.3)                        |                  |                  | 4.8)               |                    |                    | 14（                          |                              | 0                            |
|                                                                             |                             |                  | 0                |                    |                    |                    |                              |                              |                              |
|                                                                             | 1                           | 1.3)             |                  | 13 (               | 4（                 |                    |                              |                              |                              |

S s o           e CA209032 2 consists of the nivolumab monotherapy urothelial carcinoma (i.e.bladder) ）cohort t of CA209032. CA209032 2 crossover subjects are truncated at the first dose date of crossover period.

Frequencies of all-causality AEs (any grade and Grade 3-4) for CA209032 tended to be higher than the Integrated UC Population also in Extended Follow-up (see Table 43 below).

<div style=\"page-break-after: always\"></div>

Table 43 Summary of Any Adverse Events by Worst CTC Grade (Any Grade, Grade 3-4, Grade 5) with Extended Follow-up - All Treated Subjects

|                                                                                                                                                            | CA209032 N = 78                     | CA209032 N = 78                                                  | CA209032 N = 78    | CA209275 N = 270                             | CA209275 N = 270                                                        | CA209275 N = 270    | CA209032 + CA209275 N=348                      | CA209032 + CA209275 N=348                        | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------------------------|--------------------|----------------------------------------------|-------------------------------------------------------------------------|---------------------|------------------------------------------------|--------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class (8) Preferred Term (8)                                                                                                                  | Any Grade                           | Grade 3-4                                                        | Grade 5            | Any Grade                                    | Grade 3-4                                                               | Grade 5             | Any Grade                                      | Grade 3-4                                        | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     | Grade 5                     |
| TOTAL SUBJECTS WITH AN EVENT                                                                                                                               | 78 (100.0)                          | 33(42.3)                                                         |                    | 24(30.8)268(99.3)                            | 108 (40.0)                                                              | 88 3(32.6)          | 346 (99.4)                                     | 141 (40.5)                                       | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 | 112 2(32.2)                 |
| GENERAL DISORDERS AND                                                                                                                                      | 55 ( 70.5)                          | 9 (11.5)                                                         | 1                  | 1.3) 184 ( 68.1)                             | 39 (14.4)                                                               |                     | 2.6) 239 ( 68.7)                               | 48 (13.8)                                        |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| ADMINISTRATION SITE CONDITIONS PYREXIA FATIGUE ASTHENIA OEDEMA PERIPHFRAL PAIN CHILIS GENERALPHYSICAL GASTROINTESTINAL                                     | 43 11 55 .1) .5 6.4) 15.4) 16.7) 47 | 1 0o 1 1.3) 3.8) 0 0 60.3) 10 (12.8) １11０３0１ 1.3) 1.3) 1.3) 3.8) | 0o 00000           | 红虹T3688 11.9) 4.4) 6.7) 5.6) 156 (57.8) 18.5 | 33.0) C 4.1) C 2.2) ( 3.3) 37 （ 13.7) ２８１５４０６ 0.73 3.0) 0.4) 1 .5) 2.2) | 0000005 1.9) 1 （ 0  | 946620 7. 6. 4.3) 0.4) 203 87 12.              | 33 3.2) 2.0) 0 9 2.6) 47 (13.5) ３９２5７ 0.9) 2. 6) | 8 (2.3) 0o 0:0：             | 0:0 5                       | 8:0 3.0)                    | 8 (2.3) 0o 0:0：             | 8 (2.3) 0o 0:0：             | 1.4)                        | 8 (2.3) 0o 0:0：             | 8 (2.3) 0o 0:0：             | 8 (2.3) 0o 0:0：             | 8 (2.3) 0o 0:0：             | 8 (2.3) 0o 0:0：             |
| DYSPEPSIA ABDOMINAL DISTENSION ABDOMINAL PAIN UPPER FLATULFNCE STOMATITIS GASTROOESOPHAGEAL REFLUX DISEASE MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | 33153581 183 19 19. .2 10 .33 1.3)  | 1.3) oo 11 1:3) 00                                               | 0 0                | 4553378 23.7 183 53 3.0) ６６３３45              | 12 (4.4)                                                                | 0o 0 0o 0 0         | (58.3) 25.0) 6608515 18.1) 17.2) 13.8) 9 2. 6) | 0.6) 1.4 2.0) 0 7 2.0) oo                        | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              | 1( 0.3) 0 00 0              |
| DISORDERS NAUSEA CONSTIPATION DIARRHOEA VOMITING ABDOMINAL PAIN DRY MOUTH SMALL INTESTINAL OBSTRUCTION                                                     | ２１4４３１ .1) 3.8) 1.3)                |                                                                  | 0 00 0 0o 0o 00:00 |                                              | 000000                                                                  |                     | ８7７7７ 3000                                     | 11 8:3 00                                        | 0:0:0                       | 0:0:0                       | 0:0:0                       | 0:0:0                       | 0:0:0                       | 0:0:0                       | 000000                      | 0:0:0                       | 0:0:0                       | 0:0:0                       | 0:0:0                       |
| BACK PAIN ARTHRAIGIA                                                                                                                                       | 44 ( 56.4) 12 (15.4) 18 (23.1)      | 4(5.1) 人                                                         | 0 0                | 117 ( 43.3) 35 (13.0) 27                     | 4 5 2                                                                   |                     | 6 161 ( 46.3) 47 （ 13.5) 45 （ 12.9)            | 16（ 4.6) 53 （ 1.4) ( 0.9)                        | 0 0                         | 0 0                         | 0 0                         | (10.0)                      | 0 0                         | 0 0                         | 0                           | 0 0                         | 0 0                         | 0 0                         | 0 0                         |
| MYALGIA MUSCULAR WEAKNESS PAIN IN EXTREMITY MUSCULOSKELETALPAIN RESPIRATORY，THORACIC                                                                       | 87 64 10.3) 9.0)                    | 00:00                                                            | 00:00              | 78:81 83                                     | 11 8.4) 0.4) 20 7.4)                                                    | 3 1.1)              | 2525:2415 150 (43.1)                           | 11 8:3 29 8.3)                                   | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 | 0.3) 0000 4                 |
| AND MEDIASTINAL DISORDERS DYSPNOEA COUGH PLEURAL EFFUSION PNEUMONITIS                                                                                      | 43 ( 55.1)                          | 9 (11.5) 05100 6.4)                                              | 00010              | 107 39.6)                                    | C                                                                       | 00010               | 8                                              | 4.3)                                             | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          | 0o                          |
| NASAL CONGESTION                                                                                                                                           |                                     | 1.3)                                                             |                    | 53315 18:3                                   |                                                                         |                     | 25831                                          |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            | 1.3)                                |                                                                  | 1                  |                                              |                                                                         | 0 0.71 0 0.4) 00:00 |                                                |                                                  |                             |                             |                             |                             |                             | 1.1)                        |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        | 0.6)                        |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         | 0.4)                |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            | 19:526                              |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| OROPHARYNGEAL PAIN RHINORRHOEA                                                                                                                             |                                     |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| PRODUCTIVE COUGH                                                                                                                                           |                                     |                                                                  |                    | 1.1)                                         | 00006                                                                   |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    | 1. (6                                        |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     | 9987 6630                                      | 0:0:0:0                                          | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       | 0 0 0                       |
|                                                                                                                                                            | 33520                               |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     | 00000                                                            |                    |                                              |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  | 00:000             | 66357                                        |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         | 00:00               |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           | 0                           |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  | 2                           | 2                           | 2                           | 2                           | 2                           | 2                           | 2                           | 2                           | 2                           | 2                           | 2                           |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     | 27                                             |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  | 1.3)               |                                              |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         | 1 0.4)              | 7                                              | 1.7)                                             | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        | 0.3)                        |
| DYSPHONIA                                                                                                                                                  |                                     |                                                                  |                    | 2.6)                                         |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              | 2.2)                                                                    |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
| RESPIRATORYFAIIURE                                                                                                                                         |                                     |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     |                                                |                                                  | 1                           |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                                                                                                                            |                                     |                                                                  |                    |                                              |                                                                         |                     | 2.0)                                           |                                                  |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |                             |

|                                           | CA209032 N = 78      | CA209032 N = 78   | CA209032 N = 78   | CA209275 N = 270                                         | CA209275 N = 270                        | CA209275 N = 270   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   |
|-------------------------------------------|----------------------|-------------------|-------------------|----------------------------------------------------------|-----------------------------------------|--------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| System Organ Class (8) Preferred Term (*) | Any Grade            | Grade 3-4         | Grade 5           | Any Grade                                                | Grade 3-4                               | Grade 5            | Any Grade                 |                           | Grade 3-4                 | Grade 5                   | Grade 5                   |
| METABOLISM AND                            | 33 （ 42.3)           | 8 （ 10.3)         | 0                 | 109 40.4)                                                | 26 9.6)                                 | 0                  | 142 （                     | 40.8)                     | 34                        | 9.8)                      | 0                         |
| NUTRITIONDISORDERS DECRFASEDAPPETITE      | 14.1) 3              | 0 43 5 3          | 0                 | 23.0) 16 8 5.93 3.0) 17 6.3) 10 3.7) 3.0) 1i 4.1) 6 2.2) | 6 2.2) 39 1.1) 3.3) 2 0.7) 1 0 4 1.5) 0 | 1                  | 73 32 21 16 16            | 21.0) 6.6) 6.3) 6.0)      | 6 12 7                    | 1.7) 2.0) 3.4) 0.6) 0.6)  | 0 0 o 0 o 0               |
| HYPERGLYCAEMIA HYPONATRAFMIA              |                      |                   | 0                 | 62                                                       |                                         | 0 0o               |                           |                           |                           |                           |                           |
| DEHYDRATION                               | 57                   |                   |                   |                                                          |                                         |                    |                           |                           |                           |                           |                           |
| HYPOKALAEMIA                              |                      | 1.3)              |                   |                                                          | 0.4)                                    |                    |                           | 4.6)                      | 22                        |                           |                           |
| HYPOMAGNESAFMTA                           | 10. 3)               |                   |                   | 8                                                        |                                         |                    |                           | 4.6)                      | 0                         |                           |                           |
| HYPERKAIAFMIA                             | .13                  |                   |                   |                                                          |                                         |                    | 15                        | 4.3)                      | 4                         | 1.1)                      | o                         |
| HYPOALBUMINAFMIA                          |                      | 01000             | 00:000            |                                                          |                                         | 00:000             | 12                        | 3.4)                      | 0                         |                           | 0                         |
| INFECTIONS AND INFESTATIONS               | 30 (38.5) 10 ( 12.8) | 10 (12.8) 3( 3.8) | 0 0               | 108 (40.0) 49 46                                         | ( 18.1) 7.0)                            | 0.4)               | 138 ( 39.7)               | 59 （ 17.0) 22             | （ 6.3)                    | 1 C                       | 0.3)                      |
| URINARY TRACT INFECTION UPPER RESPIRATORY | 7( 9.0)              | 0                 | 0                 | (17.0) 19 11 4.1)                                        | 0                                       | 0                  | 56 (16.1) 18 （ 5.2)       | 0                         |                           | 0                         | 0                         |
| TRACT INFECTION SEPSIS                    | 1 1.3)               | 1.3)              | 0:0               | 12 4.4) 12                                               | ( 4.4)                                  | o                  | 13 L 3.7)                 |                           | 3.7                       | 0                         |                           |
| INFECTION                                 | 5.1)                 | 13 3.8)           |                   | 8 3.0)                                                   | 4 ( 1.5)                                | 0                  | 12 （ 3.4)                 |                           | 2.0)                      | 0                         |                           |
|                                           | 4 (                  | 1.3)              |                   | 5                                                        | 1                                       | 0                  |                           |                           |                           |                           |                           |
| BRONCHITIS                                | 5.1)                 | 1                 | 0                 | （ 1.9)                                                   | 0.4)                                    |                    | 9 （                       | 2.6)                      | 2 （                       | 0.6)                      | 0                         |

<div style=\"page-break-after: always\"></div>

| INVESTIGATIONS BLOODCREATININE INCREASED                                                                              | 15 40 ( 51.3) 19.2)                                     | 13 0 16.7)                  | 0 0               | 18 86 36.3) 6.7)                                             | 28 2 （ 10.4) 0.7)   | 0 o                 | 138 33 39.7) 9.5)                                   | 41 2 （ ( 11.8) 0.6)                                  | 0 o              |
|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|-----------------------------|-------------------|--------------------------------------------------------------|---------------------|---------------------|-----------------------------------------------------|------------------------------------------------------|------------------|
| WEIGHTDECREASED BLOOD ALKALINE PHOSPHATASEINCREASED                                                                   | 57 6:0)                                                 | 01 1.3)                     | 0 0               | 21 7:13                                                      | 04 ( 1.5)           | 00                  | 2518 7:2)                                           | 05 1.4)                                              |                  |
| ALANINE LIPASE INCREASED AMINOTRANSFERASE INCREASED                                                                   | 11 7 14.1) 9.0)                                         | 4 1 5.1) 1.3)               | 0 0               | 3:9)                                                         | 52 1.9) 0.7)        | 0 0                 | 81 5.2) 4.9)                                        | 93 2.6) 0.9)                                         | 0                |
| AMYLASEINCREASED ASPARTATE AMINOTRANSFERASE                                                                           | 75 9.0) 6.4)                                            | 41 1:33                     | oo                | 18 ( 3:9                                                     | 61 2:2              | oo                  | 15 ( 4:3                                            | 19 ( 2:                                              | oo               |
| INCREASED PLATELET COUNT DECRFASED                                                                                    | 7( 9.0)                                                 | 0                           | 0                 | 8 ( 3.0)                                                     | 5 (1.9)             | 0                   | 15  ( 4.3)                                          | 5（ 1.4)                                              | 0                |
| STIMULATINGHORMONE INCREASED                                                                                          | 2 （ 2.6)                                                | 0                           | 0                 | 10 (3.7)                                                     | 0                   | 0                   | 12 （ 3.4)                                           | 0                                                    | 0                |
| BLOODBILIRUBIN INCREASED                                                                                              | 1 （ 1.3)                                                | 0                           | 0                 | 10（ 3.7)                                                     | 5 1.9)              | 0                   | 11 （ 3.2)                                           | 5 ( 1.4)                                             | 0                |
| LYMPHOCYTE COUNT DECRFASED                                                                                            | 6 7.7)                                                  | 2 （ 2.6)                    | 0                 | 4 （ 1.5)                                                     | 3 ( 1.1)            | 0                   | 10 ( 2.9)                                           | 5 1.4)                                               | 0                |
| NEUTROPHILCOUNT DECREASED                                                                                             | 3 3.8)                                                  | 2 （ 2.6)                    | 0                 | 5（ 1.9)                                                      | 2 0.7)              | 0                   | 8 （ 2.3)                                            | 4 ( 1.1)                                             | 0                |
| WHITE BLOOD CELL COUNT DECREASED                                                                                      | 4 （ 5.1)                                                | 1 （ 1.3)                    | 0                 | 4 （ 1.5)                                                     | 2 0.7)              | 0                   | 8 （ 2.3)                                            | 3 （ 0.9)                                             | 0                |
| STIMULATING HORMONE DECRFASED                                                                                         | 0                                                       | 0                           | 0                 | 5（ 1.9)                                                      | 0                   | 0                   | 5 1.4)                                              | 0                                                    | 0                |
| BLOOD UREA INCREASED                                                                                                  | 5 （ 6.4)                                                | 0                           | 0                 | 0                                                            | 0                   | 0                   | 5 （ 1. 4)                                           | 0                                                    | 0                |
| SKINANDSUBCUTANEOUS                                                                                                   | 40 ( 51.3)                                              | 3 3.8)                      | 0                 | 86 (36.3)                                                    | 6 2.2)              | 0                   | 138 39.7)                                           | 9 2.6)                                               | 0                |
| TISSUE DISORDERS RASH PRURITUS RASHMACULO-PAPULAR DRY SKIN HYPERHIDROSIS FRYTHEMA ALOPECIA DERMATITISACNEIFORM ECZEMA | 24 30.8) 6.4) 21.8) 7 9.0) 1 1.3) 1240 1.3) 2.6) ( 5.1) | 0 0 2 2.6) o 0 0 0 1 1.3) 0 | 0 0 0 0 0 0 0 0 0 | 386907 11.9) 10.4) 2) 3 3) 3 3.7) 74142 (9 1.5) 0.4) 5) 0.7) | 0 31 00:00 0:0      | oo 0 o 0 0 0 0 0    | 38 56 16.1) 9.5) 6.6 16 4. 11 3.2) 98 2. 1.7) 54 1. | 0 33 0.9) (9 0.9) 6) 0:0:00 3) 4) 1 0.3) 1.1) 0 1.1) | oo 0 0 0 0 0 0 o |
| NEOPIASMS BENIGN, MALIGNANT AND UNSPECIFIED                                                                           | 24 ( 30.8)                                              | 1 （ 1.3)                    | 21 (26.9)         | 95 （ 35.2)                                                   | 19 7.0)             | 71 (26.3)119 (34.2) |                                                     | （ 5.7)                                               | 92 (26.4)        |
| ）(INCL CYSTS AND POLYPS)                                                                                              | 22 (28.2)                                               | 1.3)                        |                   |                                                              |                     |                     | 20                                                  |                                                      | (25.0)           |
| MALIGNANT NEOPLASM PROGRESSION METASTASES TO CENIRAL NERVOUS SYSTEM                                                   | 0                                                       | 1 0                         | 21 (26.9) 0       | 78 (28.9) 12 6 （ 2.2)                                        | （ 4.4) 66 5 1.9)    | (24.4) 100 0 6      | (28.7) 13 ( 1.7) 5                                  | 3.7) 87 （ 1.4)                                       | 0                |
| TUMDUR PAIN CANCER PAIN TRANSITIONAL CELL                                                                             | 0 10 1.3)                                               | 0                           | 00 0              | 533                                                          | 320 1.1) 0.7)       | 003 543             | 1.4 320                                             | 0.9) 0.6)                                            | 03 0 C 0.9)      |
|                                                                                                                       |                                                         |                             |                   |                                                              |                     | 1.1)                | 1. 19                                               |                                                      |                  |

CARCINOMA

|                                                              | CA209032 N = 78   | CA209032 N = 78   | CA209032 N = 78   | CA209275 N = 270   | CA209275 N = 270     | CA209275 N = 270   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   |
|--------------------------------------------------------------|-------------------|-------------------|-------------------|--------------------|----------------------|--------------------|---------------------------|---------------------------|---------------------------|
| System Organ Class (%) Preferred Term (%)                    | Any Grade         | Grace 3-4         | Grade 5           | Any Grade          | Grade 3-4            | Grade 5            | Any Grade                 | Grade 3-4                 | Grade 5                   |
| NERVOUS SYSTEM DISORDERS                                     | 31 （ 39.7)        | 3 3.8)            | 0                 | 75 (27.8)          | 10 3.7)              | 1 ( 0.4)           | 106 (30.5)                | 13 （ 3.7)                 | 1 0.3)                    |
| HEADACHE DIZZINESS PARAESTHESIA DYSGEUSIA PERIPHERAL SENSORY | 14.1) 5.13        | 10000 ( 1.3)      | 00000             | 13470              | 01200 0.4) 0.7)      | 00000              | 8饥＆                       | 11200 C 0.3) 0.6) 0. 3)   |                           |
| BLOODANDLYMPHATIC SYSTEMDISORDERS                            | 30.8)             | （ 7.7)            | 1 ( 1.3)          | 64 ( 23.7) 17.     | 28 10.4) 20 7.4 0.73 |                    | １1555２ 20                 | 26 7.5) 0.6)              | ( 0.3)                    |
| ANAEMIA THROMBOCYTOPENIA                                     | 3.8) 13           | ６02000 ( 2.6)     | 01 C              | .4) 1 5)           | 21120 0.4) 0.4)      | 000000             | 311. 3                    | 35 (10.1)                 | 01０00０ 0.3)               |
| NEUROPATHY EOSINOPHILIA                                      | C 10.3)           |                   | 0                 | 5)                 |                      |                    |                           |                           | 00000                     |
|                                                              | 28 (35.9)         | 7 （ 9.0)          | 00 1.3)           | 52 19.3)           | ８２１２                 | 0                  | 92 （ 26.4)                |                           | 1                         |
| IEUKOCYTOSIS LYMPHOPENIA NEUTROPENIA                         | 29 （ 37.2) 17     |                   | 0                 |                    | 0.7) 19 7.0)         |                    | 1. 0.                     | ２312０ 0.9 0.3) 0.6)       |                           |
| RENAL AND URINARY DISORDERS HAFMATURIA ACUTE KIDNEY INJURY   | 10                | 11 ( 14.1) 4400-  | 0 00:00-          | TZ79               | 43:00- 5）            | 0                  | 81 23.3)                  | 30 8.6) 2.3) 2.0)         | 0                         |
| DYSURIA URINARY INCONTINENCE                                 | 8                 | 1.3)              | 000               |                    | C （ 0.7)             | 00:00-             | 35:97-82920 7718 9360     | 8700- C 0.9)              | 00:00-                    |
| PSYCHIATRICDISORDERS INSOMNIA ANXIETY                        | 16.7)             |                   |                   | 88.5               | 0.7)                 |                    |                           |                           |                           |
|                                                              |                   | １00               |                   | 339                | 20２                  | 00:0               |                           | ３0２ 0.6)                  | 0:00                      |
| VASCULARDISORDERS                                            |                   | 2.6)              |                   |                    | 3:93                 | 0.7)               |                           |                           | ( 0.6)                    |
| HYEOTENSION                                                  |                   | ２0１１              |                   | 614:05 3272-       |                      | 20:00              | 691376315-                |                           | 2                         |
| HYPERTENSION                                                 |                   |                   | 00:00             |                    |                      |                    | 2570                      |                           |                           |
|                                                              |                   | 1:3               |                   |                    | 8:49                 |                    |                           |                           | 0:00                      |
| DEEPVEIN THROMBOSIS                                          |                   |                   |                   |                    |                      |                    |                           | 16:8                      |                           |
| ENDOCRINEDISORDERS                                           | 11.5)             |                   |                   | 13.7               | 0.4)                 |                    |                           |                           |                           |
| HYPOIHYROIDISM                                               | 973               | 00:0-             |                   |                    |                      |                    |                           | C 0.3)                    |                           |
|                                                              | 10:6              |                   | 00:0-             | 10. .03            | 10:0-                | 00:0-              |                           |                           | 0:0:o                     |
|                                                              | 3.8)              |                   |                   |                    |                      |                    |                           |                           |                           |
| HYPERTHYROIDISM                                              |                   |                   |                   |                    |                      |                    |                           |                           |                           |
|                                                              |                   |                   |                   | 4.4)               |                      |                    |                           |                           |                           |

<div style=\"page-break-after: always\"></div>

| EYEDISORDERS              | 11 (14.1)   | 1 1.3)   | 0   | 18 6.7) 721   | 0 0 0          | 29        | 8.3) 1      | 0      |
|---------------------------|-------------|----------|-----|---------------|----------------|-----------|-------------|--------|
| VISIONBLURRED             | 221 2.6)    | 0        | 0   | 2.6)          | 0              | 2.6)      | 0.3) 00     | 0      |
| LACRIMATIONINCREASED      | 2.6)        | o        | 0   | 0.7) 0 0.4)   | o              | 942 1.1)  |             | 0      |
| CWONUUNCTIVAL HAFMORRHAGE | 1.3)        | 0        | 0   | 0             | 0              | 0.6)      | 0           | 0      |
| EYE PRURITUS              | 2( 2.6)     | 0        | 0   | 0 0           | 0              | 2 0.6)    | 0           | 0      |
| CARDIACDISORDERS          | 3 3.8)      | 0        | 0   | 23 8.5)       | 2 0.7)         | 26 7.5)   | 1.4)        | 2 0.6) |
| TACHYCARDIA               |             | 0o       | 0   | 5１２00 3.7)    | 1.9) 0.4) 0.7) | 10 2.9)   | 512000 0.3) | 0      |
| ATRIALFIBRILLATION        |             |          | 0   | 1.1)          | 00             | 3332 0.9) | 0.6)        | 0      |
| SINUSBRADYCARDIA          |             |          | 0   | 1.1)          | 00o            | 0.9)      |             | 000    |
| SINUSTACHYCARDIA          | 00:021 2.6) | 000      | o   | 0.4)          |                | 0.9)      |             |        |
| PALPITATIONS              | 1.3)        |          | 0   | 0.4) 0        |                | 0.6)      |             |        |

Includes events reported between first dbse and 1o0 days after last dose of study therapy. CA209032 consistsofthenivolumabmonotherapyurothelialcarcinoma (i.e. bladder) cohort of CA209032. CA209032 2crossoversubjectsaretruncatedatthefirstdosedateofcrossoverperiod.

## Drug-related AEs

In the Integrated UC Population, any-grade drug-related AEs were reported in 68.7% of subjects (Table 44).The  most  frequently  reported  drug-related  AEs  were  fatigue  (21.0%),  pruritus  (13.8%),  diarrhoea (8.9%), nausea (8.3%), and decreased appetite (7.8%)

In the Integrated UC Population, Grade 3-4 drug-related AEs were reported in 19.0% of subjects (Table 44).The most frequently reported Grade 3-4 drug-related AEs were lipase increased (2.3%) and fatigue (2.0%).

Table  44  Drug-related AEs by Worst CTC Grade Reported in ≥ 5% of Treated Subjects CA209275 and Integrated UC Population

|                                                    |             |                   |         | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   |
|----------------------------------------------------|-------------|-------------------|---------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class (8) Preferred Term (&)          | Any Grade   | N = 270 Grade 3-4 | Grade 5 | Any Grade                   | Grade                       | 3-4                         | Gradk                       |
| TOTALSUBJECTS WITHANEVENT                          | 174 ( 64.4) | 48 (17.8)         | 3( 1.1) | 239(6 68.7)                 |                             | 66 (19.0)                   | 4                           |
| GENERALDISORDERSAND ADMINISTRATION SITE CONDITIONS | 80 29.6)    | 10 3.7)           | 0       | 109 31.3)                   | 12                          | 3.4)                        | 0                           |
| FATIGUE                                            | 45 16.7)    | 5 1.9)            | 0       | 73 ( 21.0)                  | 7 (                         | 2.0)                        | 0                           |
| ASTHENIA                                           | (6          | 4 1.5)            | 0       | 18 5.2)                     | 4                           | 1.1)                        | 0                           |
| PYREXIA                                            | 156         | 0                 | 0       | 17 4.9)                     | 0                           |                             | 0                           |
| SKINANDSUBCUTANEOUS TISSUE DISORDERS               | 54 （ 20.0)  | 6 2.2)            | 0       | 88 (25.3)                   | 9                           | 2.6)                        | 0                           |
| PRURITUS                                           | 26          | 0                 | 0       | 13.8)                       | 0                           |                             | 0                           |
| RASH                                               |             | 1.1)              | 0       | 10:9                        | 33                          | 0.9)                        |                             |
| RASHMACULO-PAPULAR                                 | 95 4        | 31 0.4)           | 0       | 8218 5.2)                   |                             | 0.9)                        | 0                           |
| GASTROINIESTINALDISORDERS                          | 饥记 20.0)    | 7 2.6)            | 0       | 78 22.4)                    | 9                           | 2.6)                        | 0                           |
| DIARRHOEA                                          | 8. 9)       | ５１ 1. 9)          | 0:0     | 31 (6.8                     | 52                          | 1.4)                        | 0                           |
| NAUSEA                                             | 7.0)        | 0.4)              |         | 29 8.3)                     | (                           | 0.6)                        | 0                           |
| ENDOCRINEDISORDERS HYPOTHYROIDISM                  | 21          | 0.4)              |         | 25 10.6) 7.2)               | OT (                        | 0.3)                        | 00                          |
| METABOLISMAND NUIRITION DISORDERS                  | 27 (10.0)   | 3 1.1)            | 0       | 37 (10.6)                   | 5                           | 1.4)                        | 0                           |
| DECREASED APPETITE                                 | 22 8.1)     | 0                 | 0       | 27 ( 7.8)                   | 0                           |                             | 0                           |
| BLOODANDLYMPHATICSYSTEM DISORDERS                  | 20 ( 7.4)   | 7 2.6)            | 0       | 31 ( 8.9)                   | 8                           | 2.3)                        | 0                           |
| ANAFMIA                                            | 11 4.1)     | 4 1.5)            | 0       | 19 5.5)                     | 4                           | 1.1)                        | 0                           |

MedDRA Version: 19.0 mrlereian4n

The biggest difference in AE rates between the 2 studies (CA209275 and CA209032), is in the any grade drug-related  AEs  category:  83.3%  any  grade  drug-related  AEs  were  noted  in  all  treated  subjects  in CA209032 as compared to 64.4% in CA209275. In all other categories of safety variables assessed, the rates noted were mostly similar between the 2 studies or there was a ≤ 5.5% difference between the 2 studies with no consistent pattern of increase noted specific to CA209032. Drug-related SAEs (any grade and  Grade  3-4)  were  similar  between  both  studies,  as  were  drug-related  Grade  3-4  drug-related discontinuation rates.

<div style=\"page-break-after: always\"></div>

Study drug-related death rate was higher in CA209032 (2.6%) vs. CA209275 (1.1%). When incidence rates  were  exposure-adjusted,  the  AE  rates  were  similar  between  CA209032,  CA209275,  and  the Integrated  UC  Population  (2355.4,  2184.9,  and  2234.2  [respectively]  incidence  rate  per  100  person years) (5% cut-off).

## Late-Emergent AEs

Late-emergent drug-related AEs were defined as drug-related AEs with an onset date &gt; 100 days after the last dose of study therapy. No late-emergent drug-related AEs were reported for study CA209032. One subject  (0.4%)  in  CA209275  experienced  a  Grade  3  late  emergent  drug-related  AE  of  organizing pneumonia.

## AEs in the Integrated UC Population and Across Pooled Monotherapy Studies

A summary of AEs (all causality and drug-related) for nivolumab-treated subjects in the Integrated UC Population  is  shown  side-by-side  with  the  integrated  safety  data  from  pooled  nivolumab  monotherapy studies in other tumor types in Table 45. Anaemia was the only newly reported all-causality PT reported in  &gt;20%  subjects,  which  is  consistent  with  haemoglobin  being  a  known  prognostic  variable  in  the Integrated  UC  population.  A  summary  of  AEs  (all  causality  and  drug-related)  for  nivolumab  treated subjects in individual studies CA209275 and CA209032 is shown side-by-side with the integrated safety data from pooled nivolumab monotherapy studies in other tumour types in Table 46.

Table 45 Adverse Events and Reactions with Nivolumab Monotherapy in Clinical Trials using Re-mapped Terms

|                                                    | CA209032+CA209275 N =348   | CA209032+CA209275 N =348   | Nivo Mono in Other Tumor Types N=2227   | Nivo Mono in Other Tumor Types N=2227   |
|----------------------------------------------------|----------------------------|----------------------------|-----------------------------------------|-----------------------------------------|
| Preferred Term (%)                                 | Any Grade                  | Grace 3-4                  | Any Grace                               | Grade 3-4                               |
| TOIALSUBJECTSWITHANEVENT (REGARULESS CF CAUSALITY) | 345 ( 99.1)                | 180 ( 51.7)                | 2163 ( 97.1)                            | 955 ( 42.9)                             |
| FATIGUE                                            | 161 46.3)                  | 21 6.0)                    | 1076 48.3)                              | 89 4.0)                                 |
| MUSCULOSKELETALIAIN                                | 112 32.2)                  | 8 2.3)                     | 726 32.6)                               | 74 3.31                                 |
| COUGH                                              | 68 19.5)                   |                            | 558 25.1)                               | 7 0.3)                                  |
| NAUSEA                                             | 83 23.9)                   | 3 0.9)                     | 535 24.0)                               | 18 0.8)                                 |
| RASH                                               | 69 19.8)                   | 7 2.0)                     | 512 (23.0)                              | 24 1.1)                                 |
| DIARRHOEA                                          | 60 17.2)                   | 8 2.3)                     | 501 22.5)                               | 36 1.6)                                 |
| DYSPNOFA                                           | 58 16.7)                   | 13 3.7)                    | 458 20.6)                               | 67 3.0)                                 |
| ANAEMTA                                            | 72 20.7)                   | 24 6.9)                    | 345 15.5)                               | 82 3.7)                                 |
| DEOREASEDAPIETITE                                  | 70 (20.1)                  | 6 1.7)                     | 441 (19.8)                              | 19 0.9)                                 |
| TOIALSUBJECTSWITHANEVENT (DRUG-RELAI5D)            | 239 ( 68.7)                | 66 (19.0)                  | 1617 ( 72.6)                            | 316 ( 14.2)                             |
| FATIGUE                                            | 86 5 (24.7)                | 11 3.2)                    | 674 30.3)                               | 36 1.6)                                 |
| RASH                                               | 49 14.1)                   | 7 2.0)                     | 380 17.1)                               | 19 0.9)                                 |
| NAUSEA                                             | 29 8.3)                    | 2 0.6)                     | 278 12.5)                               | 0.1)                                    |
| PRURITUS                                           | 48 13.8)                   | 0                          | 276 12.4)                               | m2 <0.1)                                |
| DIARRHOEA                                          | 31 8.9)                    | 5 1.4)                     | 274 12.3)                               | 21 0.9)                                 |
| DEOREASEDAPIETITE                                  | 27( 7.8)                   | 0                          | 202 9.1)                                | 0.1)                                    |

Types, CTC Version 4.0

Momotherapy Iooled group consists ofnivolumab momotherapy treatment group from sturdies CA209063,CA209017,CA209057，CA209037, CA209066, CA209067, CA209025, CA209039 (cHL subjeCts), ,CA209205, amd CA209141.

Aderay Aprgs jo asop 1ser range slep oe pue asop 1sity uempeq pepaodat squara sapntoui

CA209032 oonsists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of CA209032.

Grade 3-4 by worst CTC grade.

CA209032 crossover subjects are tnuncated at the first dose date of crossover period.

Sotre preferred tenms are re-mapped or deleted based on BMS medical review.

Source: Appendix BL.6.8a (AEs, remapped) amd Appendix BL.6.9a (drug-related AEs, relrapped); refer to Appendix HN.438 ((AEs, sad1q xourg raupo ut elep Aderauououl qeimtoitu xog Sos NHoog au Jo (paddeuat 'sgy papetat-brup) 6tr'N xipuaddy pue (peddeire1

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious adverse event (SAEs)

SAEs  consisted  mainly  of  events  in  the  neoplasms  benign,  malignant  and  unspecified  (incl  cysts  and polyps), infections and infestations, and gastrointestinal disorders SOCs in the Integrated UC Population.

Drug-related SAEs consisted mainly of events in the gastrointestinal disorders and respiratory, thoracic and mediastinal disorders SOCs in the Integrated UC Population.

In the Integrated UC Population, SAEs were reported in 52.6% of subjects (Table 46), 54.4% of subjects in Study CA209275 and 46.2% of subjects in Study CA209032. In the Integrated UC Population Grade 34  SAEs  were  reported  in  35.1%  of  subjects  and  the  most  frequently  reported  SAEs  were  malignant neoplasm  progression  (11.5%),  urinary  tract  infection  (5.2%),  general  physical  health  deterioration (2.6%),  sepsis  (2.3%),  and  diarrhoea  and  small  intestinal  obstruction  (2.0%).  The  most  frequently reported SAEs were in Study CA209032 and Study CA209275 respectively: malignant neoplasm (9.0% vs. 12.2%) and urinary tract infection (3.8% vs. 5.6%).

The frequencies of SAEs (any Grade, and Grade 3-4) in treated subjects in the CA209275 and CA209032 populations were similar for Grade 3-4 events to the Integrated UC Population. Grade 5 SAEs occurred at higher  frequencies  in  the  CA209275  treated  population  (11.5%)  compared  to  the  Integrated  UC Population (10.9%) and CA209032 (9.0%).

In the Integrated UC Population, drug-related SAEs were reported in 9.5% of subjects (Table 47). Grade 3-4  drug-related  SAEs  were  reported  in  6.6%  of  subjects.  Drug-related  SAEs  reported  in  at  least  2 subjects  were  pneumonitis  and  diarrhoea,  5  (1.4%)  each;  fatigue,  3  (0.9%);  colitis,  nausea,  and pemphigoid, 2 (0.6%) subjects each.

The  frequencies  of  drug-related  SAEs  (any  grade,  Grade  3-4,  and  Grade  5)  in  treated  subjects  in theCA209275 and CA209032 populations were consistent with the Integrated UC Population.

<div style=\"page-break-after: always\"></div>

Table 46 SAEs (All Causality) by Worst CTC Grade Reported in ≥1% of Treated Subjects CA209275 and Integrated UC Population

|                                                                                                         | CA209275 N = 270                              | CA209275 N = 270                      | CA209275 N = 270   | CA209032+ CA209275 N = 348            | CA209032+ CA209275 N = 348        | CA209032+ CA209275 N = 348   |
|---------------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------|--------------------|---------------------------------------|-----------------------------------|------------------------------|
| System Organ Class ($) Preferred Term (%)                                                               | Any Grade                                     | Grade 3-4                             | Grace 5            | Any Grade                             | Grade 3-4                         | Grace 5                      |
| TOIAL SUBJECTS WITH AN EVENT                                                                            | 147 ( 54.4)                                   | 99( 36.7)                             | 31 ( 11.5)         | 183 ( 52.6)                           | 122 ( 35.1)                       | 38 (10.9)                    |
| NEOPIASMS BENIGN, MALIGNANT AND UNSPECIFIED(INCL CYSTS AND                                              | 46 ( 17.0)                                    | 21 (7.8)                              | 21 (7.8)           | 53 ( 15.2)                            | 22 (6.3)                          | 27 (7.8)                     |
| POLYPS) MALIGNANTNEOPIASMPROGRESSION METASTASES TOCENIRAL NERVOUS CANCER IAIN SYSTEM                    | 33 4 (12.2)                                   | 12 4.4)                               | 20 0 0 （ 7.4)      | 40 11 5                               | 13 2 3 3.7) 0.6) 0.9)             | 26( 0 0 7.5)                 |
| INFECTIONS ANDINFESTATIONS URINARY TRACT INFECTION SEPSIS INFECTION UROSFPSIS GASTROINTESTINALDISORIERS | 36 (13.3) 15 8:22 3.0) 5.6) 0.71 0.7) 24 8.9) | 31 (11.5) 12 8:21 4.4) 3.0) 0.71 0.4) | 0 000 0            | 47 (13.5) 18 854 5.2) 3) 1.1) 32 9.2) | 39 (11.2) 14 853 4.0) 0.9) 7.2)   | 0 000 0 0                    |
| DTARRHOFA SMALL INTESTINAL OBSTRUCTION ABDOMINALIAIN VOMITING                                           | 66 mm 1.1) 1.1)                               | 19 54 1.9) 7.0) 23 1.5) 0.7) 1.1)     | 000:0:0            | 77 2.0 5m 2.0) 1.4) 0.9)              | 1.4) 1 1.1) 1.4) 3 0.9) 21 （ 6.0) | 00 0:0 0.9)                  |
| GENERAL DISORDERS AND ADMINISTRATIONSITECONDITIONS GENERALPHYSICALHEAITH                                | 24 ( 8.9) 9( 3.3)                             | 17 6.3) 2.2)                          | 3 （ 1.1)           | 30 (8.6)                              | 6 ( 1.7)                          | 2（ 0.6)                      |
| DETERIORATION PYREXTA IAIN RENALAND URINARY DISORDERS ACUTE KIDNEY INJURY                               | 1.1) 1.1) 13 4.8)                             | 1 0.4) 3 1.1)                         | 2( 0.7) 0 0        | 9 (2.6) 5 1.4) 4 1.1)                 | 2 0.6) 3 0.9)                     | 0 0                          |
| HAFMATURTA RESPIRATORY，THORACIC AND                                                                     | 2 0.7) 3 1.1)                                 | 11 4.1) 1 0.4)                        | 00 0 3 1.1)        | 18 5.2) 1.4) 1.4)                     | 16 4.6) 4 1.1) 4 1.1)             | 0                            |
|                                                                                                         | 15 ( 5.6)                                     | 2 0.7) 11 4.1)                        | 0                  | 18 ( 5.2)                             |                                   |                              |
|                                                                                                         | 4 5                                           | 5                                     |                    |                                       | 13 3.7)                           |                              |
| CARDIACDISORDERS ATRIAL FIBRILIATION                                                                    | 8 3.0)                                        |                                       | 2 ( 0              |                                       |                                   | 0                            |
| MEDTASTINALDISORDERS DYSPNOEA                                                                           |                                               |                                       |                    | 1.4)                                  |                                   | 1.1)                         |
| INEUMONITIS                                                                                             |                                               |                                       | 0.4)               |                                       | 1.4)                              | 0 2                          |
| RESPIRATORYFATLURE                                                                                      |                                               |                                       | 0.7)               | .4) 9 2.6)                            | 2 0.6) 4 1.1)                     |                              |
|                                                                                                         |                                               |                                       | 0.4)               | .4)                                   |                                   | 0.6)                         |
|                                                                                                         |                                               |                                       |                    | 3                                     |                                   | 0.3)                         |
|                                                                                                         | 1.1)                                          |                                       |                    | 0.9)                                  |                                   |                              |
|                                                                                                         |                                               | 2                                     |                    |                                       |                                   |                              |
|                                                                                                         |                                               | 0:3)                                  |                    |                                       | 1,1) 2 0.6)                       | 2 0.6) 0                     |
|                                                                                                         | 3 (                                           | 2                                     |                    |                                       |                                   | 0                            |
|                                                                                                         |                                               | 0.7)                                  | 0                  | 6 1.7)                                | 4 1.1)                            |                              |
| BIOOD AND LYMEHATIC SYSTEM DISORDERS                                                                    | 1.1)                                          |                                       |                    |                                       |                                   |                              |
| ANAFMTA                                                                                                 | 2( 0.7)                                       | 1 0.4)                                | 0                  | 1.1)                                  | 2                                 |                              |
| HEIATOBTLIARYDISORIERS                                                                                  | 4                                             | 4 1.5)                                |                    | 4                                     | 0.6)                              | 0                            |
| HEPATIC FATLURE                                                                                         | 1.5) 3 1.1)                                   | 3                                     |                    | 3                                     | 4 1.1) 3 0.9)                     | 0                            |
|                                                                                                         |                                               | 1.1)                                  |                    |                                       |                                   | 0                            |
|                                                                                                         |                                               |                                       |                    | 0.9)                                  |                                   |                              |
|                                                                                                         |                                               |                                       |                    | 1.1)                                  |                                   |                              |

MedDRA Version: 19.0,

CTC Version 4.0 Includes events reported between first cose and 30 days after last dose of stuidy therapy. CA209032 CA209032 crossover subjects are truncated atthe first dose date of crossover period.

Table 47 Drug-Related SAEs by Worst CTC Grade Reported in at Least 2 Treated Subjects CA209275 and Integrated UC Population

| Syatan Organ Class() Preferred Term(9)                  | CA209275 N=270            | CA209275 N=270        | CA209275 N=270   | C209032+0A209275 BK-N      | C209032+0A209275 BK-N     | C209032+0A209275 BK-N   |
|---------------------------------------------------------|---------------------------|-----------------------|------------------|----------------------------|---------------------------|-------------------------|
| Syatan Organ Class() Preferred Term(9)                  | Nny Grado                 | Gradn 3-4             | Grade 5          | Any Grade                  | Grade 3-4                 | Grade 5                 |
| TOTAL.SUBJECTS WLTH AN EVENT                            | 25 9.3)                   | 18 （ 6.7)             | 3（ 1.1)          | 33（ 9.5)                   | 23 6.6)                   | 4(1.1)                  |
| GLSTTODTTESTDNALDESORDERS DLARRHOEA NNSEA COLITIS       | 6 2.2) 4 1.5) 1 0.4) 0.4) | 6 2.21 1.5) 0.4) 0.4) | 0 0 00           | 10 2.9) 5 1.4) NN 0.6 0.6) | 8 2.3) 4 1.1) NN 0.6 0.6) | 0 0 00                  |
| RESPIRATURY,THORACICAD MEDTASTINALDESOROERS INEUMONETIS | 6 2.2) 1.5)               | E 1.11 2 0.71         | 2 0.7) 1（ 0.4)   | 2.0) 5( 1.4)               | 3 （ 0.90 2 0.6            | 3 (6'0 2 0.6)           |
| GERAL DESDROERS AND AMGNTSTRATIONSITE OOOITIOS FATIGE   | 3 C 1.1) 2 0.7)           | 2 0.7) 2 0.71         | 0 0              | 4 （ 1.1) 3 0.9)            | 3 0.9) E 0.9)             | 0 0                     |
| SCDNADSURCTREDUSTISSUE DESORDERS                        | E 1.1)                    | 3 1.1)                | 0                | 3 0.9)                     | 3 0.9)                    | 0                       |
| PEMHIGID                                                | 2 0.7                     | 2 0.71                | 0                | 2( 0.6                     | 21 0.6                    | 0                       |

McDRA Verslon: 19.0

CC Vesion4.0

O2o902cansistsof theniolumabmonotherapyurothelialoarcinra（l.e.bladber）cohortof CA2090.

Q209032 crodsover subjects ane truncated at the flnst dose dabe of crossover perlod.

## Deaths

As of the 30-May-2016 and 24-Mar-2016 database locks for CA209275 and CA209032, respectively, a similar proportion of subjects died in each study (Table 48). Disease progression was the most common cause  of  death  for  both  studies,  including  deaths  occurring  within  30  days  of  last  dose  and  deaths occurring within 100 days of last dose. A higher proportion of subjects died within 30 days of last dose in CA209275 than in CA209032.

<div style=\"page-break-after: always\"></div>

## Table 48 Summary of Deaths - All Treated Subjects

|                                                           | CA209032 N=78   |          |     | CA209275 N=270   |     |     | CA209032+CA209275 N=348   |       |
|-----------------------------------------------------------|-----------------|----------|-----|------------------|-----|-----|---------------------------|-------|
|                                                           | 36(46.2)        |          |     | 138(51.1)        |     |     | 174（50.0)                 |       |
| PRIMARY REASON FOR DEATH ()                               |                 |          |     |                  |     |     |                           |       |
| DISEASEPROGRESSION                                        | 31 (39.7)       |          | 121 | (44.8)           |     | 152 | 43.7)                     |       |
| STUDY DRUG TOXICITY                                       | 1               | 1.3)(A)  | 3   | 1.1)             | (B) | 4   | 1.1)                      | (A,B) |
| UNKNOWN                                                   | 3               | 3.8)     | 1   | 0.4)             |     | 4   | 1.1)                      |       |
| OTHER                                                     | 1               | 1.3)     | 13  | 4.8)             | (C) | 14  | 4.0)                      |       |
| NUMBER OF SUBJECTS WHO DIED WITHIN 30 DAYS OF LAST DOSE（) | 7（              | 9.0)     |     | 53(19.6)         |     |     | 60(17.2)                  |       |
| PRIMARY REASON FOR DEATH （)                               |                 |          |     |                  |     |     |                           |       |
| DISEASEPROGRESSION                                        | 6               | 7.7)     | 39  | （ 14.4)          |     | 45  | （ 12.9)                   |       |
| STUDY DRUG TOXICITY                                       | 1               | 1.3) (A) |     | 1.1)             | (B) | 4   | （ 1.1)                    | (A,B) |
| UNKNOWN                                                   | 0               |          | 0   |                  |     | 0   |                           |       |
| OTHER                                                     | 0               |          | 11  | 4.1)             |     | 11  | 3.2)                      |       |
| NUMBER OF SUBJECTS WHO DIED WITHIN10ODAYSOFLASTDOSE（%)    | 25(32.1)        |          |     | 121(44.8)        |     |     | 146(42.0)                 |       |
| FRIMARY REASON FOR DEATH （)                               |                 |          |     |                  |     |     |                           |       |
| DISEASE PROGRESSION                                       | 21 26.9)        |          | 104 | 38.5)            |     | 125 | 35.9)                     |       |
| STUDY DRUG TOXICITY                                       | 1               | 1.3) (A) |     | 1.1)             | (B) | 4   | 1.1)                      | (A,B) |
| UNKNOWN                                                   | 2               | 2.6)     | 1   | 0.4)             |     | 3   | 0.9)                      |       |
| OTHER                                                     | 1               | 1.3)     | 13  | 4.8)             |     | 14  | 4.0)                      |       |

(A)E For CA209032，1 death was due to dug-relatedpneumonitis.One other death, not included in the cancinoma,which was subsequently updated to dnug-related thranbocytopenia post database lock.

(C)One subject had cause of death as Other,noted as acute respiratory failure (not related) and also had related Grade3pneumonitis ongoing at the time of death.

(B) Deaths in study CA209275 attributed by the investigator to nivolumab therapy included drugrelated cardiovascular failure,drug-relatedpneumonitis,and drug-related respiratory failure in 1subject each (seeSection1.2.1).

CA209032 consists of the nivolumab monotherapy urothelial carcincma (i.e.bladder)cohort of CA209032.

## Deaths Attributed to Study Drug Toxicity

6 (1.7%) deaths assessed by the investigator due to study drug toxicity.

There  were  3  deaths  in  CA209275  due  to  study  drug  toxicity  as  assessed  by  the  investigator (pneumonitis, respiratory failure (preceded by interstitial lung disease)- and cardiovascular failure-). In addition,  in  one  subject,  although  pneumonitis  was  considered  related  to  nivolumab,  the  investigator deemed immediate cause of death to be due to multifactorial acute respiratory failure unrelated to study drug.  However,  this  death  was  assessed  as  related  by  BMS  medical  surveillance  team,  due  to  the consideration that the immunomodulatory nature of nivolumab led to the development of pneumonitis in the first instance, causing acute respiratory failure with fatal outcome.

In  study  CA209032, one subject died due to pneumonitis. The patient had a metastatic spread of the tumour  in  the  lung  at  baseline.  Although  other  contributing  factors  such  as  lung  metastases  and concomitant  lung  infections  could  not  be  excluded,  a  causal  association  between  study  therapy  and pneumonitis  was  considered  possible.  The  fatal  outcome  was  likely  attributable  to  multiple  factors, including underlying malignancy and the possible lung infection. In addition, 1 subject had a drug-related event post database lock, died due to thrombocytopenia. This subject's death was initially attributed to a reason  of  'Other,'  verbatim  terms  for  which  was  reported  as  'thrombocytopenia  of  unknown  cause, metastatic  bladder  cancer'.  The  cause  of  subject's  death  was  subsequently  updated  to  drug-related thrombocytopenia.  Considering  that  available  information  was  not  suggestive  of  other  alternative aetiologies, a causal association between study therapy and thrombocytopenia was considered possible.

<div style=\"page-break-after: always\"></div>

## Deaths Attributed to Other Reasons

The following 14 cases were reported: hepatic failure due to disease under study; perforated bowel with subsequent respiratory failure with sepsis likely; cardiac arrest in basic disease; Grade 5 cardiopulmonary arrest; cardiac arrest; hepatic failure; small bowel obstruction (disease progression) resulted in subject death;  acute  respiratory  failure;  bowel  perforation;  brain  stroke;  sepsis,  bradycardia,  hypotension; respiratory distress-possible PE; bowel obstruction; liver disorder.

One death was attributed to a reason of 'Other'. The verbatim term for this reason was reported as sepsis that was not considered related to study drug by the investigator. The subject died 59 days after the last dose of nivolumab.

## Select adverse events / adverse events of special interest (AESI)

Select  AEs  were  AEs  of  special  clinical  interest  meeting  defined  criteria  and  multiple  event  terms  that were grouped into select AE categories (regardless of treatment with immune modulating medication).

Based on defined guiding principles and taking into account the types of AEs already observed across studies of nivolumab monotherapy, endocrinopathies, diarrhoea/colitis, hepatitis, pneumonitis, interstitial nephritis,  and  rash  are  currently  considered  to  be  select  AEs.  Hypersensitivity/infusion  reactions  were analyzed along with the select AE categories because multiple event terms may be used to describe such events and pooling of terms was therefore necessary for full characterization. Hypersensitivity/infusion reactions do not otherwise meet criteria to be considered select AEs.

Other events of special interest (OESIs) are events that do not fulfil all criteria to qualify as select AEs. These events may differ from those caused by non-immunotherapies and may require immunosuppression  as part  of  their  management.  Analyses  of  OESIs  had  extended  follow-up(100-day window).OESIs included the following categories: demyelination, encephalitis, Guillain-Barre syndrome, myasthenic  syndrome,  pancreatitis,  and  uveitis.  Additional  events  in  the  categories  of  myositis, myocarditis,  and  rhabdomyolysis  were  recently  identified  as  OESIs  but  were  not  included  in  the programmed outputs.

In  the  Integrated  UC  Population,  the  majority  of  select  AEs  reported  were  Grade  1-2,  and  most  were considered drug-related by the investigator. The most frequently reported any-grade drug-related select AE categories with nivolumab treatment were skin (23.0%) and gastrointestinal (9.5%) (Table 49).

<div style=\"page-break-after: always\"></div>

Table 49 Summary of Select AEs Reported Up to 30 Days After Last Dose -All Treated Subjects in CA209275 and Integrated Population

<!-- image -->

|                                                                                                                                | Nuber (b) Subjects   | Nuber (b) Subjects   | Nuber (b) Subjects       | Nuber (b) Subjects       |
|--------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|--------------------------|--------------------------|
|                                                                                                                                | CA209275 (N =270)    | CA209275 (N =270)    | CA209032+CA209275(N=348) | CA209032+CA209275(N=348) |
|                                                                                                                                | Any Grade            | Grade 3-4            | Any Grade                | Grade 3-4                |
| AIL CAUSALTTY SELECTAES,BY CAIBGLRY                                                                                            |                      |                      |                          |                          |
| DUORDNE                                                                                                                        | 15-3                 |                      | 14.9) 18.4) 12.9)        | 1192161                  |
| CASTROINTESTINAL                                                                                                               |                      |                      |                          |                          |
| HEPATIC                                                                                                                        | 12.2)                |                      |                          |                          |
| FULMONARY (a)                                                                                                                  | 4.4)                 | 71                   | 4.0)                     |                          |
| PDNAL                                                                                                                          | 10.4)                |                      | 14.4)                    |                          |
| SKON                                                                                                                           | 27.01                | NS                   | 31.3)                    |                          |
| HYIERSDNSITIVITY/INEUSIONPEACTION                                                                                              | 1.9)                 | (7.0                 | 00 2.3)                  |                          |
| DROG-REIAIFD SEIECT AES,BY CAIDGURY                                                                                            |                      |                      |                          |                          |
| DIORINE                                                                                                                        | 14.4)                |                      | 12.9)                    |                          |
| GASTROINTESTDNAL                                                                                                               | 9.3)                 |                      | 9.5)                     |                          |
| HEPATIC                                                                                                                        | 3.7)                 |                      | 858189 4.0)              |                          |
| FUIMONARY (a)                                                                                                                  | 4.11                 |                      | 3.71                     | 66                       |
| RENAL                                                                                                                          | 1.11                 |                      | 2.9                      |                          |
| SKIN                                                                                                                           | 47 17.4)             | 1. 5)                | 23.0)                    | 7                        |
| HYEERSDNSITIVITY/INEUSION PEACTION                                                                                             | 3 1.1)               | 0.4)                 | 1.4)                     | HPOmNWH 0.3)             |
| MedlRA Versicn: 19.0 CIC Versicn 4.0 Includes events reported between first dose and 30 days after last dose of stucy therapy. |                      |                      |                          |                          |

Across  select  AE  categories,  the  majority  of  events  were  manageable,  with  resolution  occurring  when immune-modulating  medications  (mostly  systemic  corticosteroids)  were  administered.  Some  endocrine select AEs, though well-controlled with hormone replacement therapy, were not considered resolved due to the continuing need for hormone replacement therapy.

## Endocrine Events

The  endocrine  select  AE  category  included  the  following  subcategories:  adrenal  disorders,  diabetes, pituitary disorders, and thyroid disorders.

In  the  Integrated  UC  Population,  endocrine  select  AEs  (all-causality,  any  grade)  were  reported  in  52 (14.9%) subjects treated with nivolumab, 43 (15.9%) in CA209275 and 9 (11.5%) in CA209032.

45 (12.9%) subjects in the Integrated UC Population had endocrine select AEs that were considered to be drug-related by the investigator (Table 50), 39 (14.4%) in CA209275 and 6 (7.7%) in CA209032. The most commonly reported drug-related event was hypothyroidism (7.2%, 7.8% and 5.1%, respectively). With the exception of one Grade 3 event of hypophysitis reported in CA209275, all drug-related endocrine events were Grade 1-2 and none led to discontinuation of nivolumab.

The median time to onset of drug-related endocrine AEs was 8.57 weeks.

Of  the  5  subjects  who  were  treated  with  immune-modulating  medication  (median  duration  of  6.14 weeks), 2 resolved with resolution time ranging from 0.6 to 22.1+ weeks. Overall, 16 of the 45 subjects with drug-related endocrine select AEs resolved, with time to resolution ranging from 0.6 to 51.1+ weeks.

<div style=\"page-break-after: always\"></div>

|                                                                                                        | CA209275 N=270                   | CA209275 N=270   | CA209275 N=270   | CL209032+CA209275 8E=N              | CL209032+CA209275 8E=N   | CL209032+CA209275 8E=N   |
|--------------------------------------------------------------------------------------------------------|----------------------------------|------------------|------------------|-------------------------------------|--------------------------|--------------------------|
| Sub Category (b) PreferredTerm (e)                                                                     | Any Grade                        | Grade3-4         | Grade5           | Any Grade                           | Grade 3-4                | Grade5                   |
| TOTALSUBJECTSWITHAN EVENT                                                                              | 39(14.4)                         | 1 （ 0.4)         | 0                | 45(12.9)                            | 1 （ 0.3)                 | 0                        |
| THYROID DISCRDER HYEERTHYROTDTSM BLOOD THYROID STDMULATINGHORMDNE INCREASED                            | 32 13.0) 7.8) 10 4.1) 3.7)       | 0 0 00           | 0000             | 41 (11.8) 25 7.2) 14 4.0) 11 （ 3.2) | 0000                     | 00:00                    |
| ELOOD THYROTD STDMULATING HORMDNE DECREALSFD THYROIDITIS                                               | 5( 1.9)                          | 0                |                  | 5( 1.4)                             | 0                        |                          |
| THYROXINE INCREASED AUTOIMMINETHYROTDITIS THYROKINEDECREASED THYROKINE FREE INCREASED ADRENAL DISCRDER | 22111 （ 0.7) 0.7) 0.4) 0.4) 0.4) | 0 00 0 0         | 00000            | 22H1H 0.6) 0.6) 0.3) 0.3) 0.3)      | 00000                    | 00000                    |
| ADRENAL INSUEFICTENCY                                                                                  | 21 0.7) 21 0.7)                  | 0                | 00               | 2 （ 0.6) 2 （ 0.6)                   | 00                       | 00                       |
| PITUITARY DTSCRDER                                                                                     | 21 0.7) 0.7                      | 11 0.4) 0.4)     | 00               | 22 0.6) 0.6)                        | 11 8:3                   | 00                       |
| DLABETES TYEE1 DTABETES                                                                                | 1 0.4) 1                         | 0 0              | 00               | 1 0.31 1                            | 00                       | 00                       |
| MELLTTUS                                                                                               | 0.4)                             |                  |                  | 0.31                                |                          |                          |

Table 50 Summary of Drug-related Endocrine Select Adverse Events by Worst CTC Grade Reported Up to 30 days After Last Dose - All Treated Subjects in CA209275 and Integrated UC Population

<!-- image -->

## Gastrointestinal Events

In the Integrated UC Population, gastrointestinal select AEs (all-causality, any grade) were occurring in 64 (18.4%) subjects treated with nivolumab, 48 subjects (17.8%) in CA209275 and 16 subjects (20.5%) in CA209032.

33 (9.5%) subjects had GI select AEs that were considered to be drug-related by the investigator (Table 51). The majority of drug-related diarrhoea events were Grade 1-2; 5 (1.4%) subjects experienced Grade 3-4 diarrhoea events. Two of the 3 colitis events were Grade 3-4. One event (Grade 3 diarrhoea) led to permanent discontinuation of nivolumab.

The median time to onset of drug-related GI select AEs was 6.43 weeks. Of the 9 subjects who were treated  with  immune  modulating  medications  (high-dose  corticosteroids  for  a  median  duration  of  1.29 weeks), 8 subjects had resolution of their events. Overall, 29 of the 33 subjects with drug-related GI select AEs had resolution of their events, with a median time to resolution of 2.14 weeks.

<div style=\"page-break-after: always\"></div>

Table 51 Summary of Drug-related Gastrointestinal Select Adverse Events by Worst CTC Grade Reported Up to 30 days After Last Dose - All Treated Subjects in CA209275 and Integrated UC Population

<!-- image -->

|                                                                                             |                                                                                             |                                                                                             |                                                                                             | CA209032+CA209275 N=348                                                                     | CA209032+CA209275 N=348                                                                     | CA209032+CA209275 N=348                                                                     |                                                                                             |
|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Preferred Temm (6)                                                                          | Any Grade                                                                                   | Grade 3-4                                                                                   | Grade 5                                                                                     | Any Grade                                                                                   | Grade 3-4                                                                                   | Grade 5                                                                                     |                                                                                             |
| TOTALSUBECTSWTTHAN EVENT                                                                    | 25 (9.3)                                                                                    | 6 (2.2)                                                                                     | 0                                                                                           | 33 (9.5)                                                                                    | 7(2.0)                                                                                      | 0                                                                                           |                                                                                             |
| DIARRHOEA                                                                                   | 24 ( 8.9)                                                                                   | 5 1.91                                                                                      | 0                                                                                           | 8.91                                                                                        | 1.4)                                                                                        | 0                                                                                           |                                                                                             |
| COLITIS                                                                                     | 27 0.7)                                                                                     | 1(0.4)                                                                                      |                                                                                             | 370.9)                                                                                      | 2 10.6                                                                                      | 0                                                                                           |                                                                                             |
| MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. | MedDRA Version:19.0 CIC Version4.0 Endbcrine Adverse Events are not included in this table. |

## Hepatic Events

In  the  Integrated  UC  Population,  hepatic  select  AEs  (all-causality,  any  grade)  were  reported  in  45 (12.9%)  subjects.  14  (4.0%)  subjects  had  hepatic  select  AEs  considered  to  be  drug-related  by  the investigator (Table 52). 6 subjects had Grade 3-4 drug-related events. None of the hepatic select AEs led to permanent discontinuation of nivolumab.

The median time to onset of drug-related hepatic events was 5.86 weeks. Four subjects were treated with immune modulating  medications  for  a  median  duration  of  13.71  weeks  and  none  of  the  subjects  had resolution of the event at the time of the database locks. Overall, 7 of the 14 subjects with drug-related hepatic select AEs had resolution of their events; median time to resolution 6.71 weeks.

Table 52 Summary of Drug-related Hepatic Select Adverse Events by Worst CTC Grade Reported Up to 30 days After Last Dose - All Treated Subjects and Integrated UC Population

|                                              | CA209275 N = 270   | CA209275 N = 270   | CA209275 N = 270   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   |
|----------------------------------------------|--------------------|--------------------|--------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| PreferredTerm (%)                            | Any                | Grade              | Grade 3-4          | Grade 5 Any               |                           | Grade                     | Grade 3-4                 | Grade5                    |
| TOTALSUBJECTS WITHAN EVENT                   | 10                 | 3.7)               | 5 1.9)             | 0                         | 14                        | 4.0)                      | 6 1.7)                    | 0                         |
| ALANINEAMINOIRANSFFRASE INCREASED            | 8                  | 3.0)               | 2 ( 0.7)           | 0                         | 11                        | 3.2)                      | 2 0.6)                    | 0                         |
| ASPARTATE AMINOTRANSFERASE                   | 6                  | 2.2)               | 3 1.1)             | 0                         | 7                         | 2.0)                      | 4 1.1)                    | 0                         |
| INCREASED BLOODALKALINE PHOSPHATASEINCREASED | 3                  | 1.1)               | 2 0.7)             | 0                         | 4                         | 1.1)                      | 2 0.6)                    | 0                         |
| BLOODBILIRUBIN INCREASED                     | 2                  | 0.7)               | 1 ( 0.4)           | 0                         | 3                         | 0.9)                      | 1 0.3)                    | 0                         |
| LIVER FUNCTION TEST INCREASED                | 2                  | 0.7)               | 1 ( 0.4)           | 0                         | 2                         | 0.6)                      | 1 0.3)                    | 0                         |
| TRANSAMINASESINCREASED                       | 2                  | 0.7)               | 0                  | 0                         | 2                         | 0.6)                      | 0                         | 0                         |
| HYPERBILIRUBINAEMIA                          | 1                  | 0.4)               | 0                  | 0                         | 0.3)                      | 0                         |                           | 0                         |

<!-- image -->

## Pulmonary Events

In  the  Integrated  UC  Population,  pulmonary  select  AEs  (all-causality,  any  grade)  were  reported  in  14 (4.0%) subjects with pneumonitis being the most frequently occurring pulmonary select AE.

<div style=\"page-break-after: always\"></div>

13 (3.7%) subjects had pulmonary select AEs considered to be drug-related by the investigator (Table 53). Twelve of these drug-related events were pneumonitis; 2 of the 12 were Grade 3-4. In addition to the  pneumonitis events, a Grade 3-4 drug-related event of interstitial lung disease; was reported. Six drug-related  pulmonary  select  AEs,  including  the  event  of  interstitial  lung  disease,  led  to  permanent discontinuation of nivolumab.

The  median  time  to  onset  of  drug-related  pulmonary  events  was  15.0  weeks.  Eleven  subjects  were treated with immune modulating medication for a median duration of 2.43 weeks, and 3 subjects had resolution  of  the  event.  Overall,  4  of  the  13  subjects  with  drug-related  pulmonary  select  AEs  had resolution of their events, with a median time to resolution of 16.14 weeks.

Table  53  Summary  of  Drug-related  Pulmonary  Select  Adverse  Events  by  Worst  CTC  Grade Reported Up to 30 days After Last Dose - All Treated Subjects in CA209275 and Integrated UC Population

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | C209275 N=270                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | C209275 N=270                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | C209275 N=270                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | C209032+CA209275 N=348                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | C209032+CA209275 N=348                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | C209032+CA209275 N=348                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preferred Term (t)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Any Grade                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Grade3-4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Grade5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Any Grade                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Grade3-4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Grade5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| TOTALSUBJECTSWITHAN EVENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11（ 4.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 3( 1.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1（                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.4）13（3.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3（ 0.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2(0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PNEUHONITIS (a) 0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10(3.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2(0.7）                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1（0.4）12（3.4）                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2(0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2（                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| DNIERSTITTAL LUNG ESVESIO                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1（0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1（0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1(0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1（0.3）                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. | MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. | MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. | MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. | MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. | MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. | MedDRAVersion:19.0 CTC Version4.0 (a)In both CA209275 and CA209032,1subjectin eachstudyhaddrug-related Grade5pneumonitis assessed by the investigator.SeeSectian 2.2[Deaths]for further detailsofstudy drug toxicities. Includesevents reportedbetween firstdbseand 30daysafter last dbse ofstudy therapy. CA20g032consists of the nivolumab monotherapy urothelialcarcinoma （i.e.bladder)cohortof CA209032. CA209032crossoversubjects are truncatedat the firstdbsedate of crossover period. |

## Renal Events

In the Integrated UC Population, renal select AEs (all-causality, any grade) were reported in 50 subjects (14.4%) treated with nivolumab. Renal select AEs were reported more frequently in CA209032 than in CA209275 (28.2% vs. 10.4% for any-grade events); however, the low frequency of events and small sample size limit interpretation.

10 subjects (2.9%) had renal select AEs considered to be drug-related by the investigator (Table 54). The majority of events were Grade 1-2 and no events lead to permanent discontinuation of nivolumab.

The median time to onset was 10.57 weeks. One subject was treated with high dose corticosteroids with resolution of the event. Overall, 5 of the 10 subjects with drug-related renal select AEs had resolution of their events; median time to resolution was 16.29 weeks.

<div style=\"page-break-after: always\"></div>

Table 54 Summary of Drug-related Renal Select Adverse Events by Worst CTC Grade Reported Up to 30 days After Last Dose - All Treated Subjects in CA209275 and Integrated UC Population

<!-- image -->

## Skin Events

In the Integrated UC Population, skin select AEs (all-causality, any grade) were reported in 109 (31.3%) subjects.

Drug-related skin select AEs were reported in 80 (23.0%) subjects (Table 55). The most frequently reported drug-related events were pruritus (13.8%), rash (6.0%), and rash maculopapular (5.2%). No event of toxic epidermal necrolysis was reported. The majority of drug-related events were Grade 1-2; 6 (1.7%) subjects experienced Grade 3-4 skin events. Two subjects experienced drug-related skin select AEs which led to permanent discontinuation of nivolumab.

The median time to onset of drug-related skin select AEs was 4.0 weeks. 25 subjects were treated with immune modulating medication for a median of 18.29 weeks with resolution of the event in 10 subjects. Overall, 45 of 80 subjects with drug-related skin select AEs had resolution of their events with a median time to resolution of 17.14 weeks.

Table 55 Summary of Drug-related Skin Select Adverse Events by Worst CTC Grade Reported Up to 30 days After Last Dose - All Treated Subjects in CA209275 and Integrated UC Population

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Hypersensitivity/Infusion Reactions

In  the  Integrated  UC  Population,  hypersensitivity/infusion  reactions  (all-causality,  any  grade)  were reported in 8 subjects (2.3%). 5 (1.4%) subjects had hypersensitivity/infusion reactions considered to be drug-related by the investigator (Table 56). A Grade 3-4 infusion reaction was reported in 1 subject. No hypersensitivity/infusion reactions led to permanent discontinuation of nivolumab.

The  median  time  to  onset  of  drug-related  hypersensitivity/infusion  reactions  AEs  was  2.14  weeks.  2 subjects were treated with immune-modulating medication, both resolved, with median time to resolution of 0.50 weeks.

|                           | CA209275 N=270   | CA209275 N=270   | CA209275 N=270   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   | CA209032+CA209275 N=348   |
|---------------------------|------------------|------------------|------------------|---------------------------|---------------------------|---------------------------|
| Preferred Term (%)        | Any Grade        | Grade 3-4        | Grade 5          | Any Grade                 | Grade3-4                  | Grade5                    |
| TOTALSUBJECTSWITHAN EVENT | 3 (1.1)          | 1( 0.4)          | 0                | 5 (1.4)                   | 1(0.3)                    | 0                         |
| INFUSION RELATED REACTION | 2（ 0.7)          | 1(( 0.4)         | 0                | 3（ 0.9)                   | 1 (0.3)                   | 0                         |
| HYPERSENSITIVITY          | 1( 0.4)          | 0                | 0                | 2（ 0.6)                   | 0                         | 0                         |

Table  56  Summary  of  Drug-related  Hypersensitivity/Infusion  Reactions  Reported  Up  to  30 days After Last Dose - All Treated Subjects and Integrated UC Population

<!-- image -->

## Other Events of Special Interest

Other events of special interest (OESIs) are events that do not fulfil all criteria to qualify as select AEs. These events may differ from those caused by non-immunotherapies and may require immunosuppression as part of their management. Analyses of OESIs had extended follow-up (100-day window).

OESIs included the following categories: demyelination, encephalitis, Guillain-Barre syndrome, myasthenic syndrome, pancreatitis, and uveitis.

The only OESI reported in the Integrated UC Population was a Grade 3-4 OESI of pancreatitis reported in CA209032. Time to onset of 46.4 weeks and time to resolution of 3.1 weeks. The event did not lead to treatment discontinuation nor was it treated with immune-modulating medication.

No other OESIs were reported between first dose and 100 days after last dose of study therapy in the Integrated UC Population. No OESIs were considered drug-related or serious AEs by the investigator. No events in the categories of myositis, myocarditis, and rhabdomyolysis were identified.

The total number of subjects in the UC population with at least one immune related adverse reaction was 40.5% (any grade) ad 7.5% (Grade 3-4) (Table 57). These events are defined as any drug-related select adverse  event  (using  30  days  safety  windows)  from  any  of  the  following  categories:  gastrointestinal, hepatic, pulmonary, renal, skin, endocrine, and hypersensitivity/infusion adverse events.

The  rate  of  any  grade  event  was  higher  in  study  CA209032  (51.3%)  compared  to  study  CA209275 (37.4%) mainly due to the difference in rates of select adverse events from the skin category (42.3% vs 17.4%, refer to Appendix BL.6.102 of the EU UC SCS). The rate of high grade event from any category (6.4% vs.7.8%) was similar between studies.

<div style=\"page-break-after: always\"></div>

Table 57 Summary of Any Drug-Related Select Adverse Event (Any Category) by Worst CTC Grade - All Treated Subjects

<!-- image -->

## Adverse drug reactions

Table 58: Frequencies of adverse drug reactions included in the SmPC section 4.8 - Integrated UC population and nivolumab monotherapy population in other tumour types

|                                                                            | Integrated UCPopulation n=348 treated subjects                             | Integrated UCPopulation n=348 treated subjects                             | Integrated UCPopulation n=348 treated subjects                             | Integrated UCPopulation n=348 treated subjects                             | PooledNivolumabMonotherapyPopulation in Other Tumor Types(excluding UC) n = 2227treated subjectsa   | PooledNivolumabMonotherapyPopulation in Other Tumor Types(excluding UC) n = 2227treated subjectsa   | PooledNivolumabMonotherapyPopulation in Other Tumor Types(excluding UC) n = 2227treated subjectsa   |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| ADRb,Cd                                                                    | No.of Subjects                                                             | % of subjects                                                              | Designation of frequency                                                   | Source Appendix                                                            | No.of Subjects                                                                                      | % of subjects                                                                                       | Designation of frequency                                                                            |
| Totalno.of nivolumab-monotherapy                                           | Totalno.of nivolumab-monotherapy                                           | Totalno.of nivolumab-monotherapy                                           | Totalno.of nivolumab-monotherapy                                           | Totalno.of nivolumab-monotherapy                                           | Totalno.of nivolumab-monotherapy                                                                    | Totalno.of nivolumab-monotherapy                                                                    | Totalno.of nivolumab-monotherapy                                                                    |
| Infectionsandinfestations                                                  | Infectionsandinfestations                                                  | Infectionsandinfestations                                                  | Infectionsandinfestations                                                  | Infectionsandinfestations                                                  | Infectionsandinfestations                                                                           | Infectionsandinfestations                                                                           | Infectionsandinfestations                                                                           |
| Upper respiratory tract infection                                          | 2                                                                          | 0.6                                                                        | Uncommon                                                                   | BL.6.9a                                                                    | 22                                                                                                  | 1.0                                                                                                 | Common                                                                                              |
| Pneumonia                                                                  | 1                                                                          | 0.3                                                                        | Uncommon                                                                   | BL.6.9a                                                                    | 15                                                                                                  | 0.7                                                                                                 | Uncommon                                                                                            |
| Bronchitis                                                                 | 0                                                                          | 0                                                                          |                                                                            | BL.6.9a                                                                    | 4                                                                                                   | 0.2                                                                                                 | Uncommon                                                                                            |
| Neoplasms henign, malignant and unspecified (including cy sts and polyp s) | Neoplasms henign, malignant and unspecified (including cy sts and polyp s) | Neoplasms henign, malignant and unspecified (including cy sts and polyp s) | Neoplasms henign, malignant and unspecified (including cy sts and polyp s) | Neoplasms henign, malignant and unspecified (including cy sts and polyp s) | Neoplasms henign, malignant and unspecified (including cy sts and polyp s)                          | Neoplasms henign, malignant and unspecified (including cy sts and polyp s)                          | Neoplasms henign, malignant and unspecified (including cy sts and polyp s)                          |
| Hi stiocytic necrotising lymphadenitis (Kikuchi lymphadenitis)             | 0                                                                          | 0                                                                          |                                                                            | BL.6.9a                                                                    | 1                                                                                                   | <0.1                                                                                                | Rare                                                                                                |
| Blood and lymphaticsystem disorders                                        | Blood and lymphaticsystem disorders                                        | Blood and lymphaticsystem disorders                                        | Blood and lymphaticsystem disorders                                        | Blood and lymphaticsystem disorders                                        | Blood and lymphaticsystem disorders                                                                 | Blood and lymphaticsystem disorders                                                                 | Blood and lymphaticsystem disorders                                                                 |
| Eosinophilia                                                               | 3                                                                          | 0.9                                                                        | Uncommon                                                                   | BL.6.9a                                                                    | 5                                                                                                   | 0.2                                                                                                 | Uncommon                                                                                            |
| Immune system disorders                                                    | Immune system disorders                                                    | Immune system disorders                                                    | Immune system disorders                                                    | Immune system disorders                                                    | Immune system disorders                                                                             | Immune system disorders                                                                             | Immune system disorders                                                                             |
| Infusi on related reaction                                                 | 3                                                                          | 0.9                                                                        | Uncommon                                                                   | BL.6.9a                                                                    | 77                                                                                                  | 3.5                                                                                                 | Common                                                                                              |
| Anaphylacti c reaction                                                     | 0                                                                          | 0                                                                          |                                                                            | BL.6.3a                                                                    | 2                                                                                                   | <0.1                                                                                                | Rare                                                                                                |
| Hypersensitivity                                                           | 2                                                                          | 0.6                                                                        | Uncommon                                                                   | BL.6.9a                                                                    | 35                                                                                                  | 1.6                                                                                                 | Common                                                                                              |
| Endocrine disorder's                                                       | Endocrine disorder's                                                       | Endocrine disorder's                                                       | Endocrine disorder's                                                       | Endocrine disorder's                                                       | Endocrine disorder's                                                                                | Endocrine disorder's                                                                                | Endocrine disorder's                                                                                |
| Hypothyroi dism                                                            | 25                                                                         | 7.2                                                                        | Common                                                                     | BL.6.9a                                                                    | 134                                                                                                 | 6.0                                                                                                 | Common                                                                                              |
| Hyperthyroidism                                                            | 14                                                                         | 4.0                                                                        | Common                                                                     | BL.6.9a                                                                    | 41                                                                                                  | 1.8                                                                                                 | Common                                                                                              |

<div style=\"page-break-after: always\"></div>

| Hyperglycaemia                                 | 7                                   | 2.0                                 | Common                              | BL.6.9a                             | 25                                  | 1.1                                 | Common                              |
|------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Adrenal insuffciency                           | 2                                   | 0.6                                 | Uncommon                            | BL.6.9a                             | 10                                  | 0.4                                 | Uncommon                            |
| Hypopituitarism                                | 0                                   | 0                                   |                                     | BL.6.9a                             | 5                                   | 0.2                                 | Uncommon                            |
| Hypophysiti s                                  | 2                                   | 0.6                                 | Uncommon                            | BL.6.9a                             | 6                                   | 0.3                                 | Uncommon                            |
| Thyroiditis                                    | 3                                   | 0.9                                 | Uncommon                            | BL.6.9a                             | 13                                  | 0.6                                 | Uncommon                            |
| Diabetic keto acidosis                         | 0                                   | 0                                   |                                     | BL.6.9a                             | 2                                   | <0.1                                | Rare                                |
| Di ab etes mellitus                            | 1                                   | 0.3                                 | Uncommon                            | BL.6.9a                             | 1                                   | <0.1                                | Rare                                |
| Metabolism and nutrition disorder's            | Metabolism and nutrition disorder's | Metabolism and nutrition disorder's | Metabolism and nutrition disorder's | Metabolism and nutrition disorder's | Metabolism and nutrition disorder's | Metabolism and nutrition disorder's | Metabolism and nutrition disorder's |
| Decreased appetite                             | 27                                  | 7.8                                 | Common                              | BL.6.9a                             | 202                                 | 9.1                                 | Common                              |
| Dehydration                                    | 3                                   | 0.9                                 | Uncommon                            | BL.6.9a                             | 12                                  | 0.5                                 | Uncommon                            |
| Metabolic acidosisf                            | 1                                   | 0.3                                 | Uncommon                            | BL.6.8a                             | 3                                   | 0.1                                 | Uncommon                            |
| Hepatobiliary disorders                        | Hepatobiliary disorders             | Hepatobiliary disorders             | Hepatobiliary disorders             | Hepatobiliary disorders             | Hepatobiliary disorders             | Hepatobiliary disorders             | Hepatobiliary disorders             |
| Hepatitis                                      | 0                                   | 0                                   |                                     | BL.6.9a                             | 5                                   | 0.2                                 | Uncommon                            |
| Hyperbilirubinemia                             | 1                                   | 0.3                                 | Uncommon                            | BL.6.9a                             | 3                                   | 0.1                                 | Uncommon                            |
| Cholestasis                                    | 0                                   | 0                                   |                                     | BL.6.9a                             | 2                                   | <0.1                                | Rare                                |
| Nervous system disorders                       | Nervous system disorders            | Nervous system disorders            | Nervous system disorders            | Nervous system disorders            | Nervous system disorders            | Nervous system disorders            | Nervous system disorders            |
| Peripheral neuropathy                          | 3                                   | 0.9                                 | Uncommon                            | BL.6.9a                             | 47                                  | 2.1                                 | Common                              |
| Headache                                       | 6                                   | 1.7                                 | Common                              | BL.6.9a                             | 93                                  | 4.2                                 | Common                              |
| Dizziness                                      | 4                                   | 1.1                                 | Common                              | BL.6.9a                             | 45                                  | 2.0                                 | Common                              |
| Polyneurop athy                                | 1                                   | 0.3                                 | Uncommon                            | BL.6.9a                             | 3                                   | 0.1                                 | Uncommon                            |
| Guillain-Barre syndrome                        | 0                                   | 0                                   |                                     | BL.6.9a                             | 1                                   | <0.1                                | Rare                                |
| Demyelination                                  | 0                                   | 0                                   |                                     | BL.6.9a                             | 1                                   | <0.1                                | Rare                                |
| Myasthenic syndrome Autoimmune neurop athy     | 0                                   |                                     |                                     | BL.6.9a                             | 1                                   | <0.1                                | Rare                                |
| (including facial and abducens nerve paresis)& | 0                                   | 0                                   |                                     | BL.6.9a                             | 2                                   | <0.1                                | Rare                                |
| Eye disorders                                  | Eye disorders                       | Eye disorders                       | Eye disorders                       | Eye disorders                       | Eye disorders                       | Eye disorders                       | Eye disorders                       |
| Vision blurred                                 | 0                                   | 0                                   |                                     | BL.6.9a                             | 18                                  | 0.8                                 | Uncommon                            |
| Dry eye                                        | 1                                   | 0.3                                 | Uncommon                            | BL.6.9a                             | 20                                  | 0.9                                 | Uncommon                            |
| Uveitis                                        | 0                                   | 0                                   |                                     | BL.6.9a                             | 9                                   | 0.4                                 | Uncommon                            |
| Cardiac disorders                              | Cardiac disorders                   | Cardiac disorders                   | Cardiac disorders                   | Cardiac disorders                   | Cardiac disorders                   | Cardiac disorders                   | Cardiac disorders                   |
| Tachycardia                                    | 0                                   | 0                                   |                                     | BL.6.9a                             | 8                                   | 0.4                                 | Uncommon                            |
| Arrhythmia (including ventricular arrhythmia)  |                                     | 0                                   |                                     | BL.6.9a                             | 1                                   | <0.1                                | Rare                                |
| Atrial fibrillation                            | 0                                   | 0                                   |                                     | BL.6.9a                             | 1                                   | <0.1                                | Rare                                |
| Vascular disorders                             | Vascular disorders                  | Vascular disorders                  | Vascular disorders                  | Vascular disorders                  | Vascular disorders                  | Vascular disorders                  | Vascular disorders                  |
| Hypertension                                   | 2                                   | 0.6                                 | Uncommon                            | BL.6.9a                             | 27                                  | 1.2                                 | Common                              |
| Vasculitis                                     | 0                                   | 0                                   |                                     | BL.6.9a                             | 2                                   | <0.1                                | Rare                                |

<div style=\"page-break-after: always\"></div>

| Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   | Respiratory, thoracic and mediastinal disorder's   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Pneumonitis                                        | 13                                                 | 3.7                                                | Common                                             | BL.6.9a                                            | 66                                                 | 3.0                                                | Common                                             |
| Dyspnoea                                           | 16                                                 | 4.6                                                | Common                                             | BL.6.9a                                            | 101                                                | 4.5                                                | Common                                             |
| Cough                                              | 7                                                  | 2.0                                                | Common                                             | BL.6.9a                                            | 108                                                | 4.8                                                | Common                                             |
| Pleural effusion                                   | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 6                                                  | 0.3                                                | Uncommon                                           |
| Lung infiltration                                  | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 1                                                  | <0.1                                               | Rare                                               |
| Gastrointestinal disorders                         | Gastrointestinal disorders                         | Gastrointestinal disorders                         | Gastrointestinal disorders                         | Gastrointestinal disorders                         | Gastrointestinal disorders                         | Gastrointestinal disorders                         | Gastrointestinal disorders                         |
| Diarrhoea                                          | 31                                                 | 8.9                                                | Common                                             | BL.6.9a                                            | 274                                                | 12.3                                               | Very common                                        |
| Nausea                                             | 29                                                 |                                                    | Common                                             | BL.6.9a                                            | 278                                                | 12.5                                               | Very common                                        |
| Colitis                                            | 3                                                  | 0.9                                                | Uncommon                                           | BL.6.9a                                            | 20                                                 | 0.9                                                | Uncommon                                           |
| Stomatitis                                         | 5                                                  | 1.4                                                | Common                                             | BL.6.9a                                            | 68                                                 | 3.1                                                | Common                                             |
| Vomi ting                                          | 9                                                  | 2.6                                                | Common                                             | BL.6.9a                                            | 122                                                | 5.5                                                | Common                                             |
| Ab dominal pain                                    | 8                                                  | 2.3                                                | Common                                             | BL.6.9a                                            | 81                                                 | 3.6                                                | Common                                             |
| Constipation                                       | 5                                                  | 1.4                                                | Common                                             | BL.6.9a                                            | 108                                                | 4.8                                                | Common                                             |
| Dry mouth                                          | 9                                                  | 2.6                                                | Common                                             | BL.6.9a                                            | 58                                                 | 2.6                                                | Common                                             |
| Pancreatiti s                                      | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 7                                                  | 0.3                                                | Uncommon                                           |
| Gastritis                                          | 1                                                  | 0.3                                                | Uncommon                                           | BL.6.9a                                            | 2                                                  | ≤0.1                                               | Rare                                               |
| Duodenal ulcer                                     | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 1                                                  | <0.1                                               | Rare                                               |
| Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              | Skin and suhcutaneoustissue disorders              |
| Rash                                               | 49                                                 | 14.1                                               | Very common                                        | BL.6.9a                                            | 380                                                | 17.1                                               | Very common                                        |
| Pruritus                                           | 48                                                 | 13.8                                               | Very common                                        | BL.6.9a                                            | 276                                                | 12.4                                               | Very common                                        |
| Vitiligo                                           | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 69                                                 | 3.1                                                | Common                                             |
| Dry skin                                           | 8                                                  | 2.3                                                | Common                                             | BL.6.9a                                            | 87                                                 | 3.9                                                | Common                                             |
| Eryth ema                                          | 2                                                  | 0.6                                                | Uncommon                                           | BL.6.9a                                            | 85                                                 | 1.7                                                | Common                                             |
| Alopecia                                           | 2                                                  | 0.6                                                | Uncommon                                           | BL.6.9a                                            | 25                                                 | 1.1                                                | Common                                             |
| Erythema multiforme                                | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 3                                                  | 0.1                                                | Uncommon                                           |
| Psoriasis                                          |                                                    | 0                                                  |                                                    | BL.6.9a                                            | 3                                                  | 0.1                                                | Uncommon                                           |
| Rosacea                                            | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 3                                                  | 0.1                                                | Uncommon                                           |
| Urticaria                                          | 1                                                  | 0.3                                                | Uncommon                                           | BL.6.9a                                            | 6                                                  | 0.4                                                | Uncommon                                           |
| Toxic epidermal necrolysis                         | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 2                                                  | <0.1                                               | Rare                                               |
| Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     | Musculoskeletal and connectivetissue disorders     |
| Musculoskeletal pain                               | 22                                                 | 6.3                                                | Common                                             | BL.6.9a                                            | 161                                                | 7.2                                                | Common                                             |
| Arthral gia                                        | 16                                                 | 4.6                                                | Common                                             | BL.6.9a                                            | 128                                                | 5.7                                                | Common                                             |
| Polymyalgia rheumatica                             |                                                    | 0                                                  |                                                    | BL.6.9a                                            | 3                                                  | 0.1                                                | Uncommon                                           |
| Arthritis                                          | 1                                                  | 0.3                                                | Uncommon                                           | BL.6.9a                                            | 21                                                 | 0.9                                                | Uncommon                                           |
| Myopathy                                           | 0                                                  | 0                                                  |                                                    | BL.6.9a                                            | 1                                                  | <0.1                                               | Rare                                               |

<div style=\"page-break-after: always\"></div>

| Renaland urinary disorders                          | Renaland urinary disorders                          | Renaland urinary disorders                          | Renaland urinary disorders                          | Renaland urinary disorders                          | Renaland urinary disorders                          | Renaland urinary disorders                          | Renaland urinary disorders                          |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Tubulointerstitial nephritis                        | 0                                                   | 0                                                   |                                                     | BL.6.9a                                             | 4                                                   | 0.2                                                 | Uncommon                                            |
| Renal failure(including acute kidney injury)        | 3                                                   | 0.9                                                 | Uncommon                                            | BL.6.9a                                             | 15                                                  | 0.7                                                 | Uncommon                                            |
| General disordersand administration site conditions | General disordersand administration site conditions | General disordersand administration site conditions | General disordersand administration site conditions | General disordersand administration site conditions | General disordersand administration site conditions | General disordersand administration site conditions | General disordersand administration site conditions |
| Fatigue                                             | 86                                                  | 24.7                                                | Very common                                         | BL.6.9a                                             | 9                                                   | 30.3                                                | Very common                                         |
| Pyrexi a                                            | 17                                                  | 4.9                                                 | Common                                              | BL.6.9a                                             | 128                                                 | 5.7                                                 | Common                                              |
| Oedema (including peripheral oedema)                | 5                                                   | 1.4                                                 | Common                                              | BL.6.9a                                             | 67                                                  | 3.0                                                 | Common                                              |
| Pain                                                | 3                                                   | 0.9                                                 | Uncommon                                            | BL.6.9a                                             | 18                                                  | 80                                                  | Uncommon                                            |
| Chest pain                                          | 2                                                   | 0.6                                                 | Uncommon                                            | BL.6.9a                                             | 18                                                  | 0.8                                                 | Uncommon                                            |
| Increased AST                                       | 78/330                                              | 23.6                                                | Very common                                         | BL.7.11-SI                                          | 570/2151                                            | 26.5                                                | Very common                                         |
| Increased ALT                                       | 57/329                                              | 17.3                                                | Very common                                         | BL.7.11-SI                                          | 456/2160                                            | 21.1                                                | Very common                                         |
| Increased alkaline phosphatase                      | 107/330                                             | 32.4                                                | Very common                                         | BL.7.11-SI                                          | 520/2148                                            | 24.2                                                | Very common                                         |
| Increased lipase                                    | 68/325                                              | 20.9                                                | Very common                                         | BL.7.27-SI                                          | 169/871                                             | 19.4                                                | Very common                                         |
| Increased armylase                                  | 54/296                                              | 18.2                                                | Very common                                         | BL.7.27-SI                                          | 100/752                                             | 13.3                                                | Very common                                         |
| Increased creatinine                                | 125/329                                             | 38.0                                                | Very common                                         | BL.7.11-SI                                          | 430/2167                                            | 19.8                                                | Very common                                         |
| Lymphocyte absolute (lymphop aenia)                 | 141/330                                             | 42.7                                                | Very common                                         | BL.7.11-SI                                          | 881/2155                                            | 40.9                                                | Very common                                         |
| Leukocyte absolute (leucopenia)                     | 42/331                                              | 12.7                                                | Very common                                         | BL.7.11-SI                                          | 316/2175                                            | 14.5                                                | Very common                                         |
| Platelet count (thrombocytopeni a)                  | 54/331                                              | 16.3                                                | Very common                                         | BL.7.11-SI                                          | 274/2169                                            | 12.6                                                | Very common                                         |
| Haemoglobin (B) (anemia)                            | 135/333                                             | 40.5                                                | Very common                                         | BL.7.11-SI                                          | 772/2169                                            | 35.6                                                | Very common                                         |
| Hypercalcaemia                                      | 19/326                                              | 5.8                                                 | Common                                              | BL.7.11-SI                                          | 227/2076                                            | 10.9                                                | Very common                                         |
| Hyperkalaemia                                       | 62/328                                              | 18.9                                                | Very common                                         | BL.7.11-SI                                          | 396/2112                                            | 18.8                                                | Very common                                         |
| Hypokalaemia                                        | 26/328                                              | 7.9                                                 | Common                                              | BL.7.11-SI                                          | 223/2112                                            | 10.6                                                | Very common                                         |
| Hypomagnesaemia                                     | 59/324                                              | 18.2                                                | Very common                                         | BL.7.11-SI                                          | 271/1878                                            | 14.4                                                | Very common                                         |
| Hyponatraemia                                       | 129/329                                             | 39.2                                                | Very common                                         | BL.7.11-SI                                          | 575/2113                                            | 27.2                                                | Very common                                         |
| Increased totalbilirubin                            | 29/329                                              | 8.8                                                 | Common                                              | BL.7.11-SI                                          | 177/2157                                            | 8.2                                                 | Common                                              |
| Ab solute neutrophil count(neutropenia)             | 38/330                                              | 11.5                                                | Very common                                         | BL.7.11-SI                                          | 241/2158                                            | 11.2                                                | Very common                                         |
| Hypermagnesaemi a                                   | 15/324                                              | 4.6                                                 | Common                                              | BL.7.11-SI                                          | 82/1878                                             | 4.4                                                 | Common                                              |
| Hypernatraemia                                      | 10/329                                              | 3.0                                                 | Common                                              | BL.7.11-SI                                          | 107/2113                                            | 5.1                                                 | Common                                              |
| Hypocalcaemia                                       | 80/326                                              | 24.5                                                | Very common                                         | BL.7.11-SI                                          | 358/2076                                            | 17.2                                                | Very common                                         |
| Wei ght decreased                                   | 5                                                   | 1.4                                                 | Common                                              | BL.6.9a                                             | 49                                                  | 2.2                                                 | Common                                              |

a Monotherapy Pooled group consists of nivolumab monotherapy treatment group from studies CA209063, CA209017, CA209057, CA209037, CA209066, CA209067, CA209025, CA209039 (cHL subjects), CA209205, and CA209141. Source: Refer to Table 2.9.1.4-1 of SCCHN SCS

b MedDRA Version: 19.0 (Integrated UC Population), 18.1 (Pooled Nivolumab Monotherapy Population), CTC Version 4.0

c Includes events reported between first dose and 30 days after last dose of study therapy

d Unless otherwise noted, some preferred terms are re-mapped or deleted based on BMS medical review.

e This event frequency comes from an unmapped output.

f This event frequency is based on all causality output.

g Includes events autoimmune neuropathy, VIth nerve paralysis, and VIIth nerve paralysis

h Includes events acute kidney injury and renal failure

i BMS used the laboratory abnormality change from baseline. This presentation is a conservative approach intended to capture the frequency of all laboratory abnormalities regardless of causality. In doing so, the denominator used to compute frequency is the number of patients for whom laboratory abnormalities data were reported, as opposed to ALL treated patients. Hence, there is variability in the denominator for each individual laboratory abnormality and their respective reported frequencies.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Laboratory measurements were recorded regardless of causality and some were correlated with reported laboratory-based AEs. Laboratory results reported after first dose and within 30 days of last dose of study therapy are presented in the sections below.

## Haematology

In the Integrated UC Population, abnormalities in haematology tests were primarily Grade 1-2.The majority of subjects did not have on-study worsening in haematology parameters (Table 59). The only hematologic abnormalities that worsened to Grade 3-4 relative to baseline in ≥ 5% of subjects were decreased absolute lymphocytes (9.7%) and decreased haemoglobin (8.1%).

Table 59 Summary of On-Treatment Worst CTC Grade Haematology Tests that Worsened Relative to Baseline - SI Units - All Treated Subjects in CA209275 and Integrated UC Population

|                         | CA209275   | CA209275   | CA209275   | Number of Subjects (B) CA209032+CA209275   | Number of Subjects (B) CA209032+CA209275   | Number of Subjects (B) CA209032+CA209275   |
|-------------------------|------------|------------|------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| LabTestDescription      | N(A)       | Grade1-4   | Grade3-4   | (N                                         | Grade1-4                                   | Grade3-4                                   |
| HEMOGTBIN(B)            | 256        | 101(39.5)  | 18 7.0)    | 333                                        | 135(40.5)                                  | 27(8.1)                                    |
| PLATPTETCOUNT           | 254        | 39(15.4)   | 6（ 2.4)    | 331                                        | 54(16.3)                                   | 7（2.1)                                     |
| LEUROCYTES              | 255        | 27(10.6)   | 0          | 331                                        | 42(12.7)                                   | 0                                          |
| LYMPHOCYTES(ABSCLUTE)   | 254        | 106(41.7)  | 23 9.1)    | 330                                        | 141(42.7)                                  | 32（ 9.7)                                   |
| ABSOLUTENEUTROPHILCOUNT | 254        | 25（ 9.8)   | 1 【 0.4)   | 330                                        | 38(11.5)                                   | 3(0.9)                                     |

ToocicityScale:CTcVersion4.0

study therapy.

Includeslaboratory results reportedafter the first dose amd within 30 days oflast dose of

(A）N:Subjects with a CTC Graded Iahoratory Result forthe given paraneter fron both Baseline and On-treatment.

Percentages are basedon Nas denanirator.

CA209032consists ofthe nivolumab momotherapyurothelialcarcinoma（i.e.bladder)cohortof CA209032.CA209032crossover subjectsare truncated atthe firstdose date of cssoverperiod.

## Serum Chemistry

## Liver Function Tests

In the Integrated UC Population, abnormalities in hepatic parameters (all increases) were primarily Grade 1-2.  The  majority  of  subjects  did  not  have  on-study  worsening  in  l  hepatic  parameter  (Table  60).  No hepatic parameters worsened to Grade 3-4 relative to baseline in ≥5%.

Table  60  Summary  of  On-Treatment  Worst  CTC  Grade  Liver  Function  Test  Results  that Worsened Relative to Baseline - SI Units - All Treated Subjects in CA209275 and Integrated UC Population

|                           | Number of Subjects (6)   | Number of Subjects (6)   | Number of Subjects (6)   | Number of Subjects (6)   | Number of Subjects (6)   | Number of Subjects (6)   |
|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                           | CA209275                 | CA209275                 | CA209275                 | CA209032 + CA209275      | CA209032 + CA209275      | CA209032 + CA209275      |
| Lab Test Description      | N (A)                    | Grade 1-4                | Grade 3-4                | N (A)                    | Grade 1-4                | Grade 3-4                |
| ALKALTNE THOSIHATASE      | 255                      | 85 ( 33.3)               | 14 5.51                  | 330                      | 107 ( 32.4)              | 16 ( 4.81                |
| ASIARTATEAMTNOTRANSFERASE | 255                      | 62 ( 24.3)               | 9 3.51                   | 330                      | 78 ( 23.6)               | 10 3.01                  |
| ALANINEAMTNOTRANSFERASE   | 254                      | 45 (17.7)                | 3 1.2)                   | 329                      | 57( 17.3)                | 51 1.5)                  |
| BILIRUBIN, TOIAL          | 254                      | 24 ( 9.4)                | 9 3.51                   | 329                      | 29 1 8.8)                | 91 2.7)                  |

Toxicity Scale: CTC Version 4.0

Includes laboratory results reported after the first dose amd within 30 days of last dose of study therapy.

and On-treatment.

Permentages are based on N as denqmirator.

CA209032 oonsists of the nivoluuab monotherapy urothelial carcimoma (i.e. bladder) oohort of CA209032. CA209032 crossover subjects are tnincated at the first dose date of crossover period.

<div style=\"page-break-after: always\"></div>

In the Integrated UC Population, 9 subjects in the nivolumab group (all from CA209275) had concurrent ALT  or  AST  elevation  &gt;3  x  ULN  with  total  bilirubin  &gt;  2  x  ULN  within  1  day,  and  10  subjects  in  the nivolumab group had concurrent ALT or AST elevation &gt; 3 x ULN with total bilirubin &gt; 2 x ULN within 30 days of last dose of study therapy (Table 61).

There  were  9  subjects  who  met  the  protocol-specified  criteria  for  drug-induced  liver  injury  (DILI; concurrent [within 1 day] ALT or AST &gt; 3 x ULN and total bilirubin &gt; 2 x ULN within 100 days of the last dose of nivolumab).

Table 61: Summary of On-Treatment Laboratory Abnormalities in Specific Liver Tests - (SI Units) - All Treated Subjects in CA209275 and Integrated UC Population

|                                                                               | CA209275 N = 270   | CA209032+CA209275 N=348   |
|-------------------------------------------------------------------------------|--------------------|---------------------------|
|                                                                               | N = 255 20（ 7.8)   | N = 330 24 7.3) 13 3.9)   |
| ALT OR AST > 3XUIN ALT OR AST>5XULN                                           | 10 3.9)            |                           |
| ALT OR AST>10XUIN                                                             |                    |                           |
| ALT OR AST>20XUIN                                                             | 1.2) 1 ( 0.4)      | 3 0.9) 0.3)               |
| TOTALBILIRUBIN>2XUIN                                                          | N= 254 13 (5.1)    | N =329 13 (4.0)           |
| CONCURRENTAITORASTEIEVATION>3XUIN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY | N = 254            | N = 329                   |
| CONCURRENTAITORASTEIEVATION>3XUIN                                             | 9(3.5)             | 9(2.7)                    |
| WITHTOTALBILIRUBIN>2XULNWITHIN3ODAYS                                          | 10 (3.9)           | 10 (3.0)                  |

Denominatorcorrespondstosubjectswith atleast one ontreatmentmeasurementofthe corresponding laboratory parameter.

CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of CA209032.

Includes laboratory results reported after the first dbose and within 30 days of last dose of study therapy:

## Kidney Function Tests

In the Integrated UC Population, the majority of subjects with at least 1 on-treatment measurement had normal creatinine values during the treatment reporting period. The majority of subjects did not have onstudy worsening in creatinine. Creatinine worsened to Grade 3-4 relative to baseline in 1.8% of subjects.

## Thyroid Function Tests

In  the  Integrated  UC  Population,  the  majority  of  subjects  in  both  groups  had  normal  TSH  levels  at baseline and throughout the treatment period (Table 62).

<div style=\"page-break-after: always\"></div>

Table 62 Summary of On-Treatment Laboratory Abnormalities in Specific Thyroid Tests - (SI Units) - Treated Subjects with at Least One On- Treatment TSH Measurement in CA209275 and Integrated UC Population

|                                                                                                                               | CA209275 N = 251        | CA209032+CA209275 N = 326   |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------------|
| TSH >UIN TSH >UIN                                                                                                             | 72 (28.7)               | 95 (29.1)                   |
| WITH TSH <= UIN AT BASELINE TSH >UIN                                                                                          | 51 (20.3)               | 68 (20.9)                   |
| WITHAT IEAST ONEFT3/FT4TEST VALUE <LIN (A) WITH ALL OTHER FT3/FT4 TEST VAIUES >= LIN (A) WITH FT3/FT4 TEST MISSING (A) (B)    | 31 (12.4) 19 7.6) (8.8) | 40 (12.3) 32 9.8) 23 (7.1)  |
| TSH < LIN                                                                                                                     | 60 (23.9)               | 75 (23.0)                   |
| TSH < LIN NITISNHNII=<HSLHLIM                                                                                                 |                         |                             |
| TSH < LIN                                                                                                                     | 51 (20.3)               | 64 (19.6)                   |
| WITH AT IEAST ONE FT3/FT4 TEST VALUE >UIN (A) WITH ALL OIHER FT3/FT4 TEST VAIUES <= ULN (A) WITH FT3/FT4 TEST MISSING (A) (B) | 21 8.4) 16 6.4) 23 9.2) | 25 ( 7.7) 25 7.7) 25 7.7)   |

Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy.

(B）Includes subjects with TSH abnormality and with noFT3/FT4test values inthe 2-week window with non-abnormal value(s)from only one of the two tests and no value fram the other test. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of CA209032.CA209032 crossover subjects are truncated at the first dose date of crossover period.

(A)Within a 2-week window after the abnormal TSH test date.

## Electrolytes

In the Integrated UC Population, most subjects had normal electrolyte levels at baseline and during the treatment reporting period. Abnormalities in electrolytes during treatment were primarily Grade 1 to 2 in severity. The majority of subjects did not have on-study worsening in electrolyte parameters (Table 63). The only electrolyte abnormality that worsened to Grade 3-4 relative to baseline in ≥5% of subjects was hyponatremia (10.0%); these subjects were mostly from the CA209275 population.

Table 63 Summary of On-Treatment Worst CTC Grade Electrolyte Levels that Worsened Relative to Baseline - SI Units - All Treated Subjects in CA209275 and Integrated UC Population

|                    | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   | Number of Subjects(%)   |
|--------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                    | CA209275                | CA209275                | CA209275                | CA209275                | CA209032+CA209275       | CA209032+CA209275       | CA209032+CA209275       | CA209032+CA209275       | CA209032+CA209275       | CA209032+CA209275       |                         |                         |
| LabTestDescriptian | N (A)                   | Grade 1-4               | Grade 3-4               |                         | N (A)                   | Grade 1-4               | Grade 3-4               |                         |                         |                         |                         |                         |
| SODIUM             |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |
| HYPERNATREMIA      | 254                     | 2.0)                    | 0                       |                         | 329                     | 10（ 3.0)                | 0                       |                         |                         |                         |                         |                         |
| HYPONATREMIA       | 254                     | 105 ( 41.3)             |                         | 28 (11.0)               | 329                     | 129 ( 39.2)             |                         | 33 (10.0)               |                         |                         |                         |                         |
| POTASSIUM          |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |
| HYPERKAIFMIA       |                         | 49 (19.4)               | 31 3                    | 1.2)                    | 328                     | 62 (18.9)               |                         | 0.9)                    |                         |                         |                         |                         |
| HYPOKALEMIA        | 23                      | 21 (8.3)                |                         | 1.6)                    | 328                     | 26 (7.9)                | 4                       | 1.2)                    |                         |                         |                         |                         |
| CAICIUM            |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |
| HYPERCAICEMIA      | 252                     | 18 (7.1)                | 12                      | 0.4)                    | 326                     | 19 (5.8)                | 12                      | 0.3)                    |                         |                         |                         |                         |
| HYPOCALCEMIA       | 252                     | 65 ( 25.8)              |                         | 0.8)                    | 326                     | 80 ( 24.5)              |                         | 0.6)                    |                         |                         |                         |                         |
| MAGNESIUM          |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |                         |
| HYPERMAGNESEMIA    | 250                     |                         | 1                       | 0.4)                    | 324                     | 15 4.6)                 |                         | 0.3)                    |                         |                         |                         |                         |
| HYPOMAGNESEMIA     | 250                     | 8  15:2                 | 0                       |                         | 324                     | 59 (18.2)               |                         | 0.3)                    |                         |                         |                         |                         |

Toxicity Scale: CTC Version 4.0

( and On-treatment.

Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy.

Percentages are based on N as denominator.

CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of CA209032. CA209032 crossover subjects are truncated at the first dose date of crossover period.

## Glucose Tests

In  the  Integrated  UC  Population,  abnormalities  in  fasting  glucose  values  (hyperglycemia)  during treatment  were  primarily  Grade  1  to  2  in  severity.  The  majority  of  subjects  did  not  have  on-study

<div style=\"page-break-after: always\"></div>

worsening  in  fasting  glucose.  Fasting  glucose  worsened  to  Grade  3-4  relative  to  baseline  in3.5%  of subjects.

## Pancreas Function Tests

In the Integrated UC Population, the majority of subjects did not have on-study worsening in amylase or lipase (Table 64). Amylase and lipase worsened to Grade 3-4 relative to baseline in 5.7% and 7.1% of subjects, respectively. There were no discontinuations of study therapy due to reported elevated lipase and/or amylase AEs. Grade 4 amylase or lipase abnormalities not associated with symptoms or clinical manifestation of pancreatitis.

Table 64 Summary of On-Treatment Worst CTC Grade Amylase and Lipase that Worsened Relative to Baseline - All Treated Subjects in CA209275 and Integrated UC Population

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                           | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    | Number of Subjects (%)                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                           | CA209275                                                                                                                                                                                                                                                                                                                                                                                  | CA209275                                                                                                                                                                                                                                                                                                                                                                                  | CA209275                                                                                                                                                                                                                                                                                                                                                                                  | CA209032+CA209275                                                                                                                                                                                                                                                                                                                                                                         | CA209032+CA209275                                                                                                                                                                                                                                                                                                                                                                         | CA209032+CA209275                                                                                                                                                                                                                                                                                                                                                                         | CA209032+CA209275                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                           |
| LabTest Descriptian                                                                                                                                                                                                                                                                                                                                                                       | N (A)                                                                                                                                                                                                                                                                                                                                                                                     | Grade 1-4 Grade 3-4                                                                                                                                                                                                                                                                                                                                                                       | Grade 1-4 Grade 3-4                                                                                                                                                                                                                                                                                                                                                                       | N (A)                                                                                                                                                                                                                                                                                                                                                                                     | Grade 1-4                                                                                                                                                                                                                                                                                                                                                                                 | Grade 3-4                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                           |
| AMYLASE,TOTAL                                                                                                                                                                                                                                                                                                                                                                             | 227                                                                                                                                                                                                                                                                                                                                                                                       | 40 (17.6) 10                                                                                                                                                                                                                                                                                                                                                                              | 4.4)                                                                                                                                                                                                                                                                                                                                                                                      | 296                                                                                                                                                                                                                                                                                                                                                                                       | 54 (18.2)                                                                                                                                                                                                                                                                                                                                                                                 | 17 ( 5.7)                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                           |
| LIPASE,TOTAL                                                                                                                                                                                                                                                                                                                                                                              | 250                                                                                                                                                                                                                                                                                                                                                                                       | 51 (20.4)                                                                                                                                                                                                                                                                                                                                                                                 | 17 (6.8)                                                                                                                                                                                                                                                                                                                                                                                  | 325                                                                                                                                                                                                                                                                                                                                                                                       | 68 (20.9)                                                                                                                                                                                                                                                                                                                                                                                 | 23 (7.1)                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                           |
| Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of | Toxicity Scale:CTC Version 4.0 Includes laboratory results reportedafter the first dose and within30days of last dose of study therapy. (A) N: Subjects with a CIC Graded Laboratory Result for the given parameter from both Baseline andOn-treatment. PercentagesarebasedonNasdenominator. CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of |

## Safety in special populations

## Intrinsic and Extrinsic Factors

In the Integrated UC Population, the frequencies of all-causality and drug-related AEs among all treated subjects for subgroups of gender, race, age, and region were consistent with the AE frequencies in the overall  treated  population.  Small  numerical  differences  in  frequencies  of  AEs  were  observed  in  the following subgroups:

- -Any-grade and Grade 3-4 drug-related AEs for male (67.5% and 17.0%) vs. female (72.3% and 25.3%). There were 265 male and 83 female treated subjects.
- -Slightly  higher  frequencies  of  any-grade  and  Grade  3-4  drug-related  AEs  were  reported  in subjects in Japan (73.9% and 17.4%) and US (72.1% and 21.8%) versus Rest of World (64.4% and 16.3%). There were 23, 165, and 160 treated subjects in Japan, US, and Rest of World.

Frequencies  of  AEs  leading  to  dropout,  accident  and  injuries,  cardiac  and  vascular  disorders  increased slightly across the age groups (&lt;65; 65-74; 75-84; &gt;=85 years), but were otherwise consistent for all age groups.

<div style=\"page-break-after: always\"></div>

## Table 65 summary of On-treatment Adverse Events by Age Group All Treated Subjects Pooled UC CA209275 + CA209032

|                                                                               | Age Group (Years)   | Age Group (Years)   | Age Group (Years)   | Age Group (Years)   | Age Group (Years)   |
|-------------------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| MedDRA Terms (%)                                                              | <65 N = 159         | 65-74 N = 141       | 75-84 N = 44        | >= 85 N= 4          | Total N = 348       |
| TOTALSUBJECTS WITHANEVENT                                                     | 158 ( 99.4)         | 140 ( 99.3)         | 43 (97.7)           | 4 (100.0)           | 345 ( 99.1)         |
| SERIOUSAE-TOTAL                                                               | 85 53.5)            | 74 52.5)            | 22 50.0)            | 2 ( 50.0)           | 183 52.6)           |
| FATAL                                                                         | 34 21.4)            | 29 20.6)            | 6 13.6)             | 0                   | 69 19.8)            |
| HOSPITALIZATION/PROLONGATION                                                  | 74 46.5)            | 67 47.5)            | 21 47.7)            | 2 (50.0)            | 164 47.1)           |
| LIFE-THREATENING                                                              | 4 2.5)              | 4 2.8)              |                     | 0                   | 8 2.3)              |
| CANCER                                                                        | 7 4.4)              | 4 2.8)              | 0:0                 | 1 (25.0)            | 12 3.4)             |
| DISABILITY/INCAPACITY                                                         | 0                   | 0                   | 0                   | 0                   | 0                   |
| IMPORTANT MEDICAL EVENT                                                       | 6 3.8)              | 3 2.1)              | 0                   | 0                   | 6 2.6)              |
| AELEADINGTODISCONTINUATION                                                    | 25 (15.7)           | 27 ( 19.1)          | 10 (22.7)           | 0                   | 62 (17.8)           |
| PSYCHIATRICDISORDERS                                                          | 28 ( 17.6)          | 23 (16.3)           | 7 (15.9)            | 1 ( 25.0)           | 59 ( 17.0)          |
| NERVOUS SYSTEM DISORDERS                                                      | 49 ( 30.8)          | 37 (26.2)           | 13 ( 29.5)          | 0                   | 99 (28.4)           |
| ACCIDENTANDINJURIES                                                           | 10 (6.3)            | 10（ 7.1)            | 4 (9.1)             | 0                   | 24 (6.9)            |
| CARDIAC DISORDERS                                                             | 6.3)                | 10 7.1)             | 5 (11.4)            | 0                   | 25 (7.2)            |
| VASCULARDISORDERS                                                             | 23 (14.5)           | 24 (17.0)           | 8 (18.2)            | 1 (25.0)            | 56 (16.1)           |
| CEREBROVASCULARDISORDERS                                                      | 3 (1.9)             | 0                   | 2 (4.5)             | 0                   | 5 (1.4)             |
| INFECTIONSANDINFESTATIONS                                                     | 60 ( 37.7)          | 56 ( 39.7)          | 17 ( 38.6)          | 0                   | 133 ( 38.2)         |
| ANTICHOLINERGICSYNDROME                                                       | 46 ( 28.9)          | 43 ( 30.5)          | 8 (18.2)            | 2 (50.0)            | 99 (28.4)           |
| QUALITY OF LIFE DECREASED                                                     | 1 (0.6)             | 0                   | 0                   | 0                   | 1 (0.3)             |
| SUMOFFOSTURALHYFOTENSION, FALLS，BLACKOUTS,SYNCOPE，DIZZINESS， ATAXIA,FRACTURES | 16 (10.1)           | 10 (7.1)            | 5 (11.4)            | 0                   | 31 (8.9)            |

CTCVersion 4.0;MecDRAVersion:19.0

Includes events reported between first dose and 30 cays after last dlose of stucly therapy. Program Source: /projects/kms217252/stats/blaclder\\_EU\\_SCs/prog/tables/rt-ae-eusumage.sas

## By Baseline PD-L1 Expression

In CA209275 and CA209032, no consistent differences were observed in the frequencies of AEs by PD-L1 expression subgroup.

## Withdrawal and Rebound

No cases of withdrawal symptoms related to nivolumab were reported during human clinical trials.

## Safety related to drug-drug interactions and other interactions

No new information.

## Discontinuation due to adverse events

In  the  Integrated  UC  Population  most  subjects  received  all  doses  of  nivolumab  without  an  infusion interruption,  infusion  rate  reduction,  or  dose  delay.  Reasons  for  infusion  interruption,  infusion  rate reduction, or dose delay are provided in Table 66. Infusion interruptions were reported for 14 (4.0%) of subjects, 6 (18.2%) of infusion interruptions were due to a hypersensitivity reaction. There were no dose interruptions in CA209032. Dose delays were reported in 135 (38.8%) of subjects. Dose delays due to AEs were reported for 66.4% (140/211) of all doses received.

16NOV2016:01:53:18

<div style=\"page-break-after: always\"></div>

Table 66 Infusion Interruption, Infusion Rate Reduction, and Dose Delays of Study Therapy All Treated Subjects

|                                                                                                             | CA209032 N=78       | CA209275 N=270                         | C209032+CA209275 8=N               |
|-------------------------------------------------------------------------------------------------------------|---------------------|----------------------------------------|------------------------------------|
| SUBJECTS WIIH NT LEAST ONEINEUSION INIERRUPIED (S)                                                          | 0                   | 14(5.2)                                | 14（4.0)                            |
| NUMBEROFINFUESIONSINTERRUPTED PER SUBJECT () 1 2                                                            | 78 0000 (100.0)     | 256 10 （94.8) 3-71 1 0-4) 1 0.4) 2 0.7 | 334 10 96.0) 2.9) 1 0.3) 0.3) 0.6) |
| TOTAL NMBER INFUSIONS INIERRUPTED/ TOTAL NUMBER INFUSIONS RSCEIVED                                          | 0/1060              | 33/2505(1.3)                           | 33/3565(0.9)                       |
| REASCN FOR INFUSION INIERRUPTION (A) HYPERSENSITIVITY RENCTION INEUSION AEMIN ISSUES OTHER                  | 000                 | 22 6 (18.2) 66.7 5 15.2)               | 18.2) 66.7) 15.2)                  |
| SUBJECISWTIHATLEASTCNE INEUSION WITH IVRAIE REDUOED(S) NUMBERCEINFUSIONS WITHIVFNTE REDUCTION PERSUBJECT () | 1（ 1.3)             | 1.1)                                   | 4(1.1)                             |
| 0 1 2 3 TOTAL NMBERIV RNTEREDUCED/TOTALNUMEERDOSE RECEIVED                                                  | 77 98.7) 100 1.3) 0 | 267 98.9) mooc 1.1) 0                  | 344 98.9) 4000 1.1) 0              |
| REASON FOR IV RATE REDUCTION (B) HYPERSENSITIVITY REACTICN INFUSION AIMIN ISSUES                            | 1/1060（<0.1)        | 3/2505（ 0.1) 0                         | 4/3565(0.1)                        |
| CIHER                                                                                                       | 001 (100.0)         |                                        |                                    |

|                                                                                                           | CA209032 N-78                        | CA209275 N70                           | CA209032CA209275 N=348                 |
|-----------------------------------------------------------------------------------------------------------|--------------------------------------|----------------------------------------|----------------------------------------|
| SUBJECTS WTTH AT LEAST ONE CYCIE DELAYED ()                                                               | 28(35.9)                             | 107(39.6)                              | 135(38.8)                              |
| NUMBER OECYCLES DELAYED PER SUBJECT 0 1 2 3                                                               | 50 64.1) 16 20.5) 7 9.0) 3 3.8) 2.6) | 163 60.4) 71 26.3) 25 9.3) 6 2.2) 1.9) | 213 61.2) 87 25.0) 32 9.2) 9 2.6) 2.0) |
| TODALNLMBERCYCLES DELAYED/ TOTAL NUMBERCYCLES REOETVED (C) REASON FOR CYCIE DELAY (D) ADVERSE EVENT OTHER | 52/982(5.3)                          | 159/2235(7.1)                          | 211/3217(6.6)                          |
| NOT REPCRIED                                                                                              | 34（65.4） 17 32.7) 1.91               | 106 （66.7） 44 9                        | 140（66.4） 61 28.9) 10 4.7)             |
| LENGIH OFDELAY(D) 4-7DAYS 8-14DAYS 15-42DAYS >42DAYS                                                      | 22 20 (38.5) 42.3) 10 19.2) 0        | 59 55 34.6) 37.1 40 5                  | 81 75 35.5) 38.4) 50 23.7) 5 2.4)      |

<!-- image -->

In the Integrated UC Population, AEs leading to discontinuation were reported in 17.8% of subjects (Table 67).  Grade  3-4  AEs  leading  to  discontinuation  were  reported  in  13.2%  subjects.  The  most  frequently reported AEs leading to discontinuation were malignant neoplasm progression (3.2%), general physical health deterioration and pneumonitis (1.4% each), and respiratory failure and small intestinal obstruction (0.9% each).

In CA209032, the frequencies of AEs leading to discontinuation were lower (7.7%) than the Integrated UC Population (17.8%), however, this difference may be of limited interpretability due to low sample size. In CA209275, the frequencie of AEs leading to discontinuation was 20.7%.

Grade 3-4 AEs leading to discontinuation were reported in 5.1% and 15.6% subjects in CA209032 and CA209275 respectively.

In the Integrated UC Population, drug-related AEs leading to discontinuation were reported in 4.3% of subjects (

Table 68 ).  Grade  3-4  drug-related  AEs  leading  to  discontinuation  were  reported  in  2.9%  of  subjects. Drug-related AEs leading to discontinuation reported in at least 2 subjects were pneumonitis (1.4%) and pemphigoid (0.6%).

<div style=\"page-break-after: always\"></div>

Table 67 AEs Leading to Discontinuation (All Causality) by Worst CTC Grade Reported in at Least 2 Treated Subjects - CA209275 and Integrated UC Population

|                                                                     | CA209275 N = 270     | CA209275 N = 270   | CA209275 N = 270   | CA209032+CA209275 N =348   | CA209032+CA209275 N =348   | CA209032+CA209275 N =348   |
|---------------------------------------------------------------------|----------------------|--------------------|--------------------|----------------------------|----------------------------|----------------------------|
| Systen Organ Class (%) Preferred Term (%)                           | Any Grace            | Grade 3-4          | Grade 5            | Any Grade                  | Grade 3-4                  | Grade 5                    |
| TOIAL SUBJECTS WITH AN EVENT                                        | 56 ( 20.7)           | 42 ( 15.6)         | 9(3.3)             | 62 ( 17.8)                 | 46 (13.2)                  | 10 (2.9)                   |
| NEOPLASMS BENIGN,MALIGNANT AND UNSPECIFIED(INCL CYSTS AND POLYPS)   | 14 (5.2)             | 11 (4.1)           | 3 (1.1)            | 15 (4.3)                   | 11 (3.2)                   | 4（ 1.1)                    |
| MALIGNANTNEOPIASM PROGRESSION                                       | 10( 3.7)             | 7( 2.6)            | 3 ( 1.1)           | 11 ( 3.2)                  | 7( 2.0)                    | 4( 1.1)                    |
| METASTASES TO CENIRAL NERVOUS SYSTEM                                | 2( 0.7)              | 2( 0.7)            | 0                  | 2 (0.6)                    | 2( 0.6)                    | 0                          |
| RESPIRATORY,THORACIC AND MEDIASTINALDISORDERS                       | 10( 3.7)             | 2.6)               | 0.4)               | 11 (3.2)                   | 8（ 2.3)                    | 1 0.3)                     |
| RESPIRATORY FATLURE INEUMONITIS                                     | 4 3 1.1) 1.5)        | 1.1) 0.4)          | 0 1 0.4)           | 0.9) 1.4)                  | 2 0.6) 0.9)                | 1 0 0.3)                   |
| GASTROINTESTINALDISORDERS SMALLINTESTINALCBSTRUCTION                |                      | 210:8              | 0 0                | 61 1.7) 3( 0.9)            | 5 1.4) 2 0.6)              | 0 0                        |
| GENERALDISORDERSAND                                                 | 6 (2.2)              | 4 (1.5)            | 0.4)               | 6 (1.7)                    | 4( 1.1)                    | 1 ( 0.3)                   |
| ADMINISTRATION STTECONDITIONS GENERAL PHYSICAL HEAITH DETERIORATION | 5 (1.9)              | 3 ( 1.1)           | 0.4)               | 5 (1.4)                    | 3 0.9)                     | 1 0.3)                     |
| INFECTIONSANDINFESTATIONS SEPSIS SEPTIC SHOCK                       | 4 1.5) 2 0.7) 1 0.4) | 0.7) 1 0.4)        | 0 0 0              | 5 1.4) 2 0.6) 1( 0.3)      | 1.4) 0.6) 1 ( 0.3)         | 0 0 0                      |
| SKINANDSUBOUTANEOUS TISSUE DISORDERS                                | 1.5)                 | 3 ( 1.1)           | 0                  | 4 (1.1)                    | 3( 0.9)                    | 0                          |
| IEMPHIGOID                                                          | 2( 0.7)              | 2( 0.7)            | 0                  | 2( 0.6)                    | 2( 0.6)                    | 0                          |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                | 0.4)                 | 1 ( 0.4)           | 0                  | 3 (0.9)                    | 3 （ 0.9)                   | 0                          |
| THROMBOCYTOIENIA                                                    | 1 ( 0.4)             | 1 ( 0.4)           | 0                  | 2（ 0.6)                    | 2( 0.6)                    | 0                          |
| HEIATOBTLIARYDISORIERS HEPATICFATLURE                               | 2 （ 0.7) 2 0.7)      | 2 ( 0.7) 2 0.7)    | 0 0                | 2( 0.6) 2( 0.6)            | 2 0.6) 2 0.6)              | 0 0                        |

MedDRA Version:19.0,CTC Version 4.0

CA209032 crossover subjects are truncated at the first dose date of crossover period.

aderayi Apras go asop pset xatge saep oe pue asop isrty ueampeg peprodat suaee sapntoun CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of CA209032.

Table 68 Drug-related AEs Leading to Discontinuation by Worst CTC Grade Reported in All Treated Subjects - CA209275 and Integrated UC Population

| System Organ Class ($) Preferred Term (%)         | CA209275 N = 270   | CA209275 N = 270   | CA209275 N = 270   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   | CA209032 + CA209275 N=348   |
|---------------------------------------------------|--------------------|--------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class ($) Preferred Term (%)         | Any Grade          | Grade 3-4          | Grade 5            | Any Grade                   | Grade 3-4                   | Grade 5                     |
| TOIALSUBJECTSWITHANEVENT                          | 13 (4.8)           | 8 (3.0)            | 2 (0.7)            | 15 ( 4.3)                   | 10 (2.9)                    | 2（ 0.6)                     |
| RESPIRATORY,THORACIC AND MEDIASTINALDISORDERS     | 6( 2.2)            | 3 ( 1.1)           | 0.4)               | 7( 2.0)                     | 4 ( 1.1)                    | 1 ( 0.3)                    |
| INEUMONITIS DYSENOEA                              | 1.5) 0.4)          | 0.4) 0.4)          | 1（ 0.4) 0          | 5 1.4) 1 0.3)               | 2 0.6) 1 0.3)               | 1 （ 0.3) 0                  |
| INTERSTITIAL LING DISFASE                         | 1( 0.4)            | 1 0.4)             | 0                  | 1 0.3)                      | 1 0.3)                      | 0                           |
| SKINANDSUBOUTANEOUSTISSUE DISORDERS               | 4( 1.5)            | 3( 1.1)            | 0                  | 4 1.1)                      | 3 ( 0.9)                    | 0                           |
| IEMPHIGOTD                                        | 2 0.7) 1 0.4)      | 2 0.7) 0           | 0 0                | 2 0.6) 1 0.3)               | 2 ( 0.6) 0                  | 0 0                         |
| RASH MACULO-PAIULAR RASH PRURITIC                 | 0.4) 0.7)          | 1 0.4) 2 0.7)      | 0 0                | 0.3) 2 0.6) 1 0.3)          | 1 0.3) 2 0.6) 1 0.3)        | 0 0                         |
| GASTROINTESTINALDISORDERS ABDOMINALIAIN DIARRHOFA | 1 0.4) 1 0.4)      | 0.4) 0.4)          | 0 0                | 1 0.3)                      | 1 0.3)                      | 0 0                         |
| BLOODANDLYMPHATICSYSTEM DISORDERS                 | 0                  | 0                  | 0                  | 1 0.3)                      | 1( 0.3)                     | 0                           |
| THROMBOCYTOPENIA                                  |                    |                    |                    |                             |                             |                             |
|                                                   | 0                  | 0                  | 0                  | 1 0.3)                      | 1 (0.3)                     | 0                           |
|                                                   | 0.4)               | 0                  | 0.4)               | 0.3)                        | 0                           |                             |
| VASCULARDISORDERS CIRCULATORY COILAISE            | 0.4)               | 0                  | 0.4)               | 0.3)                        | 0                           |                             |

MedDRA Version: 19.0

Includes events reported between first cose and 30 days after last dose of study therapy.

CTC Version 4.0

CA209032 consists of the nivolumab monotherapy urothelial carcinoma (i.e. bladder) cohort of CA209032.

CA209032crossover subiects are truncated at the first dose date of crossover period.

## Immunogenicity

The incidence of immunogenicity and impact on safety in UC is similar to that observed for other tumor types.

CA209275: Of the 219 UC subjects who were evaluable for ADA, 52 (23.7 %) subjects had at least one ADA  positive  sample  relative  to  baseline  at  any  time  after  initiation  of  treatment.  No  subjects  were

<div style=\"page-break-after: always\"></div>

persistent  positive,  and  4  subjects  (1.8%)  were  neutralizing  ADA  positive.  Of  all  subjects  who  were evaluable  for  ADA,  no  subject  that  was  ADA  positive  experienced  hypersensitivity/infusion  reaction category events. Thus, immunogenicity did not appear to have an effect on the safety of nivolumab in the UC subjects.

CA209032: The incidence of nivolumab ADA positive was low (9 subjects [13.0%] had at least one ADA positive sample relative to baseline at any time after initiation of treatment). Only 1 ADA positive subject had Grade 1 hypersensitivity/infusion reaction on Day 1 after the first dose of nivolumab. Given that this subject  was  ADA  positive  on  Days  1  (baseline),  15,  29,  and  99  and  continued  to  receive  nivolumab treatment for 6 months with no other occurrences of hypersensitivity/infusion reaction, it is unlikely that the Day 1 occurrence was ADA related.

Integrated  analysis:  An  integrated  analysis  of  immunogenicity  assessments  was  performed  with  data available from the following studies: CA209037, CA209063, CA209066, CA209017, CA209057, CA209067 (nivolumab monotherapy arm), CA209025, CA209039, CA209205, CA209141, CA209032, and CA209275. These studies included data from NSCLC, melanoma, RCC, cHL, SCCHN, and UC subjects. Overall, the incidence of nivolumab ADA was 11.4%. There was no association established between the presence of ADA and hypersensitivity or infusion reactions.

## Post marketing experience

Nivolumab was first approved on 04-Jul-2014 in Japan for unresectable melanoma and has since been approved in multiple countries, including the US and in the EU, and for other indications (e.g., metastatic NSCLC, advanced RCC, and cHL [US only]). Based on pharmacovigilance activities conducted by BMS Global Pharmacovigilance and Epidemiology, review of postmarketing safety data is consistent with, and confirms the clinical trial safety data for nivolumab.

## 2.5.1. Discussion on clinical safety

Integrated safety data were presented for 348 UC subjects from CA209275 (n=270) and CA209032 (n= 78, nivolumab monotherapy UC cohort), hereafter referred to as the 'Integrated UC Population'.

Any-grade AEs (regardless of causality) were reported in 99.1% of subjects treated with nivolumab. The most frequently reported AEs were: fatigue (37.1%), nausea (23.9%), anaemia (20.1%), decreased appetite (20.1%), and cough (17.8%). Grade 3-4 AEs (regardless of causality) were reported in 51.7% of subjects. The most frequently reported Grade 3-4 AEs were anaemia (6.9%), urinary tract infection (5.7%), malignant neoplasm progression (4.3%), dyspnoea (3.7%), asthenia (3.2%), and hyponatremia (3.2%). Frequencies of all-causality AEs (any grade and Grade 3-4) for CA209032 tended to be higher than the Integrated UC Population, however, this difference may be of limited interpretability due to low sample size.

Any-grade drug-related AEs were reported in 68.7% of subjects. The most frequently reported drugrelated AEs were fatigue (21.0%), pruritus (13.8%), diarrhoea (8.9%), nausea (8.3%), and decreased appetite (7.8%). Grade 3-4 drug-related AEs were reported in 19.0% of subjects. The most frequently reported Grade 3-4 drug-related AEs were lipase increased (2.3%) and fatigue (2.0%).

With regards to AE in the integrated UC population and across pooled monotherapy studies, anaemia was the only newly reported all-causality PT reported in &gt;20% subjects for the integrated UC population. Diarrhoea and dyspnoea for study CA209032 tended to be higher than from nivolumab monotherapy studies in other tumor types.

<div style=\"page-break-after: always\"></div>

According to the data submitted, the safety profile of nivolumab in UC population has a slight higher rate of AEs Grade 3-4 (regardless of causality and drug-related) and deaths (within 30 and 100 days) than previously submitted pooled data of nivolumab monotherapy in melanoma, NSCLC and RCC.

SAE were reported in 52.6% of subjects. Grade 3-4 SAEs were reported in 35.1% of subjects and the most frequently reported SAEs were malignant neoplasm progression (11.5%), urinary tract infection (5.2%), general physical health deterioration (2.6%), sepsis (2.3%), and diarrhoea and small intestinal obstruction (2.0%).

Drug-related SAE were reported in 9.5% of subjects. Grade 3-4 drug-related SAEs were reported in 6.6% of subjects. Drug-related SAEs reported in at least 2 subjects were pneumonitis and diarrhoea, 5 (1.4%) each; fatigue, 3 (0.9%); colitis, nausea, and pemphigoid, 2 (0.6%) subjects each.

Six (1.7%) deaths assessed by the investigator due to study drug toxicity. There were 4 deaths in CA209275 (pneumonitis, respiratory failure, cardiovascular failure and acute respiratory failure) and two deaths in CA209032 (pneumonitis and thrombocytopenia). Across both studies (CA209275 and CA209032), there were 6 deaths assessed by the investigator as due to study drug toxicity (pneumonitis [2], respiratory failure, acute respiratory failure, thrombocytopenia and cardiovascular failure).

The majority of AESIs reported were Grade 1-2, and most were considered drug-related by the investigator. The most frequently reported any-grade drug-related select AE categories with nivolumab treatment were skin (23.0%) and gastrointestinal (9.5%).The majority of events were manageable, with resolution occurring when immune-modulating medications (mostly systemic corticosteroids) were administered.

In terms of drug-related AESI, endocrine select AE were reported in 12.9% of subjects, the most commonly reported was hypothyroidism (7.2%). With the exception of one Grade 3 event of hypophysitis reported in CA209275. In the gastrointestinal category, AESIs were occurring in 9.5% of subjects, 1.4% subjects experienced Grade 3-4 diarrhoea events. Two of the 3 colitis events were Grade 3-4. Hepatic select AEs were reported in 4.0% of subjects, six subjects had Grade 3-4 drug-related events. Pulmonary select AE were reported in 3.7% of subjects. Pneumonitis being the most frequently occurring pulmonary select AE. Twelve of these drug-related events were pneumonitis; 2 of the 12 were Grade 3-4. In addition to the pneumonitis events, a Grade 3-4 drug-related event of interstitial lung disease; was reported. Renal select AR were reported in 2.9% subjects. Skin select AEs were reported in 23.0%subjects. The most frequently reported drug-related events were pruritus (13.8%), rash (6.0%), and rash maculopapular (5.2%). 1.7% subjects experienced Grade 3-4 skin events.

Hypersensitivity/infusion reactions were reported in 5 (1.4%) subjects. A Grade 3-4 infusion reaction was reported in 1 subject. No hypersensitivity/infusion reactions led to permanent discontinuation of nivolumab.

The only OESI reported in the Integrated UC Population was a Grade 3-4 OESI of pancreatitis reported in CA209032.No events in the categories of myositis, myocarditis, and rhabdomyolysis were identified.

In the Integrated UC Population, the frequencies of all-causality and drug-related AEs among all treated subjects for subgroups of gender, race, age, and region were consistent with the AE frequencies in the overall treated population. No consistent differences were observed in the frequencies of AEs by PD-L1 expression subgroup.

Discontinuation due to AE was reported in 17.8% of subjects. Grade 3-4 AEs leading to discontinuation were reported in 13.2% subjects. The most frequently reported AEs leading to discontinuation were malignant neoplasm progression (3.2%), general physical health deterioration and pneumonitis (1.4% each), and respiratory failure and small intestinal obstruction (0.9% each). Drug-related AEs leading to discontinuation were reported in 4.3% of subjects. Grade 3-4 drug-related AEs leading to discontinuation

<div style=\"page-break-after: always\"></div>

were reported in 2.9% of subjects. Drug-related AEs leading to discontinuation reported in at least 2 subjects were pneumonitis (1.4%) and pemphigoid (0.6%).

The rate of antibody positive subjects in trial CA209275, was 2-fold that of the pool of previous trials (23.7%). This finding is not considered clinically relevant taking into account that no patients was persistently positive and only 4 patients (1.8%) tested positively for neutralizing antibodies. Moreover ADA titres in ADA positive subjects were low, ranging from 1 to 32. There was no evidence of loss of efficacy in subjects with neutralizing antibodies and there were no associated adverse events. The rate of antibody positive subjects in the Phase II trial CA209032 was lower (13%). Only one patient in the UC experienced a safety event (grade 1 hypersensitivity/infusion reaction) in the phase II trial.

There was no association established between the presence of ADA and hypersensitivity or infusion reactions, suggesting nivolumab ADA does not alter the safety profile of nivolumab. Immunogenicity did not appear to have an effect on the safety of nivolumab in the UC subjects no evidence of an altered safety profile (refer PK-PD assessment). In the pooled analysis, of the 2022 patients who were treated with nivolumab monotherapy 3 mg/kg every 2 weeks and evaluable for the presence of anti-productantibodies, 231 patients (11.4%) tested positive for treatment-emergent anti-product-antibodies with fifteen patients (0.7 %) testing positive for neutralising antibodies (see SmPC section 4.8).

The overall safety profile of nivolumab 3 mg/kg in urothelial carcinoma patients (n = 348) was consistent with that established across tumour types for nivolumab monotherapy. Hence, no major SmPC changes to section 4.8 have been made. The integrated UC safety data has been added to the safety pool nivolumab monotherapy (n = 2578) in variation II/32 which is under assessment.

Patients with a baseline performance score ≥2, active brain metastases or leptomeningeal metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical trials of urothelial carcinoma (see SmPC sections 4.4., 4.5 and 5.1). In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential benefit-risk on an individual basis. Patients with brain metastases have been included as missing information in the RMP.

## 2.5.2. Conclusions on clinical safety

Based on the integrated analyses of safety from CA209275 and CA209032 of nivolumab monotherapy in patients with histologically confirmed UC of the renal pelvis, ureter, bladder or urethra with tumour progression or recurrence on or after at least 1 platinum-based regimen, the safety profile of nivolumab 3 mg/kg Q2W is considered acceptable in the context of the observed clinical activity. The frequency and severity of select AEs were acceptable, with the majority of subjects experiencing resolution when immune-modulating medications were administered. Clinically significant select AEs were manageable using treatment algorithms that recommend nivolumab dose delay or discontinuation and introduction of immune-modulating therapy or other targeted medical intervention (e.g., hormone replacement therapy for endocrine events).

No new risks in addition to those identified in previous studies in other indications were identified.

## 2.5.3. PSUR cycle

The PSUR cycle remains unchanged.

The next data lock point will be 3/07/2017.

The annex II related to the PSUR, refers to the EURD list which remains unchanged.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 7.0 is acceptable. The PRAC advice is attached.

Following subsequent list of outstanding issues and responses from the applicant, the CHMP endorsed this advice with the following changes:

Patients with active brain metastases should be included under missing information, as those subjects were excluded from the clinical trials and therefore the benefit risk is unsure in this population.

The CHMP endorsed the Risk Management Plan version 7.1 with the following content:

## safety concerns

Summary of safety concerns (changes in bold underlined)

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies Immune-related skin ARs Other immune-related ARs Severe infusion reactions                                                                                                                                                                                                                                                                                                                |
| Important potential risks    | Embryofetal toxicity Immunogenicity Cardiac arrhythmias (previously treated melanoma indication, only) Complications of allogeneic HSCT following nivolumab therapy                                                                                                                                                                                                                                                                                                                                                                                 |
| Missing information          | Pediatric patients <18 years of age Elderly patients with: - cHL ≥ 65 years of age - SCCHN ≥ 75 years of age Patients with severe hepatic and/or renal impairment Patients with autoimmune disease Patients already receiving systemic immunosuppressants before starting nivolumab Use in patients who have undergone influenza vaccination Patients with brain metastases: - Advanced melanoma, SCCHN, and UC - active brain or leptomeningeal metastases - NSCLC - active brain metastases - RCC - any history of or concurrent brain metastases |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Ongoing and planned studies in the PhV development plan

| Activity/Study title (type of activity, study title)                                                      | Objectives                                                                                                                                                                                     | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                                             | Status Planned, started   | Date for submission of interim or final reports (planned or actual)   |
|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------|
| CA209835: Registry study in patients who underwent post- nivolumab allogeneic HSCT Category 3             | To assess transplant- related complications following prior nivolumab use                                                                                                                      | Postmarketing safety assessment of the outcome of post- nivolumab allogeneic HSCT                                                                                                                                                                                                                                                                                                                     | Planned                   | Final CSR submission: 4Q2022                                          |
| CA209234: Pattern of Use, Safety, and Effectiveness of Nivolumab in Routine Oncology Practice. Category 3 | To assess use pattern, effectiveness, and safety of nivolumab, and management of important identified risks of nivolumab in patients with lung cancer or melanoma in routine oncology practice | Postmarketing use safety profile, management and outcome of immune- related pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, rash, and other immune-related adverse reactions (uveitis, pancreatitis, demyelination, Guillain-Barre syndrome, myasthenic syndrome , encephalitis, myositis, myocarditis, rhabdomyolysis, and encephalitis), and infusion reactions | Planned                   | Final CSR submission: 4Q2024 (interim report annually)                |

The PRAC, having considered the updated data submitted, was of the opinion that the proposed postauthorisation PhV development plan remains sufficient to identify and characterise the risks of the product.

The PRAC also considered that routine PhV remains sufficient to monitor the effectiveness of the risk minimisation measures.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Summary table of Risk Minimisation Measures (changes in bold underlined)

| Safety concern                                                                                                                                                                                         | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Additional risk minimisation measures                                                                                                                                                                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks                                                                                                                                                                             | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Important Identified Risks                                                                                                                                                                                                                                                                                     |
| Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies Immune related rash Other immune-related ARs | The SmPC warns the risks of immune-related pneumonitis, immune-related colitis, immune- related hepatitis, immune-related nephritis and renal dysfunction, immune-related endocrinopathies, immune- related rash, and other immune- related adverse reactions in Section 4.4 (Special warnings and precautions for use), and provides specific guidance on their monitoring and management, including treatment delay or discontinuation and intervention with corticosteroids in Sections 4.2, 4.4 and 4.8, as appropriate. Further ADRs are included in Section 4.8. In addition, the package leaflet also includes specific warnings and descriptions of the most important safety information in the language suitable for patients. | To further raise awareness of HCPs on important risks and their appropriate management, additional risk minimization activity includes a Communication Plan. The Plan comprising 2 tools to be distributed to potential prescribers at launch by BMS: • Adverse Reaction Management Guide • Patient Alert Card |
| Severe infusion reactions                                                                                                                                                                              | The SmPC warns the risk of severe infusion reactions in Section 4.4 and ADR in Section 4.8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | None                                                                                                                                                                                                                                                                                                           |
| Important Potential Risks                                                                                                                                                                              | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Important Potential Risks                                                                                                                                                                                                                                                                                      |
| Embryofetal Toxicity                                                                                                                                                                                   | SmPC includes Embryofetal Toxicity in Section 4.6 Fertility, pregnancy and lactation, Section 5.3 Preclinical safety data The package leaflet also includes specific description on the safety information in the language suitable for patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | None                                                                                                                                                                                                                                                                                                           |
| Immunogenicity                                                                                                                                                                                         | SmPC Section 4.8 Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | None                                                                                                                                                                                                                                                                                                           |
| Cardiac arrhythmias (previously treated melanoma indication, only)                                                                                                                                     | SmPC Section 4.8 Undesirable effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | None                                                                                                                                                                                                                                                                                                           |
| Missing Information                                                                                                                                                                                    | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Missing Information                                                                                                                                                                                                                                                                                            |
| Pediatric patients                                                                                                                                                                                     | SmPC Section 4.2 Posology and method of administration, subsection on Pediatric population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | None                                                                                                                                                                                                                                                                                                           |
| Severe hepatic and/or renal impairment                                                                                                                                                                 | SmPC Section 4.2 Posology and method of administration: Patients with hepatic or renal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | None                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                                                                                         | Routine risk minimisation measures                                                                                                  | Additional risk minimisation measures   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                                                                                                                                                                                                        | impairment; SmPC Section 5.2 Pharmacokinetic properties: Hepatic or renal impairment                                                |                                         |
| Patients with autoimmune disease                                                                                                                                                                       | SmPC Section 4.4 provides warning and cautionary information for patients with a history of autoimmune disease                      | None                                    |
| Patients already receiving systemic immunosuppressants before starting nivolumab                                                                                                                       | SmPC Sections 4.4 Special populations and 4.5 Systemic Immunosuppressants                                                           | None                                    |
| Patients with brain metastases: • Advanced melanoma, SCCHN, and UC - active brain or leptomeningeal metastases • NSCLC - active brain metastases • RCC - any history of or concurrent brain metastases | SmPC Section 4.4 provides warning and cautionary information for patients with active brain metastases or leptomeningeal metastases | None                                    |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.4, 4.8, 5.1, 5.2 of the SmPC have been updated.

The Package Leaflet has been updated accordingly. Annex II has also been revised to reflect the revised conditions.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable as the changes introduced in the PL as part of this variation application do not have a relevant impact on the readability of the PL.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The MAH applied for a new indication for nivolumab (Opdivo) in locally advanced unresectable or metastatic urothelial carcinoma (UC) in adults after failure of prior platinum-containing therapy.

In the EU, bladder cancer is the fifth most common cause of cancer, with approximately 124,188 new cases and 40,635 resulting deaths reported in 2012 15 . Urothelial carcinoma, also known as transitional cell carcinoma, is the most common type of bladder cancer, accounting for 90% of cases. Among patients diagnosed with UC, the majority have non-muscle invasive (approximately half) or localized muscleinvasive disease (approximately 1 in 3) at the time of diagnosis, with the remaining patients having

15  GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012

<div style=\"page-break-after: always\"></div>

metastatic disease. Approximately 50% of patients presenting with muscle-invasive urothelial cancer eventually develop metastatic recurrence after therapy for clinically localised disease.

## 3.1.2. Available therapies and unmet medical need

In locally advanced unresectable or metastatic UC after failure of prior platinum-containing therapy, the available monotherapy therapies provide a response rate ranging between 10-15%, which seems to be translated into a median overall survival of around 8-9 months at best 16 . Vinflunine, taxanes, gemcitabine and pemetrexed are the current therapeutic alternatives usually offered to this population in the EU 17 . However, taxanes-combination therapies could offer responses in a higher number of patients (30-70%), leading to an increase in OS, even though the high toxicity associated with these combinations limits their use 18 .

## 3.1.3. Main clinical studies

Two on-going studies are presented in support of the claimed indication, i.e. one Phase 1/2 study in multiple tumour types, including unresectable locally advanced or metastatic UC (CA209032) and one Phase 2 study in metastatic or unresectable urothelial cancer (CA209275).

## 3.2. Favourable effects

Outcomes from the pivotal trial (study CA209275; clinical cut-off of 21-Jul-2016) in terms of confirmed ORR by BICR (primary endpoint) showed a response rate of 20% (95% CI 15.4, 25.3) in all treated patients (n=270) (23% by investigator assessment; CI 95% 18.1, 28.4), with a median of duration of 10.35 months (more than half [34/54, 63.0%] of the responders had ongoing response at the time of the clinical cut-off) and with a time to objective response of around 2 months. Median OS was 8.57 months, even though the percentage of events was roughly 58%. Median PFS was 2 months.

Consistent results were reported from the supportive study CA209032 (n=78), where the confirmed ORR based on investigator assessment was 24% (CI 95% 15.3, 35.4) and similar PFS and OS results were achieved (median PFS 2.78 months and 9.72 months of OS).

These results were better in those patients with PD-L1 expression &gt;1%, with confirmed ORR (BICR) of 25% (CI 95% 17.7, 33.6), median OS 11.63 months (CI 95% 9,10, NA) and median PFS 3.55 months (CI 95% 1.94, 3.71) in the pivotal Study CA209275. Patients with PD-L1 expression&lt;1% had an ORR of 16%. Median PFS and median OS were 5.95 months (95% CI: 4.37, 8.08 months) and 1.9 months respectively in PD-L1 &lt;1% subgroup.

As expected, results in those subgroups of patients with poorer prognosis (visceral and hepatic metastasis, high ECOG) obtained lower ORR. Of note the response rate was according to the different age groups, where the older subgroups showed the better results.

## 3.3. Uncertainties and limitations about favourable effects

The main uncertainty in the knowledge about the beneficial effects derives from the study design as single arm trials, where there is no other treatment to compare second line treatment of urothelial carcinoma in this heterogeneous patient population. No phase III trials are ongoing or planned for

16 Bellmunt J1, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17.

17 J. Bellmunt et al., Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 25 18 Oing C, et al. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016 Feb;195(2):254-63. doi: 10.1016/j.juro.2015.06.115. Epub 2015 Sep 26.

<div style=\"page-break-after: always\"></div>

nivolumab in this setting. Therefore, uncertainties exist on the accuracy of the estimation of the benefit in the absence of an adequately designed randomised controlled trial. Nevertheless results from the two nivolumab studies are consistent with each other and the data supports the benefit observed in terms of ORR.

In the subgroups of patients with low/no tumour PD-L1 expression, results were less outstanding than that observed with patients with tumours with higher tumour PD-L1 expression. Patients with PD-L1 expression &lt;1% had an ORR of 16% compared with 25% in patients with &gt;1% PD-L1 expression. The supportive study CA209032 did not show a difference in ORR based on PD-L1 expression, with an ORR of 24% and 26% for patients with above 1% expression and below 1% expression, respectively. In terms of survival benefit, patients with PD-L1 expression below 1%, showed a shorter median survival than those classified as PD-L1&gt;1%. However, the benefit in terms of survival rate at 1 year in these patients is considered similar to chemotherapy (34% nivolumab vs 31% chemotherapy from Bellmunt et al. NEJM 2017) and the 1-year survival rate in responders was close to 96%. Furthermore, durable responses were observed across all PD-L1 subgroups.

## 3.4. Unfavourable effects

The safety and tolerability of nivolumab in patients with locally advanced unresectable or metastatic UC was similar to what has been observed in other indications with nivolumab. No new safety concerns were raised and the important safety concerns remain the same.

Any-grade drug-related AEs were reported in 68.7% of subjects treated with nivolumab in Integrated UC Population. The most frequently reported drug-related AEs were fatigue (21.0%), pruritus (13.8%), diarrhoea (8.9%), nausea (8.3%), and decreased appetite (7.8%). Grade 3-4 drug-related AEs were reported in 19.0% of subjects. The most frequently reported Grade 3-4 drug-related AEs were lipase increased (2.3%) and fatigue (2.0%).

The immunogenic potential of nivolumab was found to be low and did not appear to be affect safety profile.

## 3.5. Uncertainties and limitations about unfavourable effects

The main study as well as the supportive study had a single arm study design.  This may have affected adverse event reporting. However, this is not expected to have a large impact on the conclusions drawn for the efficacy and safety of the product.

Subjects with active brain metastases or leptomeningeal metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical trials of urothelial carcinoma and therefore the B/R is uncertain in this population. However, the current SmPC accurately reflects a warning regarding the potential risks associated with treating patients with active, known or suspected autoimmune disease.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 69: Effects Table for nivolumab for the treatment of UC (Study CA209275, data cut-off: 21-Jul-2016; tumour assessment)

| Effect               | Short Description                                                                                                                                                                | Unit                 | Treatment            | Control              | Uncertainties/ Strength of evidence                                          | References                          |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|------------------------------------------------------------------------------|-------------------------------------|
| Favourable Effects   | Favourable Effects                                                                                                                                                               | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                           | Favourable Effects                  |
| ORR                  | %of randomized subjects who achieved a best response of CR or PR (RECIST v1.1 BICR).                                                                                             | %                    | 20.0                 | N/A                  | Single arm trial PD-L1 >1% 25.0% PD-L1 <1% 15.8% Supported by study CA209032 | See discussion on clinical efficacy |
| DOR                  | Time from first confirmed response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever | Median (Months)      | 10.4                 | N/A                  | PD-L1 >1% 10.4 PD-L1 <1% NR                                                  | See discussion on clinical efficacy |
| OS                   | Time from randomization to the date of death from any cause                                                                                                                      | Median (months)      | 8.6                  | N/A                  | Single arm trial PD-L1 >1% 11.6 PD-L1 <1% 6.0 Supported by study CA209032    | See discussion on clinical efficacy |
| PFS                  | Time from randomization to first date of documented progression, or to death due to any cause.                                                                                   | Median (months)      | 2.0                  | N/A                  | Single arm trial PD-L1 >1% 3.6 PD-L1 <1% 1.9 Supported by study CA209032     | See discussion on clinical efficacy |
| Unfavourable Effects | Unfavourable Effects                                                                                                                                                             | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                         | Unfavourable Effects                |
| All Grade 3/4 AEs    | Drug related                                                                                                                                                                     | %                    | 9.5                  |                      | No new safety concerns with nivolumab monotherapy treatment                  |                                     |
| SAEs                 | Drug related serious Adverse Events                                                                                                                                              | %                    | 6.6                  |                      | were identified in UC                                                        |                                     |

<div style=\"page-break-after: always\"></div>

| Effect             | Short Description             | Unit   |   Treatment | Control   | Uncertainties/ Strength of evidence   | References   |
|--------------------|-------------------------------|--------|-------------|-----------|---------------------------------------|--------------|
| Fatigue            | Most frequent drug-related AE | %      |        21   |           |                                       |              |
| Pruritus           | Most frequent drug-related AE | %      |        13.8 |           |                                       |              |
| Diarrhoea          | Most frequent drug-related AE | %      |         8.9 |           |                                       |              |
| Nausea             | Most frequent drug-related AE | %      |         8.3 |           |                                       |              |
| Decreased appetite | Most frequent drug-related AE | %      |         7.8 |           |                                       |              |

Abbreviations: AEs (adverse events), AR (assessment report), BICR (blinded independent review committee); CR (complete response), HR (hazard ratio), PFS (progression free survival), ORR (objective response rate), OS (overall survival), PR (partial response), N/A (not assessed), NR (not reached)

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

From a clinical perspective, patients with metastatic urothelial carcinoma after failure of prior platinumcontaining therapy, have a poor prognosis. According to the bibliography, the therapeutic landscape based on monotherapies after a first treatment of platinum (vinflunine, taxanes, gemcitabine and pemetrexed) offers ORRs that range between 10-15% with a median OS of 8-9 months; with the exception of gemcitabine that as a single agent has demonstrated ORRs of 11-29%, with median OS that ranged from 5 to 13 months, as second-line therapy in a small Phase 2 study (N&lt;50). On the other hand, efficacy results reported for most taxane-based combinations seem to offer 30-70% ORRs, with longer survival than monotherapies. However, taxane-based combination therapy is accompanied by high toxicity and currently used in a minority of the patients.

Treatment with nivolumab showed consistently higher rates of tumour responses (25%) and a trend for higher OS (12 months) as compared to available monotherapy options in the subset of patients with high PD-L1 expression (i.e. &gt;1%). While the response rates in patients with tumours designated as PD-L1 &lt;1% are lower than for patients with tumours designated as PD-L1 &gt;1%,  they seem similar or slightly superior than what is observed for other available options. The responses had a clinically relevant duration across all PD-L1 subgroups, which appear better than DoRs described for all other available therapies (including combination-chemotherapy).

Although  patients  with  PD-L1  expression  below  1%  showed  a  shorter  median  survival  than  those classified as PD-L1&gt;1% (respectively 6 vs 12 months), the 1 year survival rate provided similar results to chemotherapy in the overall population of patients PD-L1&lt;1% (34% nivolumab versus 31% reported for chemotherapy in Bellmunt et al. NEJM 2017) and the 1-year survival rate in responders was close to 96% which is considered clinically meaningful. Furthermore, in patients with both PD-L1 expression&lt;1% and the  presence  of  poor  prognostic  factors,  the  OS  rates  at  1  year  appear  similar  to  those  reported  with chemotherapy in this population.

The overall safety profile of nivolumab monotherapy in CA209275 and CA209032 has been characterised. No new safety concerns were identified in UC setting.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

The safety profile of nivolumab compares favourably to chemotherapy and the benefit in those patients considered PD-L1&gt;1% is considered clinically meaningful, both in terms of durable ORR and OS. In patients with low PD-L1 expression (&lt;1%) the use of nivolumab will likely provide both comparable rates of response and similar survival benefit to that reported for chemotherapy, however the responses observed are more durable than achieved with currently available therapy. Considering the observed benefit and safety profile in the overall patient population, the indication is not restricted to patients with tumour expressing PD-L1. Furthermore, no specific PD-L1 expression cut-off that would select patients benefiting most from nivolumab could be identified and further biomarkers assessment is needed (see Annex II).

In conclusion, the benefit/risk balance is positive for nivolumab monotherapy in the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinumcontaining therapy.

## 3.7.3. Additional considerations on the benefit-risk balance

The MAH provided additional analyses for several biomarkers which might predict treatment response. Currently none of the assessed biomarkers could adequately differentiate the responders from the nonresponders. Further evaluation on the association between improved clinical outcomes to nivolumab and PD-L1 expression on both immune cells and tumour cells in a quantitative, prospective manner, using validated assays and methods, is lacking at this stage. Other biomarkers such as other gene signatures, mutational and neoantigen load remain to be evaluated.

Therefore, the CHMP considers the following measures necessary to address issues related to efficacy:

The value of biomarkers to predict the efficacy of nivolumab therapy should be further explored, specifically:

- To further investigate the value of biomarkers other than PD-L1 expression status at tumour cell membrane level by IHC (e.g., other genomic-based methods / assays, and associated cut-offs, that might prove more sensitive and specific in predicting response to treatment based on PD-L1, PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA signature, expression of components of antigen-presentation complexes and/or other inhibitory checkpoint receptors/ligands within tumour, etc.) as predictive of nivolumab efficacy. This will be provided for urothelial carcinoma studies CA209275 and CA209032  (by 30 June 2018)
- To further explore in UC patients, methods to aid in the early identification of those who did not respond to treatment with nivolumab, as well as to evaluate the association between improved clinical outcomes to nivolumab and the presence of:
- o Mutational and neoantigen load, and if feasible, PD-L1 expression on tumour- and tumour associated immune cells using validated approaches (by 30 June 2018)

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy for OPDIVO.

As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add the proposed indication, add a warning about the patient populations excluded from the clinical trial, and update the safety information. The Package Leaflet is updated in accordance.

Moreover, the updated RMP version 7.2 has been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

This CHMP recommendation is subject to the following amended conditions:

## Conditions and requirements of the marketing authorisation

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Due date       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| 4. The value of biomarkers to predict the efficacy of nivolumab and/or nivolumab + ipilimumab combination therapy should be further explored, specifically: 2.To further investigate the value of biomarkers other than PD-L1 expression status at tumour cell membrane level by IHC (e.g., other genomic-based methods / assays, and associated cut-offs, that might prove more sensitive and specific in predicting response to treatment based on PD-L1, PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA signature, expression of components of antigen-presentation complexes and/or other inhibitory checkpoint receptors/ligands within tumour, etc.) as predictive of nivolumab and/or nivolumab + ipilimumab combination therapy efficacy. This will be provided for all the approved indications: - UC: studies CA209275 and CA209032 7. To further explore in UC patients the early identification of those who do/do not respond to treatment with nivolumab, as well as to evaluate the association between improved clinical outcomes to | 30th June 2018 |